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ABSTRACT 
 
 
Access to health care for children is important. It is dependent on access 
to health professionals and also parental attitudes towards illness.  
 
Children have the right to receive medicines that are scientifically 
evaluated for both efficacy and safety. Counterfeit and substandard 
medicines unfortunately result in the death of many children worldwide. 
There have been particular problems with diethylene glycol which has 
been used as a solvent in counterfeit medicines. It has also been found in 
contaminated substandard medicines. It has been responsible for the 
death of many children in different countries throughout the world. I 
performed a literature review of all cases of diethylene glycol poisoning 
that have been published. I have described the clinical signs and 
symptoms and hope that these findings increase the awareness of 
diethylene glycol poisoning in children.      
 
It is well known that there are clear inequalities in health and access to 
health care in the UK. This inequity has been particularly noticed 
amongst certain minority groups. &KLOGUHQ RI ³DW ULVN´ JURXSV VXFK DV
Asylum Seekers and Refugees, and Gypsies and Travellers, were 
recognised as having possible barriers in accessing health care and 
medicines.   
 
I conducted a study to H[SORUHFKLOGUHQ¶VDFFHVVWRPHGLFLQHVLQWKe East 
Midlands area in the UK. Alongside determining accessibility to health 
care the study also wished to explore parental attitudes towards 
receiving treatment for pain, asthma and epilepsy. 
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Both quantitative and qualitative research methodology was used in this 
study.  The research data was gathered with the aid of semi-structured 
LQWHUYLHZV ZLWK SDUHQWV IURP WKH ³DW ULVN´ JURXSV DQG FRQWURO SDUHQWV
Fifty parents from each group were selected and interviewed regarding 
WKHLUFKLOGUHQ¶VKHDOWKDQGWKHLU access to health care and medicines. The 
semi-structured interviews allowed participating parents to state their 
opinions about any barriers they had encountered to their children 
receiving medicines.   
 
3DUHQWVIURPERWK³DWULVN´JURXSVDQGFKLOGUHQIURm the Traveller group 
had more health problems than the controls. The attitude of some Gypsy 
and Traveller parents (11%) not to immunise their children was a 
significant problem. One in six Refugee parents reported difficulties while 
obtaining medicines. The two main barriers were 
language/communication problems and financial difficulties. Both 
Refugee and Traveller children received fewer OTC medicines than the 
children of the control group. It was not clear from the interviews 
whether this was due to financial difficulties or reluctance to use 
medicines without a doctor having seen the child first. 
 
3DUHQWVIURPERWK³DWULVN´JURXSVZHUHOHVVOLNHO\WRJLYHDQDOJHVLFVIRU
treating earache than those in the control group. Parents of Refugee 
children weUHPRUHUHOXFWDQWWRWHOORWKHUVDERXWWKHLUFKLOG¶VHSLOHSV\ 
 
Access to health care is an essential human right. Children are dependent 
upon both their parents and the health system for ensuring access to 
health care. This study has identified problems both within the system 
and also in relation to parental beliefs that may affect the access to 
health care and treatment for children. It is important that both of these 
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potential barriers are addressed in order to improve the health of 
FKLOGUHQRI ³DW ULVN´JURXSV It is hopeful that the findings in this study 
will help to identify ways of improving access to health care and 
medicines for these groups.  
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CHAPTER ONE 
GENERAL INTRODUCTION 
  
1.1  Problems of Access to Medicines World-Wide 
 
7KHLVVXHRIFKLOGUHQ¶Vaccess to medicines has been considered as one of 
major concern, because health care professionals recognise that a lack of 
access to essential medicines of assured quality continues to form 
significant risks to children(1).    
 
It is unacceptable that thousands of children around the world still die 
needlessly every day because they do not have access to the essential 
medicines that could save them(2). In many different parts of the world 
children are still at high risk from many life- threatening diseases. Many 
children, for example, are not even immunised (3).  
 
Medicines are an important component in treating diseases and in 
improving human health. They are one of the most cost-effective health-
care interventions in saving lives and alleviating the suffering of patients. 
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Medicines must be effective, safe and of acceptable quality, as well as 
being used rationally to produce the desired effect (4, 5). 
 
 1.2  Medicines for Children 
Accessing appropriate medicines for ill children has always been a 
significant problem. The challenges to develop safe, appropriate, and 
effective pharmacotherapy for children are still a major global concern 
(6). Children suffer different diseases from adults, such as 
bronchopulmonary dysplasia in neonates and bronchiolitis in infants, and 
effective treatments are often not available (7, 8). 
 
The use of medicines for children is in general less evidence-based than 
for adults (1). It is recognised that few medicines are licensed for 
children, whereas most medicines are licensed for adult use. This is one 
of the reasons why off-label prescribing of medicines is more common for 
children than adults (9).  
 
Unlicensed and off-label medicines are licensed medicines being used 
outside the terms of the product licence (10). For example, they may be 
licensed for adults but not for paediatric patients. Children suffer from 
different diseases from adults and therefore require different medicines 
(11).  
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Unlicensed medicines may not have been subjected to the licensing 
process at all (10). The safety, efficacy and quality of these prescriptions 
therefore cannot be guaranteed, since no pharmaceutical company has 
performed any clinical trials on them. However, the terms off-label and 
unlicensed medicines do not necessarily imply disapproval of, or 
improper practice in, their use (1, 12).     
 
Using off-label and unlicensed medicines for children is a matter of 
considerable concern within the United States and Europe (13). Many 
formulations dispensed in hospitals to treat children are considered as 
off-label or unlicensed medicines (10). For example, diazepam rectal 
solution, which has been used for children under one year of age is not 
licensed for this age group (14). 
 
A study was conducted in five centres in Europe where 624 children were 
admitted to the paediatric wards and received 2262 prescribed drugs 
(14). About 46% of these drugs were off-label [872] or unlicensed [164]. 
Two thirds [421] of the inpatient children received off-label or unlicensed 
drugs. 
 
More studies have been conducted in relation to medicines given to 
children (15). For example, studies conducted in the UK, Australia and 
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1HZ =HDODQG VKRZHG VRPH LPSURYHPHQWV LQ FKLOGUHQ¶V DFFHVV WR
medicines and the number of medicines licensed for children between 
DQGEXWDVHULRXV LPEDODQFHEHWZHHQFKLOGUHQ¶VDQGDGXOWV¶
access still exist in all three countries (16).  
 
1.2.1 Challenges of age and formulation 
The size of a dose administered to a child varies with age and weight 
(17), and therefore different formulations are required for children of 
different ages.  
 
Formulations for children are needed in different ranges of concentrations, 
and different forms including liquids and solids. However, the availability 
of appropriate forms may be limited by factors such as solubility, 
chemical and physical stability, formulation microbiology and 
homogeneity. The volume and dose of liquid medicines may be limited by 
the solubility of the active ingredients of a drug in solvents or flavouring 
and sweeteners (17). The development of these formulations has also 
been limited by the financial returns for such a small market.  
 
Appropriate formulations for children, such as suitable oral formulations, 
are essential in medical treatment. Such formulations result in better 
adherence to treatment and enable individualised dosing. Lack of 
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DYDLODELOLW\RIVXLWDEOHGRVDJHIRUPVFDQLPSDLUFKLOGUHQ¶VDFFHVVWRVDIH
medicines.  (16).  
 
The persistent problems of limited numbers of paediatric medicines and 
inappropriate dosage forms can result in difficulties in the availability and 
supply of appropriate medicines for children (18). Therefore, regulatory 
authorities and the pharmaceutical industry need to ensure that children 
have access to appropriate formulations of medicines (19, 20).  
 
1.3  WHO and Make Medicines Child Size 
The World Health Organisation (WHO) has taken many steps to map the 
JOREDOVLWXDWLRQFRQFHUQLQJFKLOGUHQ¶VDFFHVV to, and use of, medicines. It 
has also designed specific strategies to fill existing gaps, and to raise 
awareness and accelerate action to address the importance of improved 
access to and availability of safe and specific medicines for children (1). 
WHO has launched a campaign in 2007, HQWLWOHG µ0DNH0edicines Child 
SL]H¶ (21).  A key feature of this campaign is the importance of access to 
health care and medicines for children, an area that has been 
inadequately explored (22). For example, world-wide two million children 
die each year from pneumonia (3, 23).  The majority of these children 
would survive if they received an appropriate antibiotic.  
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The World Health Assembly (WHA) discussed the topic of paediatric 
medicines in depth and the Department of Essential Medicine and 
Pharmaceutical Policies initiated many actions to lead to 'better 
medicines for children'. These actions include many aspects such as 
ensuring that existing and new medicines are safe for use with children, 
ensuring that requirements  of labelling and  licensing for medicines are 
upgraded, and ensuring that skills and resources are available to improve 
use of medicines in children (1).  
 
1.4 Regulation RI&KLOGUHQ¶V0edicines  
1.4.1 The US regulations 
Several tragedies involving children have led to an increase in drug 
regulation in the US. In 1902, the contamination of diphtheria toxin with 
live tetanus bacilli led to the deaths of many children (24). Therefore, the 
Biologics Control Act was passed to ensure the safety and purity of 
vaccines. In 1939, at least 105 people, 33% of them children, died after 
ingesting poisonous diethylene glycol mixed as a vehicle with 
sulphanilamide elixir and distributed for use without safety testing (24). 
This episode led to legislation by the Food and Drug Administration (FDA), 
which required new medicines to be tested for safety (25). Since this 
time the US has led the way in new legislation to promote the testing of 
all appropriate new medicines for children (24, 25). 
 
  
7 
In 1997, the US Congress enacted the Food and Drug Administration 
Modernisation Act (FDAMA). It contained provision establishing economic 
incentives for the pharmaceutical industry to conduct paediatric studies. 
This was soon recognised to be an insufficient incentive therefore the 
1998 Paediatric Rule was enacted. This required the pharmaceutical 
industry to test drugs and biological products for children. It applied to 
new licensing applications for active ingredients, dosage forms, 
indications, and routes of administration (24). This was an important 
change to try to ensure paediatric safety in drug dosing, and efficacy  (24, 
26). 
 
In support of these initiatives, guidelines were passed by the National 
Institute of Health (NIH) to increase the number of child participants in 
federally-funded research (27). Consequently, the FDA was authorised by 
Congress to grant a six month extension to patent protection of new 
pharmaceutical products that were labelled for use in children. This rule 
was applied through the programme of paediatric exclusivity for 
pharmaceutical industries completing FDA-requested paediatric studies. 
The success of this programme led to an increase in paediatric drug 
studies, in addition to an increase in the number of drugs that had 
labelling changes for use with children. Consequently, the net economic 
return to the companies from the participation in this programme was 
high due to the extension to patent protection (28, 29). 
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European regulations were strongly influenced by both the experiences of 
the US paediatric exclusivity and the European regulation in 1999 on 
orphan medicines (24). The major goal of the European regulation was 
the improvement of children¶V health in Europe, by improving the 
development of medicines, increasing information on the use of 
medicines with children and ensuring the appropriate evaluation and 
labelling of medicines (24, 28). 
 
1.4.2 European regulations  
After the US efforts at the end of the last century, European regulatory 
changes were seen as the start in improving knowledge of drugs given to 
children. In the latest development (2007) (30), the European regulation 
on paediatric medicines added a legal requirement that all commonly 
used medicines are tested on children. The regulation requires that the 
SKDUPDFHXWLFDO FRPSDQ\¶V paediatric investigation plan describes 
measures to develop an appropriate  formulation for paediatrics and 
make its use more acceptable, safer, easier and more effective (30). 
 
Within the January 2007 updated European legislation, new regulations 
were introduced to govern the authorisation and development of 
medicines for use in children aged 0 to 18 years (30). The European 
Medicines Agency (EMA) established a Paediatric Committee (PDCO) to 
support the legislation on FKLOGUHQ¶VPHGLFLQHV7KHLUDLPVDUHWRHQVXUH
that there is scientific evidence for using medicines in children and that 
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they have an appropriate formulation (13, 30). All these efforts set the 
scene for more developments affecting legislation covering the clinical 
trials for paediatric medicines in the EU (13, 30). 
 
1.4.3 Access to medicines under International Human Rights Law 
Access to essential medicines is considered a basic human right. However, 
these essential medicines are often denied to poor people in low- and 
middle- income countries (31).  
 
The lack of full access to essential medicines or vaccines due to economic 
problems raises new issues in human rights among both high income 
countries and the rest of low- and middle-income countries (31). 
 
According to human rights principles, health care must be provided 
without distinction of any kind on the basis of ethnic group, race, religion, 
language, colour or any other status. A human rights framework also 
emphasises the importance of non-discrimination for marginalised and 
vulnerable groups. Moreover, it sets out the connection between access 
to medication and the right to adequate standards of health care (32).  
 
Both the Convention on the Rights of the Child and the European 
Convention for the Protection of Human Rights state that access to 
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appropriate medication LV D FULWLFDO FRPSRQHQW RI FKLOGUHQ¶V ULJKWV WR
standard health(32). The international framework of child rights also, 
plays a major role in taking action to improve child health and ensure 
that all children have the same opportunity to access necessary medical 
assistance and health care (33). 
 
All the efforts in this area go towards improving health care services and 
access to appropriate medication. Equality and human rights legislation 
have been passed by the British government to ensure that health staffs 
do not discriminate against individuals because of their race, religion or 
colour, and that equal opportunities exist for optimum treatment. This 
legislation gives everyone the right to equal treatment (34). 
 
1.5 Essential Medicines  
1.5.1 Definition of essential medicines 
Essential medicines are considered as fundamental to every public health 
programme (35). The main aim of these medicines is to reduce morbidity 
and mortality rates in all countries around the world. Most of the 
important public health programmes which mainly depend on essential 
medicines include child health and survival programmes, control of 
epidemic diseases such as tuberculosis and malaria, antenatal care, and 
medications for respiratory and enteric pathogens (31). 
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Essential medicines are defined, by the World Health Organisation (WHO) 
DV WKRVH ³medicines that satisfy the priority health care needs of the 
population¶¶ (36). They are selected according to strict criteria:  
x evidence of safety and efficacy  
x prevalence of disease   
x with due regard to cost effectiveness.  
 
The first WHO Model List of Essential Medicines for Children, the purpose 
of which was to 'make medicines child size', was published in October 
2007.  In compiling the list, preparatory work was carried out by a 
special subcommittee formed to work on the selection and use of 
essential medicines based on the WHO treatment guidelines. The 
subcommittee also emphasised the importance of establishing 
mechanisms to control the prices of these essential medicines for 
children (1, 18). The WHO library for essential medicines is considered to 
be one of the most valuable information databases for drug and 
therapeutic committees in all member states, international organisations 
and health insurance organisations (37, 38). Model lists of essential 
medicines are also used by the United Nations High Commission for 
Refugees (UNHCR), the United Nations International Children's 
Emergency Fund (UNICEF) and many other non-governmental 
organisations (NGOs) to raise awareness of, and to promote, the 
availability, affordability, accessibility, and quality of medicines (38).  
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Careful selection of essential medicines leads to better health care, better 
access to medicines and acceptable prices. All essential medicines should 
be available at all times in sufficient amounts and suitable dosage forms, 
with assured quality and at an affordable price to all individuals in the 
community(31). 
 
1.5.2 The concept of essential medicines 
The concept of essential medicines is international. It was launched with 
the first publication of the Model List of Essential Medicines in 1977 by 
WHO (37). Since then the List remains a strong tool within public health 
and has been revised and updated every two years (38). Both its process 
and the content by which it is updated are intended as models for low- 
and middle-income countries. Today, many of these countries have their 
own national list of essential medicines, most of which have been 
updated in the past five years. The original concept of essential 
medicines is seen nowadays as a breakthrough in global public health (37, 
38).  
 
It is recognised that in many low-and middle-income countries the lack of 
a free and accessible health care system and poor access to essential 
drugs result in many children being deprived of appropriate treatment. 
Today, over one-WKLUG RI WKH ZRUOG¶V SRSXODWLRQ DQG RYHU KDOI RI WKH
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poorest people in Africa and Asia, still suffer from lack of access to 
essential medicines (1).  
 
1.5.3 Problems of access to essential medicines in low-and 
middle-income countries 
Essential medicines for the main diseases should be both available and 
affordable in the low- and middle-income countries. Problems related to 
access to essential medicines in many low-and middle-income countries 
around the world include the lack of availability. This is due to prohibitive 
cost, poor quality and counterfeit medicines, and the potential impact of 
the agreements of the World Trade Organisation (WTO) on drug 
availability world-wide. These agreements resulted in patents for many 
medicines which invariably are associated with higher prices and often 
result in such medicines being too expensive for poor countries. All these 
issues may result in significant difficulty in accessing essential medicines 
in low- and middle-income countries (31, 39). The following sections 
highlight these issues in detail. 
 
1.5.3.1 Withdrawal of essential drugs 
Essential medicines which have been used for the treatment of diseases, 
including tuberculosis and African trypanosomiasis, have become 
unavailable because they are no longer considered to be profitable (31). 
Many old essential medicines are no longer available in high-income 
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countries. An example of this was in Nigeria in 1996 when more than 
100,000 cases were reported in an epidemic of Neisseria meningitis. An 
effective treatment for meningococcal meningitis is chloramphenicol in 
oily suspension. This medication is a tenth of the cost of ampicillin. Its 
simple administration orally makes it a suitable treatment for patients in 
rural areas in low-income countries. However, the manufacturer 
(Roussel-Uclaf) stopped producing chloramphenicol in oily suspension in 
1995 and the availability of this product is no longer guaranteed (31, 39).  
 
1.5.3.2 Prohibitive costs 
The purchase of medicines represents a major expenditure of total health 
spending for both individuals and governments (31). It is also one of the 
main causes of household impoverishment in high-income countries as 
well as low- and middle- income countries. The high price of medicines 
affects access to them, even in countries such as the UK which have 
universal insurance with co-payments (40).  
 
Prohibitive pricing is another issue in access to essential medicines in 
many low- and middle-income countries (31). This is well known with 
regard to acquired immunodeficiency syndrome, which is best treated 
with antiretroviral medicines that are, however, often inaccessible due to 
their high cost. New vaccines such as the ones against Haemophilus and 
hepatitis B are other examples of essential medicines which are not 
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affordable to many of the poorest and most at risk populations around 
the world, due to their high cost (31, 41).  
 
Since 1979, Shigella dysenteriae type 1 has been the cause of large 
epidemics in the poorest countries in Africa. Unfortunately, this disease 
became resistant to nalidixic acid, the traditional medication, and the 
only effective treatment today is fluoroquinolones (31). Fluoroquinolones 
are approximately ten times more expensive than nalidixic acid ($20 vs 
$2) per course of treatment (31). Without introducing regulations and 
changes into the pharmaceutical market, significant improvements will 
not be achieved. 
 
1.5.3.3 Patent of medicines 
Patents of pharmaceutical products give the owners the exclusive right to 
make, sell and distribute their products. The price of a medicine only 
comes down when the patent expires. Therefore, essential medicines are 
initially less affordable for the poor in low- and middle-income countries 
(31). 
  
Furthermore, access to essential medicines remains poor, mainly due to 
inadequate purchasing power and  infrastructure (transportations to 
clinics, and storage places) (31, 39). Directors of pharmaceutical 
industries in high-income countries also indicate that the lack of 
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protection for innovations is the main reason for their limited 
investments in low- and middle-income countries (31). 
 
Pharmaceutical companies must be compelled to choose whether to 
protect their patents of new medicines in high-income countries, or in 
low- and middle-income countries, but not have the option of both. For 
diseases which affect countries all around the world like cancer, 
companies could choose to protect their patents in high-income countries. 
However, for those diseases which almost entirely affect low- and 
middle-income countries like malaria, they could choose to protect their 
patent in high-income countries only, so the treatment cost would not be 
prohibitive(34, 39). 
 
Formerly, many low- and middle-income countries and some high-income 
countries excluded medicines from being patented, even if they met the 
criteria of being inventive and new. Today, all these countries are 
members of the WTO and implement the agreement to trade-related 
aspects of intellectual property rights (TRIPS) in their systems. This 
agreement probably has the greatest effect on the access to medicines. 
It set some standards, such as 20 years of patent for pharmaceutical 
products, by dealing with the laws of patent (29, 42). By establishing the 
priorities of public health, expensive medicines similar to other medicines 
which are supplied by international organisations like UNICEF must now 
be provided to poor countries. This can be achieved by cooperation 
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between pharmaceutical companies and governments, or between the 
companies themselves. For example, Bayer laboratories and Medecins 
Sans Frontieres (MSF) reached a special agreement in 1997 to produce 
ciprofloxacin treatment for 50,000 patients with a price of $2 per 
treatment. Such examples demonstrate the ability of pharmaceutical 
companies to find short-term solutions between themselves (31, 39, 41). 
 
1.5.4 Problems of access to essential medicines in high-income 
countries 
The increasing demand for medicines and their rising costs are 
international problems not limited to low- and middle-income countries. 
Over the last decade, expenditure on pharmaceutical products in the USA 
rose dramatically due to an ageing population, an increase in the basic 
cost of medications (5-6% per year) and consumer advertising (38). 
Problems of access to medicines and health care in high-income countries 
are related to living in rural settings, belonging to certain minority ethnic 
groups, socioeconomic status and communication issues (43). Immigrant 
populations in some high-income countries are affected 
disproportionately by the lack of health insurance and their inadequate 
knowledge of the health care system in the host country (43, 44). More 
recent research in North America has revealed that in both the United 
States and Canada, children of different ethnic groups or without 
insurance may be less likely to receive medicines(45-47).  
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1.6 The Global Problem of the Quality of Medicines and 
Counterfeiting  
 
The quality of medicines is a comprehensive concept which includes the 
identity, purity, efficacy and safety of all chemical products contained in 
each medicine. History has shown that poor quality products still exist in 
both low- and high-income countries. Therefore, the quality of medicines 
is a major concern for drug regulatory agencies, health organisations and 
healthcare professionals (48, 49).  
 
The assessment of drug quality is a very complex process. Scientific 
regulation is essential from the pharmaceutical manufacturing operation 
till the pharmacovigilance stage (49). Poor manufacturing practices or 
inappropriate storage can result in products of poor/low quality (50).  For 
this reason all governments should make it a priority to regulate the 
process of drug manufacturing, storage and distribution. Medicinal 
preparations must be prepared according to good manufacturing 
practices (51). These standards assure the quality of administered 
medicines. The three most important criteria for medicines are quality, 
safety and efficacy. These criteria are used by governments to regulate 
pharmaceutical products (52), and should be verified at all stages 
throughout all the processes of manufacturing, distributing, storage and 
dispensing. Such specifications are cornerstones of the functioning of 
each public health care system (48, 53).  
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Medicines, unfortunately, are not exempt from counterfeiting (54). The 
problem of substandard and counterfeit medicines has a long history. In 
earlier centuries, herbal medicines were often adulterated; for example, 
Valeriana officinalis root was adulterated by mixing congeners with root 
to treat cholera which reduced their effectiveness and led eventually to 
loss of faith in genuine treatment (55). In the 17th century, the first 
effective treatment of malaria, Peruvian Cinchona bark (48), was 
adulterated with aloes and other astringent barks. Huge demand from 
Europe for the bark, because of endemic malaria, precipitated this 
adulteration. After a while, loss of confidence in this herbal medicine 
induced a decrease in demand and a price decline, leading to a 
temporary ruin of the exporting markets (48-50). 
 
Any manufactured medicinal product is at risk of imitation. Such 
medicines are often marketed under the name of the original commercial 
product (54). Pharmaceutical companies worry about the imitation of 
their products because they may lose the confidence of both prescribers 
and patients. Since these counterfeit products may be difficult to 
distinguish from the genuine products, they present great danger to the 
SXEOLFDQGSDWLHQWV¶KHDOWK(54).  
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The dangers to public health of counterfeit and substandard drugs have 
been well documented and crucially the problem has now reached global 
proportions due to easy access of these products through internet 
technology and the ease of transportation and travel (54).  
 
Counterfeiting is the mimicking of an original product (56). The WHO 
defines counterfeit medicines as those which are mislabelled deliberately 
and fraudulently with respect to identity or source (51, 57).  Counterfeit 
medicines may include products without active ingredients, with 
insufficient active ingredients, the wrong ingredients or even the correct 
ingredients.  They may also include products with fake packaging (58).    
 
Substandard medicines are genuine medicines produced by legitimate 
manufacturers that fall short of meeting the required quality 
specifications (50).  Substandard medicines may contain less or even 
more of the active ingredient than specified on the package.  
Unfortunately, many low- and middle-income countries do not possess 
sufficient resources (financial, technical, or human) to apply appropriate 
manufacturing standards and controls which safeguard medicines. 
Furthermore, some pharmaceutical companies in some industrialised 
countries such as India and China tend to apply fewer restrictions to 
manufactured products designed for exportation (56) because this lowers 
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the cost of production, thereby giving them a competitive advantage in 
the global market. 
 
For example, Malaria is an infection which is curable when an anti-
malarial drug with the correct quality is taken. A recent study by Nayyar 
et al (59) reported that one-third of anti-malarial medicines were fake. 
The study included anti-malarial drugs from 28 countries sold between 
1999-2010. 36% of 1437 tested drugs from Southeast Asia and 20% of 
tested drugs in the sub-Saharan Africa were fake (59). 
 
1.6.1  How big is the problem? 
The WHO has said that it is difficult to estimate the level of medicinal 
counterfeiting accurately (60). 15% of all medicines worldwide are 
believed to be substandard or counterfeit (54).  A wide variation has 
been noticed in the prevalence of counterfeiting between countries. In 
the markets of low- and middle-income countries, 10-30% of medicines 
are estimated to be counterfeit (60). This percentage increases with the 
high demand during epidemics and the presence of poor drug regulations. 
For example, approximately 30% to 50% of an important anti-malarial 
WUHDWPHQW µ$UWHVXQDWH¶ ERXJKW LQ 6RXWKHDVW $VLD ZDV FRXQWHUIHLW (54). 
Moreover, a high percentage of discovered counterfeit medicines in 
central Africa were the antiretroviral agents, such as lamivudine-
zidovudine and stavudine-lamivudinenevirapine(54).  
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In contrast, in high-income countries, the percentage of counterfeit 
medicines is estimated to be only 1% (60). This is clearly related to the 
strict enforcement of drug regulations in countries in North America, 
European Union, and Japan which enhance protection against 
counterfeiting(60).  
 
1.6.2 Underlying causes of counterfeit and substandard 
medicines 
The prevalence of counterfeit medicines is a global problem(60). 
Intellectual Property (IP) Laws and the global markets of medicines 
create the opportunity for counterfeit medicines. Counterfeiters always 
follow the money. High pricing ratios attract them to counterfeit 
expensive patented and trademark medicines (58). 
  
In sub-Saharan Africa many counterfeit and substandard medicines are 
sold at lower prices than expensive patented products. For example, in 
the US the triple combination of antiretroviral treatment costs over 
$11,000 per year. However in Africa, unlicensed generic companies sell 
an annual supply of a similar but poorer quality treatment  for $244 (a 
³SULFLQJ UDWLR´ RI  (58). Others have found that vaccines and 
contraceptives are much more highly priced (pricing ratio 200:1). Despite 
the efforts of relevant pharmaceutical companies and IP laws, criminal 
counterfeiting is still present (58). 
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The increasing pharmaceutical trade via the Internet has a significant 
impact on the entry and availability of counterfeit products into the 
international markets (61). This facilitates the availability and the spread 
of counterfeit medicines worldwide.  
 
Less quality assurance in low-and middle-income countries are the most 
common reasons for producing substandard medicines (50). Poor quality 
control, a limited number of Good Manufacturing Practice (GMP) certified 
manufacturers and the challenges of limited resources result in a 
widespread use of substandard and counterfeit drugs and few child-
friendly formulations in these poor countries (1, 50).  
 
The problem is not confined to low- and middle-income countries. 
Individuals from high-income countries are at risk, especially those who 
purchase substandard or counterfeit medicines from poorly regulated 
markets when travelling or through ordering via the Internet (61). 
Recently, in North America, a number of drugs such as atorvastatin, 
filgrastim, growth hormone, erythropoietin, paclitaxel, and gemcitabine 
were found to be counterfeit (54).  
 
Unfortunately these poor quality products still exist in both low-income 
and high-income countries. In the UK, counterfeit Serotide 250mcg, 
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Plavix 75mg, Zeprexa 10mg, and Lipitor 20mg have been reported 
recently (62). To date  little evidence has been identified that NHS 
patients are at risk from  counterfeit medicines (60).    
 
There are many other reasons for the spread of substandard and 
counterfeit medicines worldwide. High costs often coupled with a 
shortage of genuine products, additionally, lack of legislation, inadequate 
liaison between drug regulatory authorities, police, customs, and a lack 
of publicised information among health professionals and the public, all 
encourage the counterfeiting of medicines and make detection difficult 
(48, 52). Presence of counterfeit and substandard drugs in the 
international markets is a result of ineffective regulations and inadequate 
quality control by both importing and exporting countries (51). For this 
reason all governments need to make the regulation of drug 
manufacturing, storage and distribution a priority. 
 
1.6.3 Global efforts for detecting counterfeit medicines 
Drug regulatory authorities and the pharmaceutical industry have been 
criticised for not doing enough to tackle the problem of counterfeit 
medicines (54). In the mid-19th century, widespread adulteration of 
medicines in the UK and USA, particularly quinine, enhanced both the 
UHJXODWLRQ RI PHGLFLQH¶V WUDGH DQG GHWHFWLRQ techniques of counterfeit 
medicine (52). The first resolution against substandard and counterfeit 
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medicines was adopted by the WHA at an international health meeting in 
1988 (50, 63, 64). 
 
In the UK, regulatory guidelines were introduced in order to deal with 
counterfeit medicines. The Trademark and Copyright Act was also passed 
in 1988 to protect owner copyright and patent (54).  
 
A cooperation between the MHRA and the Royal Pharmaceutical Society 
FUHDWHV D V\VWHP IRU FKHFNLQJ UDQGRP VDPSOHV ERWK IURPSKDUPDFLVWV¶
shelves and during their inspections of the facilities of manufacturers and 
distributers. The Medicines Testing Unit of MHRA and the Defective 
Medicines Report Centre (DMRC) collaboratively analyse and assess these 
collected samples in order to detect counterfeit medicines. The MHRA has 
also collaborated with the Royal Pharmaceutical Society to publish 
guidance for helping pharmacists to ensure the security of a legitimate 
supply chain and to recognise counterfeit medicines (60). 
 
1.6.4 Information sharing on counterfeit medicines 
Pharmaceutical companies often keep the information they have about 
counterfeit medicines secret. They believe that informing the public about 
counterfeit medicines deters them from taking genuine medications (54). 
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It is difficult to obtain factual data on the extent of the drug 
counterfeiting problem. Unfortunately, information on the epidemiology 
of counterfeit medicines is also hidden from the public by governmental 
agencies. Health workers and the public do not have  access to the 
databases which would tell them which products are being counterfeited 
at any particular time (54). 
 
Legal pressure on the pharmaceutical industry to take more responsibility 
for informing the public about the counterfeiting of their products has 
increased. Fortunately, some noticeable changes have occurred. The 
Pharmaceutical Security Institution has been established under the 
authority of the International Federation of Pharmaceutical Manufacturers 
Association (IFPMA) to investigate the incidence of counterfeiting and 
report their findings. Most of their reports are only provided to the 
pharmaceutical industry. However, they should make their information 
available both to the competent authorities to enable them to take action, 
and,  ideally to the public (54). 
 
In the UK in 1989, after discovery of counterfeit Ventolin inhalers for 
asthma, the British Department of Health and Glaxo Wellcome 
pharmaceutical company faced strong criticism for hiding information 
from the public. In the UK it has been suggested that a charge of 
µFRUSRUDWHNLOOLQJ¶VKRXOGEHDSSOLHGWRSKDUPDFHXWLFDOFRPSDQLHVZKRGR
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not take responsibility for alerting the public to counterfeit products 
which may contribute to the deaths of patients (54).  
 
In the USA in 2005, the Partnership for Safe Medicines started an 
information programme to alert the public to counterfeit medicines. This 
indicates the importance of reporting unexpected therapeutic failure, in 
case it is related to substandard or counterfeit medicines  (48, 63).  
 
1.6.5 Possible actions against counterfeit problem  
The quality of purchased pharmaceutical products is now accepted as an 
important issue (49). Global efforts should be made to combat 
counterfeit drugs and ensure that high quality drugs are readily available 
(61).  
 
Industry should collaborate with governments and support them 
financially and technically; and share their information in order to curb 
drug counterfeiting (54). Moreover, the availability of inexpensive or 
even free essential medicines, with international technical or financial 
support, will contribute to prevent the spread of counterfeit medicines 
(52, 63). 
 
With the high prevalence of counterfeit medicines, regulatory authorities 
recognise that they have to be stricter in identifying areas of risk and 
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eradicating these illegal products (61). Drug regulators in each country 
should have analytical laboratories for testing suspect samples. 
Collaboration with police forces and customs to create a network for 
exchanging relevant information may help to detect the illegal 
importation or exportation of counterfeit and substandard pharmaceutical 
products (54). Low- and middle-income countries with limited resources 
must make the effort to verify the quality of imported medicines in order 
to reduce the rate of mortality and morbidity caused by substandard and 
counterfeit medicines (51, 53). 
 
Every person who deals with medicines should be alert. Drug prescribers 
and pharmacists should report any incidence of ineffectiveness or 
absence of quality to the national adverse drug reactions monitoring 
system(54).  
 
1.6.6 Counterfeiting threat 
1.6.6.1  Pharmaceutical innovation  
Drug counterfeiting is a concomitant risk to innovation. It is growing 
rapidly in the global pharmaceutical markets. In 2000, the value of 
SKDUPDFHXWLFDOFRXQWHUIHLWLQJLQWKH(8ZDVHVWLPDWHGDWDURXQG¼EQ
In 2003, it had been estimated by the UK-based Anti-Counterfeiting 
Group that pharmaceutical companies lost 5.8% of their annual income 
to drug counterfeiting. Recent estimates of the global market for 
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medicines indicated that it exceeded $500bn, and the annual loss of this 
market from counterfeiting may be over $30bn (58). If true, drug 
counterfeiting must be recognised not only as a major threat to public 
health care, but to innovation also. Therefore, criminal counterfeiting 
must be challenged (58). 
 
1.6.6.2 Therapeutic treatments  
Substandard medicines may have a detrimental effect on the success of 
treatments. This is mainly due to the complete absence of quality 
assurance during their manufacturing process. Many low- and middle-
income countries in particular suffer from insufficient financial, technical 
or human resources to apply such standards. Therefore, they are more 
likely to have substandard and counterfeit products on their markets (54).  
 
In many low- and middle-income countries, treatment failure has been 
linked to the use of substandard and counterfeit drugs. It has been 
estimated that malaria kills 1,000,000 people every year in Africa, 
predominantly children under five (54). It is largely acknowledged that 
the high percentage of substandard or counterfeit anti-malarial drugs 
contributes to these deaths (52). 
 
Serious implications for health may arise from poor quality medicines, 
such as drug resistance, adverse drug reactions and treatment failure 
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(50). For example, the poor quality counterfeit pyrazinamide and 
rifampicin was one of the reasons for the common resistance of 
Mycobacterium tuberculosis (48, 63).  
 
The high prevalence of substandard or counterfeit anti-infective 
medications containing a subtherapeutic quantity of active components, 
exacerbates the increasing rate of drug resistance (52). In Burma, 
substandard cotrimoxazole and chloramphenicol may be the reason for 
the resistance of typhoid to these antibiotics. These negative therapeutic 
results will lead eventually to the failure of treatment and increase the 
demand for the development of new treatments (63).  
 
1.6.6.3 Health  
The prevalence of counterfeiting appears to be increasing and responsible 
for a large impact on public health. It is a major cause of unnecessary 
morbidity and mortality in poorer countries (54). The most vulnerable 
and poorest people in low- and middle-income countries are at the 
greatest risk of counterfeit drugs because these countries have the 
weakest drug regulatory programmes (61). 
 
The threat of counterfeit medicines on patients and public health are 
difficult to evaluate and quantify. In 2001, it was estimated that 192,000 
patients were killed in China by counterfeit medicines (54). Chinese 
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authorities investigated 480,000 cases of counterfeit medicines estimated 
to cost $57m(US). Consequently, they closed 1300 factories involved in 
this tragedy (54). This gives an indication of the scale of the problem and 
the attendant health risk. 
 
Vaccination programmes in many low- and middle-income countries may 
be jeopardised by counterfeit vaccines. In 1995, Niger received a 
donation of meningitis vaccines from Nigeria. Local health authorities 
working with Medicines Sans Frontieres (MSF) discovered these vaccines 
were counterfeit after more than 60,000 people were inoculated with 
fake ones with no traces of active product (31). 
  
1.6.7  &KLOGUHQ¶VDFFHVVWRVDIHPHGLFLQHV 
The problem of access to safe essential medicines in many low- and 
middle-income countries is often associated with substandard and 
counterfeit medicines (52). The following tragedies involving drug 
counterfeiting indicate the scale of the problem and the need to apply 
quality control on drug manufacturing to ensure drug safety and efficacy 
for children (51). A high percentage of deaths in children around the 
world are associated with acute infectious diseases treated with fake 
paediatric formulations (65). Therefore, counterfeit medicines are 
considered to be a serious threat to children worldwide (66, 67).  
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History has indicated that replacing or adulterating intended components 
with toxic ones is responsible for several major incidents of severe 
mortality and morbidity in both adults and children (54). The catastrophic 
results which occurred during the last few decades after giving 
medications containing the industrial solvent diethylene glycol (DEG) are 
clearly illustrated by the large number of deaths (51, 64).  
 
In this thesis, I will explore the effect of substandard and counterfeit 
medicines containing diethylene glycol (DEG) in children. A systematic 
literature review will be performed in order to identify all cases and 
provide guidance to health professionals to hopefully identify future cases 
quickly.  
 
Problems with acccess to health care and medicines are well recognised 
in some developing countries and in developed countries (45-47). 
Accessibility is dependent on attitudes towards childhood illness as well 
as access to health professionals.  For example, a health 
professional/parent who does not consider that a child is in pain is highly 
unlikely to ensure that the child receives analgesia. Medical conditions 
such as epilepsy are, unfortunately, associated with a considerable 
degree of stigma in certain societies. Parents may therefore choose not 
to have their child treated (68-70).  
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We therefore also aimed to study two groups of children who might be 
less likely to have full access to medicines and health care than others. 
These are: (1) children of Asylum Seekers and Refugees; (2) children of 
Gypsies and Travellers.  The Royal College of Paediatrics and Child Health 
have identified these two groups as children who are likely to experience 
inequalities in their state of health (71) resulting from significant 
problems in accessing health care and medical treatment (72, 73). There 
have been relatively few studies looking at access to health care for 
children from these groups and to date there have been no studies in the 
UK on whether these children receive satisfactory drug therapy. 
 
The research reported in this thesis investigates whether children from 
WKH³DWULVN´JURXSVFKLOGUHQRI$V\OXP6HHNHUV5HIXJHHVDQG7UDYHOOHU
communities) are likely to receive fewer medicines than other children. It 
VHHNV WR ILOO D JDS LQ WKH OLWHUDWXUH UHJDUGLQJ FKLOGUHQ¶V DFFHVV WR
medicines and analyses the impact of identified factors on their access to 
health care and medical treatment (43, 73, 74).  
 
My study aims to identify the potential barriers to access to safe 
medicines,  then determine whether they are due to problems in relation 
to access to health care. It also will explore attitudes towards the 
treatment of medical conditions such as pain, asthma and epilepsy. 
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The results of my study will have direct implications for healthcare 
services and seeks to develop better health care for children (67). This 
study will also give individuals who have difficulty accessing health care 
the opportunity to state their opinions on any barriers they have 
encountered to their children receiving the medicines that they require. 
  
1.6.7.1  Layout of thesis 
This thesis is structured in eight chapters, including the present chapter, 
summarised as follows and in Figure (1.1).  
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Figure 1.1: Structure of thesis 
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Chapter 1 - ³*HQHUDO,QWURGXFWLRQ´WKLVacts as a preface to the thesis 
by introducing the key concepts of relevance to the research, defining 
WKHSUREOHPVRIFKLOGUHQ¶VDFFHVVWRPHGLFLQHVhighlighting the concept 
of drug quality, defining the problem of drug counterfeiting and outlining 
the aims and objectives of the study and the structure of the thesis.  
Chapter 2 - ³'LHWK\OHQH *O\FRO 7R[LFLW\ LQ &KLOGUHQ´ WKLV SUHVHQWV D
review of all the relevant publications to date so as to summarise all the 
main aspects of DEG poisoning including epidemiology, toxicity, 
mechanisms of toxicity, clinical features, diagnosis and management. It 
also demonstrates what can happen in the absence of drug quality 
control.   
Chapter 3 - ³3UREOHPV RI $FFHVV WR +HDOWK &DUH DQG 0HGLFLQHV IRU
Asylum Seekers and Refugees ± /LWHUDWXUH 5HYLHZ³ WKLV GLVFXVVHV WKH
published literature concerning barriers to health care for Asylum 
Seekers and Refugees. It starts with a general overview first of their 
background, then of the barriers they might encounter in accessing 
health care including cultural, communication, financial and health 
problems. 
 
Chapter 4 - ³3UREOHPV RI $FFHVV WR +HDOWK &DUH DQG 0HGLFLQHV IRU
Gypsies and Travellers ± Literature Review³WKLVSUHVHQWVWKH OLWHUDWXUH
review related to the current investigation LQWR WKH ³DW ULVN´ JURXSV - 
Gypsies and Travellers. The chapter discusses the relevant published 
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literature and addresses all the aspects of, and barriers relating to, their 
access to health care.  
Chapter 5 - ³0HWKRGRORJ\´WKLVconcerns the data-gathering instrument 
for this study. The last parts of this chapter describe the interview 
schedule and guide, the ethical considerations and analysis processes. 
Chapter 6 - ³5HVXOWV DQG 'LVFXVVLRQ´ WKLV SUHVHQWV DQG GLVFXVVHV WKH
data gathered from the interviews of the Asylum Seeker and Refugee 
parents who were involved in this study. 
Chapter 7 - ³5HVXOWV DQG 'LVFXVVLRQ´ WKLV SUHVHQWV DQG GLVFXVVHV WKH
data gathered from the interviews of the Gypsy and Traveller parents 
who were involved in this study. 
Chapter 8 - ³*HQHUDOGLVFXVVLRQDQG&RQFOXVLRQ´WKLVEULQJVWRJHWKHUDOO
the key findings from this work. The discussion considers and highlights 
the main research findings and their wider implications, while the 
conclusion summarises them. It also offers recommendations and 
suggestions for both future research and further improvements. 
1.7 Summary  
Children have the right to access to safe and effective medicines. This 
means that work needs to be done to improve the availability of safe 
standard paediatric formulations and, simultaneously, to ensure better 
access to them (75). Therefore, WKLVVWXG\FRQVLGHUVFKLOGUHQ¶VDFFHVVWR
safe medicines and highlights the problem of substandard and counterfeit 
medicines.  
  
38 
 
CHAPTER TWO 
 
DIETHYLENE GLYCOL TOXICITY IN 
CHILDREN 
 
2.1 Introduction 
The problem of substandard and counterfeit medicines has been 
highlighted in the previous chapter.  In this chapter, I have focused on 
the specific problems associated with a highly toxic excipient ± diethylene 
glycol (DEG).  This example illustrates the significant toxicity of 
substandard and counterfeit medicines especially in children.   
 
There have been several epidemics where predominantly young children 
have presented with an acute onset of renal failure. Incidents of mass 
poisoning with DEG have occurred in a variety of countries over the last 
20 years, with more than 300 children having died as a consequence.  
These deaths have occurred in separate incidents in different countries 
from three continents (64, 66, 76-78). The deaths were due either to the 
contamination (64, 66, 78) of medicinal products by DEG or the 
deliberate illegal use of DEG as a solvent in a medicinal product (76, 77). 
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Symptoms of DEG poisoning include renal and liver failure, seizures and 
gastro-intestinal bleeding. Outbreaks of unexplained renal failure should 
raise particular concern. Early recognition of DEG poisoning within the 
community is likely to prevent further deaths, by the removal of the 
contaminated/illegal medicines. 
 
DEG consists of two ethylene glycol molecules joined by an ether bond. 
Although first produced in France in 1869, commercial production did not 
begin until 1928.  It proved useful in a variety of industrial settings as an 
excellent solvent or ingredient in consumer products including antifreeze, 
brake fluids, lubricants, cosmetic creams, inks, dyeing agents and 
binding adhesive (75).  It has also been used as a softening agent for 
textiles, paper and packaging materials. It unfortunately has a sweet 
taste which makes it appealing to children. 
 
2.2 Aim 
The aim of reviewing the literature was to summarise all the main 
aspects of DEG poisoning including epidemiology, toxicity, mechanisms of 
toxicity, clinical features, diagnosis and management. 
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2.3 Methods  
A review of DEG poisoning was undertaken. A literature search in the 
MEDLINE, EMBASE, and Pub Med databases (1960-2009) was performed 
(Figure 1).  Key words were diethylene glycol, toxicity, symptoms and 
management.  The search was restricted to data from humans and 
papers published in English.  All articles that mentioned diethylene glycol 
were reviewed.  The following data from the publications were extracted; 
number of children and adults affected, clinical signs and symptoms, 
management and the cause of the outbreak.  Duplicates and unrelated 
abstracts were excluded.  
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Figure 2.1: Flow Chart 
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2.4 Results  
Eighty one abstracts were identified.  The 13 duplications were removed 
leaving a total of 68 publications.   Four of these were in languages other 
than English.  The 64 remaining articles were read and eight of them 
were considered to be not relevant.  This left a total of 56 publications 
from which the data was extracted. 
 
2.4.1 Clinical signs and symptoms 
Most victims of DEG poisoning have a variety of clinical signs and 
symptoms depending on the amount and duration of the exposure.  
During the first period of ingestion, intoxicants stimulate gastrointestinal 
discomfort which usually begins with nausea, vomiting, diarrhoea, 
abdominal pain and bleeding. Other later symptoms include oliguria, 
anuria, metabolic acidosis, liver failure, seizures and acute renal failure 
(Table 2.1).     
Table 2.1: Signs and symptoms of DEG poisoning 
 
Gastrointestinal Nausea, vomiting, diarrhoea, abdominal pain and bleeding, anorexia 
Urinary Diuresis, oliguria, anuria, acute renal failure, flank pain, proteinuria 
Neurological 
CNS depression, encephalopathy, seizures, tremors, weakness, lethargy, 
malaise, coma 
Hepatic Hepatitis, hepatomegaly 
Cardiovascular Hypertension, hypotension, cardiac dysrhythmias 
Respiratory Dyspnoea, tachypnoea, pulmonary oedema 
Metabolic Metabolic acidosis 
Haematological Anaemia 
Others Fever 
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2.4.2 What effect does DEG have on the body? 
Information obtained over the past few decades has demonstrated that 
DEG is a powerful nephrotoxic and neurotoxic poison (75, 79). There are 
some uncertainties regarding the principle cause of renal toxicity and 
neurological effects in DEG poisoning.  Some have raised concern that 
renal toxicity may be induced by the parent compound, but others feel 
that toxic effects are related to the metabolites. DEG is converted to 2-
hydroxyethoxyacetic acid (HEAA) via oxidation by alcohol dehydrogenase. 
 
The minimum lethal dose of DEG in humans is uncertain. There appears 
to be a wide range in relation to toxicity.  Analysis of the data from an 
outbreak in Haiti suggested that the minimum lethal dose was 0.35 
mg/kg (64). However, an outbreak that occurred in Argentina involving 
adults (age range 50-93 years) suggested that the minimal lethal dose 
for adults is likely to be between 0.014 and 0.170 mg/kg (79). 
 
2.4.3 Previous episodes of DEG poisoning 
The first reported episode of poisoning in association with the use of DEG 
in a medicine was in 1938 (80).  DEG was used as a solvent in the 
preparation of sulphanilamide elixir.  The makers of the product were 
unaware of the toxicity of DEG. It is estimated that there were 105 
deaths of which one third were those of children (80). Following this 
episode, legislation was introduced in the US that required formulations 
of new medicines to be tested for safety.  Since then there have been 
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numerous other reported cases of DEG poisoning. Following the episode 
in the USA in the 1930s, there have been five other instances where DEG 
has been used as a solvent (76, 77, 80-83) (Table 2.2).  
 
Table 2.2: DEG used as a solvent 
 
Year Country Deaths 
in 
children 
Overall 
deaths 
Overall 
cases 
Duration 
(months) 
Drug Reference 
1937 USA 34 105 353 2 Sulphanilamide 
elixir 
(80) 
1969 South 
Africa 
7 7 14 2 Sedative (81) 
1987 Spain 0 5 5 ± 1% Silver 
sulphadiazine 
(82) 
1990 Nigeria 47 47 47 4 Paracetamol 
elixir 
(77) 
1990 Bangladesh 51 236 339 36 Paracetamol 
elixir 
(76) 
2008 China 0 12 15 0.5 Armillarisin-A (83) 
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There have been eight episodes where a medicinal product has been 
contaminated with DEG (64, 66, 78, 79, 84-88) (Table 2.3).  
 
Table 2.3: Contamination with DEG 
 
 
The number of deaths per outbreak has ranged from one to over 200. 
The time taken to recognise that the outbreak was associated with DEG 
poisoning has been a major contributing factor to the number of deaths; 
i.e., the sooner it is recognised that this is DEG poisoning, the fewer the 
deaths. Unfortunately, even with prompt recognition, as in Nigeria 2008, 
following the use of a teething formula that was contaminated with DEG, 
there can still be a large number of deaths (66, 88).  This particular 
incident was probably associated with a high number of fatalities (84 
Year Country Deaths 
in 
children 
Overall 
deaths 
Overall 
cases 
Duration 
(months) 
Drug Reference 
1986 India 14 14 14 0.5 Glycerine (84) 
1992 Argentina 0 15 29 ± Upper 
Respiratory 
Tract 
infections 
(URIs) 
medicinal 
agent 
(Propolis 
syrup) 
(79) 
1995 Haiti 85 85 109 21 Paracetamol 
elixir 
(64) 
1998 India 33 33 36 3 Cough syrup (78) 
1998 India 8 8 11 2 Paracetamol (85) 
2005 Australia 0 1 7 0.1 Cleaning fluid (86) 
2006 Panama 0 78 119 10 Cough syrup (87) 
2008 Nigeria 84 84 111 2 Teething 
IRUPXODµ0\
3LNLQ¶ 
(66, 88) 
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children died) because of the young age of the patients exposed to the 
contaminated product. There have also been cases of contamination of 
toothpaste affecting adults in both the USA and Spain (89, 90). 
Fortunately there were no deaths. 
 
2.4.4 Why does DEG poisoning occur? 
All medicines contain a variety of excipients and solvents alongside the 
active drug. This is to make the medicine palatable or soluble. No major 
pharmaceutical company would deliberately use DEG as a solvent 
because they are all aware of its toxicity. Unfortunately the financial 
profit from medicines is huge and because of this there is a proliferation 
of smaller manufacturers who will make unacceptable economies to 
maximise profits (91, 92). 
 
In many cases, the individual/company responsible for the use of DEG as 
a solvent is not identified. However, judicial investigations in China 
identified the pharmaceutical company that deliberately used DEG as a 
solvent (83). Five individuals from the company were subsequently jailed 
for between four and seven years and the Deputy Director of the Food 
and Drug Administration of the region was sacked for negligence (93). 
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2.4.5 Can we prevent future episodes? 
The WHO has recognised the importance of ensuring that medicines are 
prepared safely. They have established WHO Good Manufacturing 
Practice Guidelines (1969) and also established a certification scheme 
(1975) to ensure the quality of pharmaceutical preparations sold in 
international markets (66, 94). These efforts will help to improve the 
quality of medicines available especially within low and lower-middle 
income countries. It is essential that Departments of Health and national 
regulatory agencies support these efforts.     
 
2.4.6 When to suspect DEG poisoning 
Despite the numerous deaths that have occurred in children due to DEG 
poisoning, the vast majority of health professionals worldwide will 
fortunately never see a case. The key issue, however, is for health 
professionals who see more than one case of acute unexplained renal 
failure in children to be aware that DEG poisoning is a possibility. It is 
established that adverse drug reactions are often not recognised (95). 
The lack of awareness of possible drug toxicity is even greater in relation 
to the toxicity of excipients (96).  Additionally, the signs and symptoms 
in association with DEG poisoning (Table 2.2) are extremely diverse. 
Rare causes of acute renal failure such as primary hyperoxaluria may 
affect a single individual but will not result in an outbreak. Doctors and 
pharmacists involved in renal units alongside those involve
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health, however, should be aware of the possibility of DEG poisoning, 
especially if they work in low- and middle-income countries. 
 
2.4.7 Management 
A case report of young children ingesting poisons such as brake fluid 
which contains DEG has highlighted the possibilities of enhancing the 
clearance of DEG (97). This case report alongside others (98) has 
suggested the use of fomepizole which is an alcohol dehydrogenase 
inhibitor that can be administered intravenously (97, 98). Fomepizole (4-
methylpyrazole) is increasingly being used in adults and children 
following poisoning with methanol or ethylene glycol (99). It has minimal 
toxicity and a dose of 15 mg/kg is recommended over a 30-minute time 
period. A further 10 mg/kg can be administered at 12 hour intervals (99, 
100).  
 
In the case report involving a child (97), haemodialysis was used and this 
was associated with a fall in the plasma concentration of DEG. If 
concurrent haemodialysis is used then the fomepizole can be 
administered over four hours (99). These case reports were associated 
with a good clinical outcome, but hospitals in communities where 
poisoning usually occurs are extremely unlikely to be able to cope with 
an outbreak involving large numbers of children experiencing acute renal 
failure. DEG poisoning unfortunately usually occurs in those communities 
with the poorest access to health care. If available, fomepizole and 
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haemodialysis are the treatment of choice for children with acute renal 
failure (101). Options which are more likely to be available in low-income 
countries include peritoneal dialysis and oral ethanol (0.8-1.0 ml/kg 
loading dose followed by 0.15 ml/kg/h of 95% ethanol diluted in orange 
juice)(101). Ethanol, although cheaper, is more toxic than fomepizole 
and is often not available (102, 103).  
 
2.5 Summary  
With the increase in proliferation of counterfeit medicines, DEG poisoning 
is unfortunately likely to occur again. The sudden outbreak of an 
epidemic of acute renal failure among children should make individuals 
consider the possibility of DEG poisoning as a cause. Without any action 
against this kind of medicines counterfeiting, the problem will increase 
and the result will be further deaths of children due to poisoning 
outbreaks (51).  
 
The episodes of DEG poisoning illustrate the problems associated with 
counterfeit medicines. They also illustrate what can happen if there are 
no strict regulations on drug manufacturing (54). It is highly likely that 
not all outbreaks of DEG poisoning have been identified.   
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This chapter has focused on reviewing the literature in relation to DEG 
poisoning.  The following chapter reviews the literature in relation to the 
problems experienced by Asylum Seekers and Refugees.
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CHAPTER THREE 
PROBLEMS OF ACCESS TO HEALTH CARE AND 
MEDICINES FOR ASYLUM SEEKERS AND 
REFUGEES 
    
Review of Literature  
 
3.1 Introduction  
This chapter will explore the literature related to the access to health 
care and medicines in some groups of ethnic minorities such as Asylum 
Seekers, Refugees, Aboriginals, and Latino American.  
 
This will encompass a number of areas in order to provide a 
comprehensive background to the exploration of the concept of access to 
health care, identification and categorisation of specific barriers to 
medicines and healthcare. It will also examine access among the children 
of these minority groups. 
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3.2 Method 
Literature searches of computer databases were performed using OVID, 
MEDLINE (data range, 1950-April 2012), EMBASE (data range, 1980-
April 2012), CINAHL and Pub Med (updated to April 2012), Google 
Scholar (updated to April 2012), published in English, with text and 
medical subject headings.  In addition, manual searches of the reference 
list of relevant studies were used to identify further appropriate papers. 
 
Main inclusion criteria 
The following key criteria were used to refine the search and to identify 
material that would be included in this literature review: 
x Sources covering the last 30 years 
x Evidence-based research 
x Publications in English, including peer review articles, 
extracts from books, case studies, anecdotal reports, 
government and other reports, and primary researches 
x Articles relating to the following terms, health care access, 
utilisation, ethnic minorities, Asylum Seekers, Refugees, 
FKLOGUHQ¶VDFFHVVDQGDFFHVVEDUULHUVWRKHDOWKFare and/or 
medicines. 
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Main exclusion criteria  
x Unrelated abstracts 
x Duplicate articles 
x Non- English sources  
x Other publications not compatible with the inclusion criteria.  
 
3.3 Results  
680 abstracts of publications were identified. Duplicates and unrelated 
abstracts were excluded. The resulting publications were then limited to 
papers published in English of which full texts were obtained and 
screened further to exclude studies not compatible with the inclusion 
FULWHULD8OWLPDWHO\SXEOLVKHGSDSHUVUHODWLQJWRFKLOGUHQ¶VDFFHVVWR
health care were included in this literature review (Figure 3.1). Many of 
the articles I have referred to are review articles. However to further 
explain specific points in these review articles I have referred back to the 
original papers mentioned in these reviews. This is the reason why my 
literature review contains references to many old papers. The format of 
these papers is presented in table (3.1). 
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Figure 3.1: Flow chart 
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Table3.1: Format of Publications 
 
Format No of papers Percentage 
Review   17   16% 
Case report 23 22% 
Overview 2 2% 
Personal  opinion 8 8% 
Study 
(case, prospective,  
retrospective, observational)  
33 32% 
Others 21 20% 
Total 104 100% 
 
  
The results will be presented and discussed in four broad themes which 
have emerged from reviewing the literature:  
x The first section explores the concept of access to health 
care and medicines, involves definition of access to health 
care and discusses equality of access.  
x The second section presents an overview of the concept of 
³DW ULVN´ JURXSV GHILQLQJ WKH WHUPV µ$V\OXP 6HHNHU¶ DQG
µ5HIXJHH¶ DQG SURYLGLQJ EDFNJURXQG LQIRUPDWLRQ IRU ERWK
groups.  
x 6HFWLRQWKUHHSUHVHQWVDQRYHUYLHZRIWKHµDWULVN¶FKLOGUHQ¶V
access which also considers the barriers to health care they 
experienced. 
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x Section four focuses on both general and specific barriers to 
accessing health care and medicines which arise from 
problems not only in the country of origin but also in the 
host country.  
 
These include legal rights, medical screening, detention, housing, 
economic factors, GP-related barriers, health records, language barriers, 
mental health barriers, cultural barriers, stigma and isolation (table 3.2). 
 
Table3.2: List of barriers to accessing health care and medicines  
    
Barriers to Accessing Health Care  and Medicines  
 
x Barriers arising from problems in the country of origin 
x Barriers arising from problems in the host country  
x Legal rights 
x Medical screening 
x Detention   
x Housing  
x Economic factors 
x GP-related barriers 
x Health records 
x Language problems 
x Mental health 
x Cultural  barriers  
x Stigma and discrimination 
x Isolation 
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3.4 Overview of Access to Health Care and Medicines  
3.4.1 Definitions of access to health care 
Six papers (four from the USA ± 104, 105, 107, 109 and two from the UK 
± 106, 108) gave definitions of access to health care. Access to health 
FDUHDQGWUHDWPHQWFDQEHGHILQHGDV³actual and potential entry into the 
health care system´ (104). The US Institution of Medicine defines it as 
³the optimal use of health services to gain the best possible outcome´
while for Rogers et al LWLV³providing the right service, at the right time, 
in the right place´(105, 106). A group of researchers found access to be 
a multi-IDFHWHGFRQFHSWDQGVXJJHVWWKDWLWGHVFULEHVWKH³degree of fit´
and interaction between patients and healthcare services (107). 
 
Maxwell et al (108) and Cunningham et al in a prospective study (109) 
identify access as one of the most important factors in achieving high 
quality health care. However, perceptions of the standards of accessibility 
and acceptability of services may be affected by the attitudes and beliefs 
of both patients and health care providers. 
 
3.4.2 Equality of access to health care and medicines 
Seven papers (four from the UK ± 110-112, 114; two from other 
European countries ± 43, 113 and one from the USA - 45) discussed 
equality of access to health care. Individuals seeking asylum sometimes 
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encounter difficulty through not having the same rights to access health 
care as citizens. This is especially the case when having resided in a new 
country for a year or more while waiting for decisions on their asylum 
claims. Such difficulties may adversely affect their physical and mental 
health (110, 111). 
 
Although international regulations exist to protect immigrant parents and 
their children and ensure that they, especially the children,  have the 
same rights to health care and medicines as the indigenous population, it 
has been recognised and acknowledged that even in developed countries 
not all do have the same access (112, 113). Many studies have been 
conducted in different parts of the world to evaluate the relationship 
between ethnicity and access to medicine. In most of these studies, 
disparities between different groups within a population have been 
recorded and rated in relation to such access. St Clair et al (114) indicate 
that the rate of utilisation of health services may be an objective 
indicator of the availability of access: that is to say, equality of access 
may be assessed in terms of the availability and utilisation of services 
and the health outcomes of such utilisation. 
 
The inequalities in health provision in the USA are well recognised in the 
literature. A prospective study has shown that adult patients from non-
white ethnic minority groups, whether immigrant or indigenous, are less 
likely to receive appropriate analgesia following trauma than white adult 
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patients (45). The provision of health care for some heterogeneous 
marginalised groups in EU countries also seems to be variable in quality 
and quantity, and is often based on minimal standards (43). It has been 
found that access to medicines and treatments for Asylum Seekers in 
some EU countries (such as Austria) is restricted to emergency care only 
(43, 115). 
   
3.5 Overview of Asylum Seekers and Refugees   
Seventeen papers (ten from the UK - 72, 119-122,124, 126, 127, 132, 
137; three from other European countries - 43, 123, 135; three from the 
USA ± 104, 125, 134 and one from Australia - 116) in this literature 
review discussed definitions and background of Asylum Seekers and 
Refugees. The United Nations High Commission for Refugees (UNHCR) 
was established in 1951. At that time the number of Refugees 
internationally was approximately 1.5 million (116). By the end of 2010, 
the number had increased to 15.4 million Refugees and about 850,000 
Asylum Seekers worldwide (117, 118). Particularly distressing are the 
applications for asylum by 15,000 separated or unaccompanied children, 
most of them Afghan or Somali (117). 
 
There has been a fall in the number of people seeking asylum in the UK 
over recent years. In 2008, there were 31,320 people seeking asylum. 
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This had fallen to 22,090 people seeking asylum in 2010 (figure 
3.2)(117).   
  
Figure 3.2: Asylum Applications submitted in UK 2006-2010 
 
 
Source: Asylum Levels and Trends in Industrialized Countries ± 2010 (117) 
  
 
Legal restrictions in access to health care for children and adults in some 
minority groups have been found in many countries. A better 
understanding and increased awareness of the racial, religious, and 
socio-cultural differences of minorities such as Asylum Seekers and 
Refugees seeking care are essential. Such awareness and understanding 
may have an effect on the interaction between these groups of people 
and health care providers and increase their opportunity to access health 
care and medicine (43).  
 
28,320 28,300 
31,320 30,670 
22,090 
2006 2007 2008 2009 2010 
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Mobile populations (including Asylum Seekers and Refugees) are 
considered as ethnic minorities in the UK. Most Asylum seekers and 
Refugees now living in the UK are drawn from a variety of countries 
including Zimbabwe, Pakistan, Iraq, Afghanistan, Somalia, Palestine, Sri 
Lanka and Kosovo (119) (figure 3.3). The reasons behind the dramatic 
fall in the number of Asylum Seekers and Refugees from Zimbabwe in 
2010 may be related to the updated regulation of immigration in the UK 
and that the government of the UK classified Zimbabwe as a safe 
country. Many Asylum Seekers and Refugees are being forced to live in 
poor accommodation and below the poverty threshold due to 
unemployment, both of which threaten their physical and mental health 
(120). These people may experience significant problems in accessing 
health care and medical treatment (43, 72, 121). There have been 
relatively few studies of access to health care for children from these 
groups and to date there have been no studies in the UK on whether 
these children receive satisfactory drug therapy. The Royal College of 
Paediatrics and Child Health has identified children from these two 
groups (Asylum Seekers and Refugees) as likely to experience 
inequalities in access to health care (72). However, in line with the 
International Convention on Economic, Social and Cultural Rights 
(ICESCR), they should have entitlement to free health care and free 
prescribed drugs if needed (119). According to the Convention, 
governments are under specific obligation to place no limits on access to 
medicines for all people (122). 
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Figure 3.3: Top-10 population of asylum applications in UK 2009-2010 
 
 
Source: Asylum Levels and Trends in Industrialized Countries ± 2010 (117) 
 
 
3.5.1 Definitions of Asylum Seekers and Refugees 
The terms Asylum Seeker and Refugee are often used interchangeably or 
incorrectly. There is a difference between them in relation to claim 
status.  
 
An Asylum Seeker is an individual who is seeking international protection 
and his claim for refugee status has not yet been determined (73). 
Groups of Asylum Seekers are often included with minorities. They find 
themselves in a difficult situation as they do not have the same legal 
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rights as the indigenous population or Refugees, and may face limitations 
on many aspects of their daily lives, such as access to health care, while 
they are waiting for decisions on their cases (73, 120). 
 
A Refugee is recognised as such under the 1951 Convention relating to 
the status of Refugees7KH&RQYHQWLRQGHILQHVDµ5HIXJHH¶DVDQ\SHUVRQ
who:  
¶¶RZLQJ WR ZHOO-founded fear of being persecuted for reasons of 
race, religion, nationality, membership of a particular social group 
or political opinion, is outside the country of his nationality and is 
unable or, owing to such fear, is unwilling to avail himself of the 
protection of that country; or who, not having a nationality and 
being outside the country of his former habitual residence as a 
result of such events, is unable or, owing to such fear, is unwilling 
WRUHWXUQWRLW¶¶(123).  
 
Apart from this definition, the Refugee Council in the UK defines a 
µ5HIXJHH¶DVa person who, owing to a well-founded fear of being 
persecuted for reasons of race, religion, nationality, membership of 
a particular social group or political opinion, is outside the country 
of his nationality and is unable or, owing to such fear, is unwilling 
to avail himself of the protection of that country" (124). 
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Refugees were defined by the Geneva Convention as "those 
persons who are forced to leave their countries of origin due to 
well-founded racial, religious, social, political persecution or of its 
possible persecutory threat"(125). 
 
Jones et al (119) defined a Refugee as any person who falls into 
one or more of the following categories (given verbatim):  
x those applying for asylum (refugee) status in the UK 
x those who have been given temporary admission by the 
immigration service while their applications are considered 
x those who have been given exceptional leave to remain in or 
enter the country 
x those who are required to renew their status at the Home 
Office at regular intervals 
x those given refugee status 
x those who gain the right to stay in this country indefinitely 
x those who have had their application refused and are going 
through the appeals process 
x dependants of the above groups 
x other individuals or groups who may fall outside the legal 
definition but who face similar problems²such as those 
entering the country under family reunion rules, policy, or 
discretion. 
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3.5.2 Seeking Asylum & Refugee Status 
The process of individuals seeking asylum and refugee status is, 
according to Burnett et al (126) as follow (given verbatim): 
x Asylum Seeker²asylum claim submitted, awaiting Home 
Office decision. 
x Refugee status (accepted as a Refugee under the Geneva 
Convention)- given leave to remain in the UK for four years, 
and can then apply for settled status (ILR).  
x Indefinite leave to remain (ILR)²given permanent residence 
in Britain indefinitely. Eligible for family reunion for one 
spouse and all children under 18 years, but only if able to 
support family without recourse to public funding. 
x Exceptional leave to remain (ELR)²the Home Office accepts 
there are strong reasons why the person should not return 
to the country of origin and grants the right to stay in the 
UK for four years. Expected to return if the home country 
situation improves. Ineligible for family reunion. 
x Refusal²the person has a right of appeal, within strict time 
limits. 
 
In figure 3.4, the Faculty of Public Health (2008) presented a basic 
overview of asylum process in their briefing statement of the health 
needs of Asylum Seekers (127, 128).  
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           Figure3.4: Asylum process in the UK (source: Faculty of Public Health,     
2008)(128). 
 
 
 
Groups of people or individuals, who leave their original country for 
reasons such as other civil disturbance, natural disasters, famine or in 
order to seek a better life, are not covered by the definition of Refugee. 
This was explained by UNHCR as follows: 
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¶¶5HIXJHHV IOHH EHFDXVH RI WKH WKUHDW RI SHUVHFXWLRQ DQG FDQQRW
return safely to their homes in the prevailing circumstances. An 
economic migrant normally leaves a country voluntarily to seek a 
better life. Should they elect to return home, they would continue 
WRUHFHLYHWKHSURWHFWLRQRIWKHLUJRYHUQPHQW¶¶ (129). 
 
3.5.3 Background of Asylum Seekers & Refugees 
Asylum Seekers and Refugees come from many different cultures and 
countries. In 2007, the largest group of applicants to the European Union 
(EU), representing about 14% of all claims, came from Iraq. The second 
highest percentage of claims, about 6%, came from China. However 4-
5% of claims were from Serbia, Pakistan, the Russian Federation and 
Montenegro (130, 131). Therefore, they are not a homogenous 
population.  
 
In a prospective study, Aday et al (104) indicated that in the EU, most 
Asylum Seekers cross the borders illegally to seek asylum. However, 
everyone has the right to seek asylum if he matches the UN Refugee 
&RQYHQWLRQ¶VGHILQLWLRQRIKDYLQJD µµwell founded fear of persecution on 
the grounds of race, religion, nationality, membership of a particular 
social group or political opinion¶¶(104).  
 
In EU countries, the provision of health care for Asylum Seekers varies 
widely in availability and quality. It is worth noticing that in some EU 
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countries where asylum applications are refused, their rights to health 
care are restricted to emergency treatment (43). They may also be 
stripped of their rights and forced to leave the host country even though 
if they return to their home countries they will be in danger (43). 
 
In the UK, free access to the NHS was formerly offered to failed Asylum 
Seekers, but since 2004 the government has strict regulations for failed 
Asylum Seekers and they only have access to some primary care which 
could soon be withdrawn (43, 115). Now, failed Asylum Seekers are 
denied treatment in NHS hospitals, with the exception of emergency 
treatment or continuing treatment they are already receiving. However, a 
joint review of the policy by the Home Office and the Department of 
Health ruled that children and those who could not return home would be 
allowed free health care (132). 
 
Despite all the efforts by the Committee on Economic, Social and Cultural 
Rights which, in their 2002 UK  monitoring report, stated that Asylum 
Seekers and Refugees are a vulnerable population who must be 
protected from discrimination, the government has failed to incorporate 
access rights within the legislature (122).  
 
Asylum Seekers and Refugees have a wide range of experiences in their 
own and other countries which may create difficulties in their access to 
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health care and impact negatively on their health. Many of these 
vulnerable groups leave their home countries in difficult circumstances, 
often having been exposed to violence or persecution. Their countries of 
origin are often unsafe and unstable politically, economically and socially, 
so they escape and look for another home (131).   
 
Asylum Seekers and Refugees from countries with no developed system 
of primary care will often have a poor knowledge of the UK health care 
system. They therefore expect hospital referral for some medical 
conditions that in the UK are normally treated in primary care. Because 
of their many and varying needs, this often causes Refugees 
disappointment and health workers irritation. However, addressing even 
a few of their needs may result in considerable benefits (120).     
 
It has also been recognised that Asylum Seekers and Refugees are 
vulnerable due to certain pre- and post-migration risk factors. Pre-
migration factors such as refugee trauma and torture affect their health, 
and may result in physical and mental illness. Moreover, those who seek 
asylum have often not had full access to health services in their countries 
of origin because they have been in conflict areas. Post-migration factors 
include language barriers, the length of immigration procedures, 
detention and a lack of knowledge about the health system in the host 
country (43, 133-137).  
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The numbers of Asylum Seekers and Refugees around the world continue 
to increase annually, so health care professionals will similarly be 
increasingly finding themselves having to provide optimum health care 
for this subset of the population (125). 
 
3.6 2YHUYLHZ RI $FFHVV WR +HDOWK &DUH IRU WKH ³$W 5LVN´
Children  
Access of ethnic minority children to health care has been reported in 11 
papers in this review (four from the UK ± 112,120, 145, 146; six from 
the USA ± 138, 140-144 and one from Canada ± 47). Since this research 
IRFXVHVRQFKLOGUHQ¶VDFFHVVWRPHGLFLQHVHVSHFLDOO\FKLOGUHQRI³DWULVN´
groups, this section of the literature review provides an overview of 
access barrier to health care and medicines experienced by those 
children. It includes many evidence-based publications from developed 
countries such as the USA, Canada, the UK, and Australia.  
 
3.6.1    %DUULHUVRIFKLOGUHQ¶VDFFHVVWRKHDOWKFare   
Children of Asylum Seekers and Refugees who come from unsafe 
countries may have experienced torture or violence. Consequently, some 
of these children may have mental health problems. Some psychological 
symptoms, such as anxiety, withdrawal, nightmares and hyperactivity, 
are common and may need psychiatric treatment. Furthermore, the 
children of such groups may not have had the opportunity to complete 
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their immunisations, and records of any immunisations they might have 
received may be unclear (120).  
 
Some marginalised groups encounter specific multiple barriers in 
accessing medicines, barriers which may directly or indirectly affect 
children in these groups more than those in any other groups in society 
(31). These barriers include background issues deriving from the country 
of origin such as relevant reasons for, and method of, immigration; legal 
restrictions; poverty; language and communication problems; difficulties 
in registering with a doctor; a lack of medical records; cultural 
background and beliefs; ethnic issues; mental health problems and 
SDWLHQWV¶ SULRULWLHV UHJDUGLQJ WUHDWPHQW (112). These barriers will be 
discussed in detail in the following sections of this chapter.  
 
Minority group children in some developed countries are affected 
disproportionately by the lack of health insuUDQFHDQGWKHLUSDUHQWV¶ODFN
of knowledge of the healthcare system in the host country  (43, 44). 
Recent research in North America has revealed that in both the USA and 
Canada, children of different ethnic minority groups and/or those without 
insurance may be less likely than indigenous children to access health 
care (45, 47, 138). Wasserman et al (139) indicated that the children of 
Latino immigrants were given a preschool vision test less frequently than 
any other ethnic groups, while Wood et al  reported that these children 
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also missed vaccinations, thus decreasing their immunisation rates 
(140). 
 
Many studies over decades have investigated such reasons for disparity 
in access to medicine by minority groups, and tried to establish ways of 
improving access for poor minority children. Summersett et al (2) in a 
retrospective cohort study found that large numbers of children in the 
developing world suffer from an absolute lack of access to essential 
medicines, caused mainly by the shortage of medical health resources, 
rising unemployment and decreasing or no health insurance. 
 
One US retrospective study found no difference in the treatment of 
children from different ethnic backgrounds presenting with long bone 
fractures in the emergency departments (138). Another, however, found 
that black American children were less likely than their white 
counterparts to receive a prescription medicine. Similarly, uninsured 
American children were less likely than those with private insurance to 
receive a prescription medicine (46), while a recent prospective study in 
Canada (2007) highlighted that premature white Canadian neonates 
were more likely to receive a variety of medicines and interventions than 
aboriginal (Northern First Americans, Inuit and Metis) premature 
neonates (47). 
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In a US cross-sectional study, Halfon et al (141) examined the 
relationship between immigration status and access to health care, 
ILQGLQJ WKDW FLWL]HQV¶ FKLOGUHQ KDG HDVLHU DFFHVV WKDQ QRQ-FLWL]HQV¶ DQG
that children whose parents had lived in the US for less than five years 
were less likely to have health insurance than other groups within the 
population. Halfon (141), and Newacheck (142), also recorded that these 
children received fewer prescriptions, and were at a higher risk of not 
getting specific treatment plans for certain moderately severe medical 
conditions, than white children or African American children (141, 142).  
 
A further barrier may relate to the negative attitudes of health care 
professionals. Two studies in the US indicate that Latino parents claim 
the attitudes of healthcare staff towards their asthmatic children could 
well deter them from seeking treatment for the condition, with mothers 
citing their lack of confidence in the healthcare staff as another barrier 
(143, 144). 
 
With some medical conditions, minority groups may register high rates of 
healthcare service use, which may be influenced by behavioural and 
cultural factors in addition to possible variations in disease prevalence. 
For example, children of South Asian migrants have high emergency 
hospital admission rates for asthma (145). The lack of interaction 
EHWZHHQPHGLFDOVWDIIDQGWKHFKLOGUHQ¶VSDUHQWVDQGRUSDUHQWDOEHOLHIV
can have a negative impact on the management of this condition (145). 
  
74 
 
Multifaceted support needs to be provided to the children of Asylum 
Seekers and Refugees through local schools, by learning and making 
friends (120). Social services can help to provide a sense of security and 
promote self-esteem, as well as supporting the parents to lead as normal 
a life as possible  (120, 146). 
 
3.7 Overview of Barriers to Access Health Care and 
Medicines  
Barriers arising in the country of origin and the host country have been 
discussed in a total of 63 papers of this review.  
x forty one were from the UK (115, 120, 126, 148, 150-156, 158, 
159, 163, 171, 175-178, 180,181,184-186, 189-194, 196-200, 
224, 225, 234-237); 
x thirteen were from the USA (149, 157, 172-174, 187, 
188,211,212,229,230-232); 
x five were from Australia (166-170); 
x three were from other European countries ( 43, 161, 169); 
x one was from Canada. 
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Problems with access to primary health care and medicines are 
recognised in both developing and developed countries, and identifying 
such problems or barriers is essential for the improvement of access for 
both adults and children (2, 147).  
 
Although accessing health care remains an entitlement for such socially 
vulnerable groups as Asylum Seekers and Refugees, the literature shows 
that they experience difficulties in achieving it (110). A study in Islington 
in 1992, reported that 38% of Refugees experienced difficulties when 
trying to register with a GP where prospective patients are asked for a 
valid passport, a document which a Refugee may not have (119).  
Providing health care to these vulnerable people is likely to be associated 
with barriers which may present at any time and at different points on 
the pathway (110, 120). These barriers will be addressed in detail in the 
following sections. 
 
3.7.1 Barriers arising from problems in the country of origin 
Problems originating in the country of origin impact negatively on Asylum 
6HHNHUV¶DQG5HIXJHHV¶DFFHVVWRKHDOWKFDUH3ULPDU\FDUHLQWKHKRPH
country may be poor, with low immunisation rates and limited or no 
records being kept or available (119). Health systems there have 
frequently collapsed (115, 148). These people may have experienced or 
witnessed physical or mental torture, and sexual and other organised 
violence, since most come from countries where there is upheaval and 
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violent conflict (115, 149). They are coping with cultural bereavement, 
traumatic escape histories and family separation ± many, including 
children, have no other relatives in the UK (119). They have had no 
choice but to leave their country of origin, and fear for their safety if they 
are returned by the host country (115). Thus, throughout the period of 
temporary residence they are inordinately preoccupied by worry about 
the future, all of which impacts on the physical and mental health of both 
them and their children (150-152). 
 
3.7.2 Barriers arising from problems in the host country 
Primary care for Asylum Seekers and Refugees needs to start with 
understanding their reasons for flight, psychological traumas and their 
history of exposure to infectious diseases, which may then help to collate 
the medical history and provide appropriate treatment (149). However, 
gaining such understanding is very time-consuming, which in itself acts 
as a deterrent to GPs to register them fully. Their situation may be 
exacerbated by other factors, including language difficulties, the lack of 
an advocate who understands the belief and cultural implications of the 
Asylum Seeker or Refugee and a lack of knowledge of how the health 
system in the host country works (150, 151, 153-156). 
 
A number of these barriers in accessing health care were classified by 
Norredam et al (43) as:  
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I. barriers raised by the ways in which different cultures view illness, 
and the attitudes of health care providers towards their ethnic 
minority patients;  
II. communication or language barriers related to the lack of  
provision of interpreters, resulting in inaccurate information;  
III. ODFN RI $V\OXP6HHNHUV¶ DQG5HIXJHHV¶ NQRZOHGJH RI KHDOWK FDUH
services, due to inadequate information about the health system in 
the host country;  
IV. structural barriers such as the need for identity and medical cards 
in some European countries before they can access health care 
services (43). 
 
A national survey in the US (1976) indicated that the Hispanic population 
of the southwestern United States encounter particular barriers to health 
care arising from (157):  
I. a lack of information about, and familiarity with, the services 
available;  
II. negative social implications;  
III. concerns over discrimination by a service provider and their own  
eligibility to use the services,  
IV. perceived stigma associated with medical diagnosis (157). 
 
Many Asylum Seekers and Refugees have difficulty in accessing health 
care and treatment because of the negative attitude of some of the host 
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FRXQWU\¶VSRSXODWLRQ(119). Ramsey et al (158), reported that a diverse 
range of problems had been identified by 50 GPs, at least 5 of whom 
stated their own anxiety in dealing with Refugee patients with language 
difficulties who therefore consume more time in consultation (158). 
Asylum Seekers and Refugees have been dispersed to places away from 
London and the south-east with no influence in the choice of where they 
are sent by either themselves or the local people in the places to which 
they have been sent, which creates resentment (148). Consequently, 
already traumatised by their experiences, they have become the targets 
of racism and discrimination, both face-to-face and in the local and 
national media (126). The Refugee Council has recommended that all 
service providers should look to combat negative and racist media 
coverage concerning Asylum Seekers and Refugees. Instead, they should 
promote positive images taking account of the oppression and 
discrimination they have suffered, such as recognising them as 
resourceful and capable survivors whose numbers include healthcare and 
other skilled and experienced professionals. Such positive media 
coverage could benefit both hosts and Asylum Seekers and Refugees. 
However, such recommendations have by no means always been 
adopted (148). 
 
Asylum Seekers and Refugees are often given poor housing far from any 
others of their own nationality or culture, which results in further feelings 
of isolation. They are forced into long-term poverty by regulations which 
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prevent them from working. Such destitution leads to further damage to 
physical and mental health (126, 148). 
 
Problems of access for these groups are also compounded by the length 
of time the asylum claims process can take, which can range from a few 
months to several years. The legal access of Asylum Seekers and 
Refugees to health care has changed and varied over time in some 
European countries. In Germany, for example, Asylum Seekers and 
Refugees are given access to the same health care as German nationals 
three years after arrival. However, in Luxembourg, this is granted after 
three months (43). In the UK, Asylum Seekers and Refugees are entitled 
to all NHS services without payment and those who failed are restricted 
to primary care only (119).    
 
3.7.2.1 Legal rights  
The International Covenant on Economic, Social and Cultural Rights 
(ratified by the UK in 1976) guarantees the right of everyone to the 
highest attainable standards of physical and mental health, including 
Asylum Seekers and Refugees who are desperately in need of health 
care. Denying them this only brings negative public health and economic 
consequences (159).  
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However, while local authorities are obliged to house those who have 
achieved refugee status, Asylum Seekers have few rights in UK law 
(148). Legislation in 2000 aimed to reduce the NHS services that could 
be accessed free by overseas individuals to treatment for emergency and 
life-threatening conditions, and some infectious diseases only (though 
excluding HIV/AIDS-positive); and there was a proposal to withdraw 
primary care (115). In the context of the abject poverty of failed Asylum 
Seekers who largely have to survive below subsistence level, this is 
considered by the UNHCR to be unrealistic, impractical and unkind, and 
to raise further barriers to accessing the standard of health care that 
they are entitled to in international law (115).  
 
The legislation also raises ethical questions, and a mechanism needs to 
be established to ensure ethical standards are adhered to (119). Apart 
from the fact that Asylum Seekers and Refugees may be in desperate 
QHHG RI KHDOWK FDUH ZKR GHFLGHV ZKDW LV DQ µHPHUJHQF\¶ µOLIH-
WKUHDWHQLQJ¶ DQG µLQIHFWLRXV¶" (159) 'RFWRUV¶ SURIHVVLRQDO HWKLFV REOLJH
WKHPWRSXWWKHLUSDWLHQWV¶QHHGVILUVWDQGUHFHSWLRQVWDIIDQGKHDOWKFDUH
managers are not competent to judge. If untrained personnel make 
inaccurate and arbitrary decisions, these could affect access even where 
there is entitlement (115). 
  
Currently, Asylum Seekers in the UK can apply for free prescriptions, 
dental and optical treatment, and travel costs to and from hospital; but 
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to access these they have to complete a 16-page form which is only 
available in English from the Health Benefits Division, for a certificate 
which is only valid for six months. These factors may present serious 
barriers to accessing health care especially for those on low income and 
poor or no English  (126). 
 
Hargreaves et al (115) noted that the consequences of these regulations, 
RQ ERWK LQGLYLGXDOV¶ DQG QDWLRQDO KHDOWK FDUH KDG QRW EHHQ WKRXJKW
through, and the restrictions are inconsistent with vaccination priority 
and TB control which require prompt diagnosis and treatment (115). 
Health providers challenged these government policies on the grounds 
that they would create further significant damage to health and access to 
health care (150, 156).  
 
3.7.2.2 Medical screening 
Three categories of medical screening usually apply to new arrivals.  
1) The most common strategy aims to protect the 
population of the host country from any disease 
brought in by Asylum Seekers and Refugees which 
may affect public health. 
2) Some countries, such as Australia and Canada aim to 
exclude those having health disorders such as 
HIV/AIDS in order to avoid their demands on national 
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health insurance programmes. For this reason, the 
International Health Regulations (IHR) permit the 
application of health screening measures for Asylum 
Seekers and Refugees(160).  
3) Screening is important for Asylum Seekers and 
Refugees to improve their general health outlook, for 
example in checking the immunisation status of their 
children (131).   
 
In most European countries, medical screening is systematically offered 
to new Asylum Seekers on arrival. However, in some countries, such as 
France, Austria and Britain, medical screening is carried out in induction 
or reception centres and those who do not enter such centres access 
medical screening randomly (43, 131, 161).  
 
Screening programmes in some European countries, such as Greece, are 
only offered to Asylum Seekers who have applied for permission to work, 
SUHJQDQWZRPHQRULQFRQQHFWLRQZLWKFKLOGUHQ¶VYDFFLQDWLRQSURJUDPPHV
(43).  
 
The screening of Asylum Seekers is still a debatable matter, based on the 
principles of medical ethics and fundamental human rights which insist 
on respect for human freedom, dignity and cultural differences (131, 
162). Despite the introduction in many countries of screening 
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programmes for tuberculosis, HIV infection and other disorders, such 
procedures are also criticised on both ethical and epidemiological 
grounds. A positive HIV diagnosis for example, often leads to 
discrimination and stigmatisation. Mandatory screening and the lack of 
FRQILGHQWLDOLW\ RYHU WHVW UHVXOWV UXQ FRXQWHU WR:+2¶V JXLGDQFH RQ+,9
testing and counselling(131, 163, 164). Furthermore, the International 
Organisation for Migration (IOM) indicates that it is not fair to refuse or 
exclude admission of those whose test positive for HIV. Such action may 
deny appropriate treatment to people in need of it (131, 165).  
      
Many countries clearly implement such screening programmes in ways 
which act against both the spirit and the letter of such recommendations. 
However, WHO does not have the power to enforce them because each 
country has the right to control its own border (131).  
 
3.7.2.3 Detention 
Children may be held in detention with their parents who are the primary 
detainees. Because detention centres are usually in isolated areas, and 
are surrounded by barbed wire, social, health and legal staff find them 
difficult to access. Violence among inmates is an endemic risk, yet 
children are held for indeterminate periods of social and cultural isolation 
in close confinement with adults in these centres (166).   
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In a study by Mares & Jureidini (167) of 16 adults and 20 children in 
detention for 1-2 years in Australia, all the children had at least one 
parent with mental health problems (only two of whom had these prior to 
arrival in Australia). Of the adults, 87% suffered from major depression, 
56% showed clinical symptoms of Post-Traumatic Stress Disorder 
(PTSD), 25% had a psychotic illness and 31% had made significant 
repeated attempts to self-KDUP $OO WKLV LPSDFWHG RQ WKH FKLOGUHQ¶V
mental health and wellbeing. Ten of the children were under the age of 5 
years and five of them exhibited delays in language development. Social 
and emotional development problems, difficulty in accepting regulations 
and attachment problems were also observed. There were nocturnal 
symptoms such as enuresis, and sleep disturbances including 
nightmares, sleepwalking and night terrors. In some cases, severe 
symptoms of distress included mutism, refusal to eat and drink and other 
stereotypical behaviour (167). 
 
Among the six to 17-year-olds there were also extensive mental health 
problems. All ten had PTSD, major depression and suicidal ideation, while 
eight had self-harmed ± indeed, a culture of self-harm among detainees 
was noted. Seven showed symptoms of anxiety disorder while five had 
persistent physical health symptoms; and boredom, a sense of injustice, 
difficulty in sleeping, anxiety over delays in educational progress and a 
sense of shame were consistently reported (167). At a 12-month follow-
up assessment the well-being of the five families still in detention had 
further deteriorated. Furthermore, among those who had now been 
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released an initially improved sense of well-being had proved to be 
transitory (167, 168). 
 
Steel et al (169) also conducted a study of mental health difficulties 
among 10 detained families in Australia. 14 adults and 20 children were 
detained for a minimum of two years. All the adults had experienced 
traumatic events prior to leaving their home country as well as en route 
to Australia (169). 
 
The prevalence of psychiatric disorders in both adults and children 
showed a marked increase during detention. While 21% of adults 
retrospectively reported symptoms that would lead to a diagnosis of 
major depressive disorder, and 50% were also retrospectively diagnosed 
with PTSD, the proportion after detention was 100% and 86% 
respectively. Two (14%) were diagnosed in detention with severe 
depressive disorder with psychotic features. Prior to detention none of 
the participants had experienced suicidal ideation, nor had they self-
harmed, whereas following detention 93% of adults experienced 
permanent suicidal ideation. Overall, a threefold increase in psychiatric 
problems was reported (169, 170). Furthermore, parents reported a 
marked decrease in their parenting abilities as a result of detention, 
ZKLFKFDXVHGWKHPGLVWUHVV2QO\RQH IHOW µDEOH WRFDUH IRUDQGVXSSRUW
FKLOGUHQ¶ LQ GHWHQWLRQ ZKHUHDV DOO VWDWHG WKH\ FRXOG GR WKLV SULRU WR 
detention (169). 
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Among detained children, a tenfold increase in psychiatric disturbance 
and disorders, compared with retrospective pre-detention diagnoses, was 
reported. At the time of assessment all were diagnosed with at least one 
psychiatric disorder, while 80% exhibited multiple disorders. In 
detention, 50% were diagnosed with PTSD, including some re-
experiencing symptoms directly related to events in detention. All but 
one was diagnosed with major depressive disorder, 50% with separation 
anxiety disorder and 45% with oppositional defiant disorder. Of the 20% 
suffering from enuresis four out of seven children were in the normal age 
range for this disorder. Suicidal ideation affected 55%, while 25% had 
self-harmed by head-banging or wrist-cutting. Before detention, by 
comparison, only one child had exhibited criteria for multiple disorders 
(depression, PTSD and separation anxiety), while two others were 
retrospectively diagnosed as suffering from either depression or 
separation anxiety (169, 170). 
 
All the participants in these studies reported experiencing traumatic 
events during detention. Upsetting memories of the time in detention, 
DQG µLPDJHV RI WKUHDWHQLQJ RU KXPLOLDWLQJ HYHQWV LQ GHWHQWLRQ¶ FDXVHG
distress to all the adults and 90% of children in one study. The adults all 
UHSRUWHG µIHHOLQJH[WUHPHO\VDGDQGKRSHOHVV¶DQGIHHOLQJVRI LQFUHDVHG
anger, while all the other detention-related symptoms discussed above 
caused distress in 86-100% of adults and 53-90% of children. The 
negative effects of detention on children derive from both the effect of 
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GHWHQWLRQ RQ WKHLU SDUHQWV¶ PHQWDO KHDOWK WR ZKLFK FKLOGUHQ DUH KLJKO\
sensitive, and the detention environment itself, with children exhibiting 
separation anxiety, disruptive behaviour and impaired cognitive 
development (169).  
 
Although both studies are limited by methodological problems, the 
findings nevertheless suggest that an overall deterioration occurs as a 
result of both the detention process itself and specific negative 
H[SHULHQFHV ZKLOH LQ GHWHQWLRQ DQG WKDW FKLOGUHQ¶V PHQWDO KHDOWK LV
directly affected both by the effect of detention on their parents and by 
their own first hand experiences (169, 171).  
 
3.7.2.4 Housing 
While Asylum Seekers in the UK have no rights to housing, local 
authorities are obliged to find accommodation for those who have 
achieved refugee status (119). However, there is widespread and 
dissatisfaction among Refugees over the location of housing, which is 
concentrated wherever local authorities have made it available rather 
than near others from the same or similar ethnic or cultural backgrounds 
(119).  
 
The quality is often poor. In the early years of the 21st century, up to 
2,600 people per month were dispersed in this way to regions outside 
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London and the south-HDVW &KLOGUHQ¶V KHDOWK LV HVSHFLDOO\ VHQVLWLYH WR
poor accommodation and the resulting parental stress, to the extent 
where both the physical and mental health of the whole family are 
affected (148). Furthermore, if such housing is distant from appropriately 
developed health services, these will be difficult to access especially if 
there are no other people of the same ethnic origin established in the 
area who might help them do so. This is also the case for Asylum 
Seekers who, though they may have been given access to some free 
NHS services in theory, in practice these can be hard or impossible to 
reach and therefore use (126, 148). 
 
In previous studies conducted with families from different population 
groups in the US, such as Hispanics , Wood et al (140) and Lewis et al 
(172) reported claims from parents in such vulnerable groups that 
transport difficulties and excessive waiting times for medical care also 
IXUWKHU FDXVHG WKHP WR GHIHU WKHLU FKLOGUHQ¶V PHGLFDO YLVLWV ,Q WKHVH
studies parents also cited transport problems to routine clinic visits for 
their children as among their most common difficulties, with more than 
35% of Latino mothers of children with asthma reporting that lack of 
WUDQVSRUW UHIOHFWHG QHJDWLYHO\ RQ WKHLU FKLOGUHQ¶V DFFHVV WR WUHDWPHQW
(140, 172).  
 
The area of residence itself was considered to be a further barrier to 
health care. Geographical inequalities affecting service provision remain 
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significant, especially in rural areas.  In the US, for example, children 
living in suburbs were more likely to be up to date with vaccinations than 
those living in urban or rural areas, and those who were not covered by 
health insurance. Where people live in relation to healthcare providers 
plays a significant role in accessing health care (173). A study of Latino 
immigrants in the US indicated that their children with chronic illnesses 
living in the south or west were more likely to be uninsured than those in 
the north-east or mid-west (174). 
 
3.7.2.5 Economic factors 
Health is affected by poverty, and many Asylum Seekers in the UK live 
below the poverty line (126). Legislation introduced at the turn of this 
century allowed Asylum Seekers a maximum of 70% of the state benefit 
level (then £36.54) for a single adult person per week. Of this, £10 was 
paid in cash, the remainder in vouchers to be exchanged for goods in 
participating shops. However, retailers were not allowed to give change 
ZKHQH[FKDQJLQJYRXFKHUVZKLFKFRPELQHGZLWK5HIXJHHV¶GLIILFXOWLes in 
understanding the system, ensured that the allowances were in practice, 
worth less in actual use than their face value suggests (126, 148).  
 
Asylum Seekers are forbidden to work and therefore prevented from 
supplementing their income, and as a result they are trapped in a 
humiliating poverty and absolute dependence likely to have serious 
consequences for their psychological and mental as well as their physical 
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health (120, 126). Connelly et al (148) suggested that all service 
providers should monitor sensitively the health of Asylum Seekers forced 
to live below the poverty line in this way, devoid of human right (148). 
Hargreaves, Hogan, Singer, and Williams (156, 175-177) found that 
poverty combined with social dislocation is especially liable to affect the 
mental health of both parents and their children. Health care provision 
must be complemented by housing, income and social support to achieve 
DQLQGLYLGXDO¶VJRRGKHDOWK(150).  
 
Hargreaves et al (115) concluded that it is important to manage the 
health problems that are in themselves important but not urgent, life-
threatening or emergencies, to prevent future illnesses and emergencies. 
It is not cost-effective to make treatment for these inaccessible, or even 
forbid them, if in-patient treatment is consequently needed later. 
Similarly, blocking access to primary care may later put pressure on 
hard-pressed A & E departments through failing to treat symptoms at an 
early stage (115).  
 
Poverty is also a very real barrier to access to medicines in the US, 
ZKHUHWKHFRVWRIPHGLFLQHVDQGGRFWRUV¶IHHVZHUHWKHPRVWIUHTXHQWO\
cited problems for parents from minority groups who do not have health 
insurance (172). Low income was also found to be associated with the 
decrease in the number of children whose parents could not afford health 
insurance visiting emergency departments (142). Previous studies have 
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shown children from most poor Latino families, compared with other US 
children, to be uninsured, a situation which is considered to be a 
significant cause for delaying necessary immunisations (141, 142, 174).  
 
In another US study of Latino parents, more than 60% reported that they 
were unable to afford medicines for their asthmatic children, and that 
they were therefore much less likely than those with higher incomes to 
have access to immunisations and optimal treatment (140).  
 
3.7.2.6 GP-related barriers   
Difficulties in obtaining full registration with a GP, and the entitlement to 
benefits that this brings, are widely identified in the literature from the 
UK as major barriers to accessing health care, treatment and medicines 
for Asylum Seekers and Refugees (119, 150). Previous studies indicate 
difficulties in obtaining GP registration, with lack of language support and 
a failure to meet mental health and chronic illness needs (150, 178). 
 
In a previous study in the UK (1992), 38% of Asylum Seekers and 
Refugees in Islington are recorded as having difficulty in registering 
(119). They may be asked for documentation such as passports, which 
they do not have. Because of their special needs, including language 
problems and other multiple difficulties of which health problems are only 
a part, consultations take a disproportionate amoXQW RI *3V¶ WLPH
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especially when an interpreter is needed. Additionally, they are not 
adequately resourced or compensated for this extra work. But if the 
necessary time is not taken, it leads to unsatisfactory consultations. GPs 
are also uncertain how to mDQDJH$V\OXP6HHNHUV¶DQG5HIXJHHV¶PHQWDO
health problems, and where to refer them; they are therefore reluctant 
to take on people from these minorities, and so they register them 
temporarily rather than fully(119, 153, 154).  
 
New arrivals to the UK may be identified and directed to dedicated 
services where these exist, rather than mainstream practices, because 
the latter find large influxes of new patients - especially those with such 
complex problems - difficult to cope with (150, 152). Temporary 
registration also prevents their access to past records if they exist, and 
removes the entitlement to, and therefore the need for financial 
incentives given to encourage immunisation, smear tests and other 
preventive diagnostic measures not available to the temporarily 
registered (119). 
 
Asylum Seekers in the UK are entitled to all NHS services; and though 
they can be registered with a GP, can only be issued with an exemption 
certificate for prescription, dental and optical care charges once 
accommodation has been allocated(126, 148). 
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However, Jones; Healy; and Trafford (119, 153, 154) recognised that 
PDQ\*3VDUHXQVXUHRI$V\OXP6HHNHUV¶HQWLWOHPHQWV:KLOHRQO\ WKH\
are qualified to judge what constitute tKH µHPHUJHQF\¶ µOLIH-WKUHDWHQLQJ¶
DQGµLQIHFWLRXV¶FRQGLWLRQVIRU$V\OXP6HHNHUVDQG5HIXJHHVWKHLUHWKLFV
oblige them to put the patient first. But some health problems are 
important rather than urgent, creating dilemmas in such fields as 
antenatal screening and care, child immunisation, and asthma and 
diabetes care. Though these conditions may not be life-threatening all 
the time, it is important to manage them so as to prevent future serious 
illnesses and emergencies (115).  
 
Feldman (150) has suggested that to benefit fully from the UK healthcare 
system Asylum Seekers and Refugees need access to primary care and 
full registration. Jones et al (119) indicated that providing all practices 
with guidelines for registering Asylum Seekers and Refugees would help 
to improve primary care for them. Feldman and Aldous (150, 151) 
conclude that full registration with a general practice would enable access 
to all mainstream services and a new patient full health assessment, and 
suggest that as part of core services for Asylum Seekers and Refugees 
practices might be given incentives to register and improve provision for 
these people.  
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3.7.2.7 Health records 
A major barrier to access to health care for Asylum Seekers and 
Refugees in the host country is poor primary care in the country of origin 
such as Bosnia (179), resulting in unavailable health records (119). 
Asylum Seekers and Refugees may have collections of drugs and 
medicines from the country of origin, many of which are inappropriate, 
but on arrival in the host country language problems mean that health 
workers are unable to take an adequate medical history (126). 
Availability of medical records in the host country would improve 
continuity of care and primary care for Refugees, as would recruiting 
healthcare facilitators from each specific Refugee population to help 
establish accurate and detailed medical histories (119). 
 
A further major problem highlighted by Aldous and Wilson (151, 180) is 
the lack of written reports and evaluations by the host country. Problems 
of provision are worsened by poor information on new arrivals and 
difficulty in estimating numbers, especially in London. Such a lack of 
published evaluations and reports constrains further policy development 
that could build on strengths and interventions.  
 
Little evaluation has been undertaken of the effectiveness of 
interventions, and therefore little evidence exists to guide Primary Care 
Trusts (PCTs) and others (150). Wilson (180) and Johnson (181) 
suggested that, PCTs should establish and improve data collection 
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systems to facilitate the planning and development of healthcare 
services, for example numbers and demography, by area. 
 
3.7.2.8 Language problems 
To benefit fully from the UK healthcare system Asylum Seekers and 
Refugees need access to translation, interpretation and advocacy 
services for their own languages (150). Without them they cannot access 
information, communicate with health and social workers and receive 
through them appropriate care(120, 150), nor can medical records be 
accessed where they do exist or created where there are none. Though 
Asylum Seekers and Refugees may have free access to NHS services in 
theory, in practice such language barriers in consultations may make 
these very hard to access (140, 148, 172).  
 
Furthermore, health authorities are often ignorant of which languages are 
spoken by Refugees in their areas, and the extent of the need for 
interpreters. The lack of professional interpreters makes the situation 
even worse for Refugees with psychological and emotional problems 
(119). This lack of translators and failure to use interpreters has been 
identified by health professionals as the largest barrier to accessing 
healthcare services (150) and one that affects most Asylum Seekers and 
Refugees. Language barriers are encountered when trying to travel to 
healthcare facilities, at the reception desk and when trying to make 
appointments, as well as in the consulting room (119). 
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Translators are also able to mediate, explaining the cultural context of 
V\PSWRPV +HDOWK SURIHVVLRQDOV QHHG WR NQRZ WKH µOLIH VWRULHV¶ RI
RefugeeVLIWKH\DUHWREHDEOHWRKHOSWKHP8QGHUVWDQGLQJDSDWLHQW¶V
trauma history, which may include witnessing or experiencing physical 
violence including torture and or sexual violence including rape, often in 
war situations, is vital for effective treatment, especially where such 
experiences may have led to psychiatric, trauma-related or other 
disorders. Primary care for Refugees begins with understanding their 
reasons for flight and their psychological traumas (149). Burnett et al 
(126) indicated that talking about abuse for the first time is therapeutic, 
but health workers are short of time and access to interpreters is 
limited±significant obstacles to accessing such therapy.  
 
A short semi-structured interview was undertaken by Ramsay and Turner 
in London 1993 (158). It demonstrated that because of their special 
QHHGV $V\OXP 6HHNHUV¶ DQG 5HIXJHHV¶ FRQVXOWDWLRQV ZLWK *3V WDNH D
disproportionate amount of their time, with communication problems 
increasing the time needed even more. Yet if this time is not taken, 
consultations may be unsatisfactory (119). Previous studies indicate a 
lack of language support with GPs experiencing increasing pressures of 
work as a result (150, 153).  
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Where specialist clinics using interpreters and nurse practitioners exist 
within general practices, problems can be identified in the first 
consultation, meaning that the second and subsequent consultations can 
be shorter (150). Bilingual link workers can liaise between health 
professionals and minority communities, keep healthcare staff informed, 
facilitate health promotions and increase all-round awareness of the 
services available to Asylum Seekers and Refugees (150, 182). Training 
not only health workers but also reception staff is also important and has 
been requested by both Asylum Seekers and Refugees and their 
professional workers; and the value of training and supporting bilingual 
clerical staff, especially interpreters, has also been remarked on (150, 
182).  
 
Provision for translators and interpreters was found to be variable by 
health authorities. In some areas in London, there was little use of 
bilingual health advocates, owing to the heterogeneity and changes in 
the population of Asylum Seeker and Refugee communities (150, 183). 
In other areas in East London, information is already being produced in 
appropriate languages to improve access to, and the use of, healthcare 
services (150, 184). 
 
In Doncaster in the UK, the use of a specific interpretation service (Dove) 
facilitates continuity with health services, especially where sensitive 
consultations concerning such subjects as rape, torture and mental 
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health problems are involved (150, 185). Harpweb, the Health for 
Asylum Seekers and Refugees Portal, provides electronic multilingual 
resources such as a translated appointment card, and has links to other 
DJHQFLHV¶ UHVRXUFHV /DQJXDJH /LQH ZDV DOVR ZLGHO\ XVHG IRU
interpretation services, while all the healthcare services in Doncaster¶V 
VWXG\ VDLG WKH\ FRXOG DFFHVV WKHLU ORFDO 3&7V¶  LQWHUSUHWDWLRQ
provision(150, 186).  
 
Similar conclusions were reached by Glenn Flores et al (173) in the US, 
where over 25% of Latino parents cited language problems as the 
greatest barrier to accessing health care, resulting in serious 
FRQVHTXHQFHV IRU WKHLU FKLOGUHQ¶V KHDOWK $SSUR[LPDWHO\  RI WKRVH
spoke English either not very well or not at all, and therefore some 
parents did not bring their children for primary or emergency health care 
(173, 187). Several parents also mentioned that, because of their 
language problems, their children received poor medical care resulting 
from misdiagnosis and inappropriate medication(188). 
 
The availability of appropriate interpreters and advocates is essential 
unless health care workers and their Refugee patients speak the same 
language. Using interpreters trusted by those patients, rather than family 
members or friends, provides health workers with valuable information 
on cultural and other relevant issues (120). Such interpreters can also 
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help to discuss such sensitive issues as gynaecological problems, sexual 
health and violation, torture and domestic violence (120).  
 
3.7.2.9 Mental health  
Asylum Seekers and Refugees are known to be at high risk of psychiatric 
and mental disorders. However, they often do not have access to 
appropriate treatment (189). Social and psychiatric aspects represent 
most of the problems of Asylum Seekers and Refugees. Previous surveys 
(120, 163) RQ $V\OXP 6HHNHUV¶ DQG 5HIXJHHV¶ KHDOWK LQ WKH 8. KDYH
found that infectious diseases and mental health problems are both 
considered major concerns for healthcare professionals. These surveys 
also indicated that approximately two third of such groups of people have 
mental disorders such as depression, anxiety and stress disorders. 
Furthermore, due to their experience of torture and organised violence, 
one in every six Refugees has a physical health problem severe enough 
to impact on him/her for life (131, 190).  
 
In the UK, those who are seeking asylum often face many factors which 
may undermine their physical and mental health even further, such as 
lack of social support, racial discrimination, absolute dependence and 
poverty. These factors induce inequalities in access to health care and 
DIIHFW$V\OXP6HHNHUV¶RSSRUWXQLWLHVDQGTXDOLW\RIOLIH(148, 191).  
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Identified incidences of depression, PTSD and suicidal thoughts have 
been recognised amongst Asylum Seekers and Refugees. All these are 
identified as consequences of political oppression, torture, separation 
from families, bereavement, isolation from social help and leaving their 
country, along with cultural and social factors, the effects of detention 
and the legal complexities and uncertain drawn out timescale of the 
asylum process.  Policy makers and service providers therefore expect 
high demands on health services by Asylum Seekers and Refugees (189, 
192).  
 
Asylum Seekers and Refugees may come from countries where there is 
upheaval and violent conflict, where the health systems have collapsed 
and where they fear for their lives if they are returned (115). The high 
incidence of mental illness among them is due to a combination of 
factors, and primary care needs to start with understanding their trauma 
history which may include experiencing or witnessing physical and/or 
sexual violence, including rape and torture, as well as their anxiety until 
their future is decided(115, 119). This stress may lead to psychiatric 
illness, trauma and disorders in addition to the poor physical health 
resulting from what they have been through - PTSD is known to be a 
common consequence of violence ± necessitating a holistic approach to 
their treatment (149).  
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Once they are in the UK many of them are trapped in poor housing, 
poverty, social dislocation and the humiliation of absolute dependence, 
all of which is likely to endanger their mental health still further (148). 
Children are especially sensitive to poor accommodation and parental 
stress and may exhibit symptoms of mental illness (148). 
 
Asylum Seekers and Refugees are at much higher risk of psychiatric 
disorders than others, and may not respond to drugs alone as trauma 
treatment. Behaviour therapies may be appropriate too (149). To get full 
benefit from UK health care these people need full mental and physical 
health assessments, and responses to their mental health problems as 
much as their physical ones (193, 194). Furthermore, western diagnostic 
categories may not describe Refugee problems adequately: for instance, 
symptoms of bereavement and demoralisation may be diagnosed and 
treated as depression(149). 
 
Mental illness coupled with inadequate mental health services constitute 
major problems for survivors of torture and organised violence (163, 
195). The Scrutiny Report on Access to Primary Care recorded that in 
London 2003, mental health provision needs to double or treble to be 
DGHTXDWH DQG WKH ODFN RI SV\FKLDWULF FDUH DSSURSULDWH WR D SDWLHQW¶V
culture and language may represent another barrier to effective 
treatment (186, 196). Limited mental health services are available within 
mental health trusts, or run by independent bodies. Some of these 
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include survivors of torture and violent conflict in their remit, but they 
may not be available to Asylum Seekers and Refugees (197-199). Some 
specialist practices have in-house staff, or in-house sessions with 
community health professionals such as nurses and counsellors. 
Therefore, only more serious cases are referred to mental health 
services. Pilot schemes offering mental health provision in Humberside 
and Yorkshire said they felt under-resourced(150, 200). 
 
3.7.2.10 Cultural barriers 
$V\OXP 6HHNHUV DQG 5HIXJHHV VXIIHU IURP µFXOWXUDO EHUHDYHPHQW DQG
deeply disruptive changes to their lives (119). Problems for the health 
workers caring for them include a lack of understanding of the cultural 
difficulties they encounter in a host country with different cultures, 
practices and values: for example, it is not in the culture of many 
Refugees to make demands (119, 126).  
 
Cultural bereavement is hard to address if Refugees are dispersed to 
areas with no others of the same ethnic origin and without appropriately 
developed services and language support (148). These cultural barriers 
may be addressed through involvement with existing Refugee 
communities which can source interpreters, advocates and link workers, 
and where partnership initiatives have been developed with these 
communities to supply social and counselling services. These links are 
YLWDOO\ LPSRUWDQW LQ GLVVHPLQDWLQJ LQIRUPDWLRQ DQG FDQ IDFLOLWDWH 3&7V¶
  
103 
planning and development of appropriate healthcare services. Training 
health workers and reception staff is important and has been requested 
by both Asylum Seekers and Refugees and their professional workers, 
especially in the field of cultural awareness (150, 181). 
 
Advocates from within Asylum Seeker and Refugee communities in 
particular can play an important role in overcoming cultural barriers. 
Incomers can find it easier to talk about experiences involving personal 
violation and other traumas with an advocate or interpreter who is a 
comparative stranger than with family members, especially those of the 
opposite sex, which their culture may not allow. This can lead more 
quickly to appropriate diagnoses of, and treatments for, physical 
conditions and mental illnesses (120, 150).  
 
Uba (201) highlighted the types of cultural barriers to health care for 
south-east Asian Refugees in the US. These barriers included cultural 
beliefs, and unfamiliarity with western diagnostic techniques and 
treatments leading to misunderstandings over realistic expectations and 
outcomes. 
 
This group of Refugees believed that suffering is unavoidable and the 
length of life is predetermined; therefore, medical care is inappropriate 
and life-saving care is worthless, both of which inhibit them from seeking 
medical help (201). Stoicism in the face of suffering is also believed to be 
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commendable, causing further delays. Beliefs concerning the sources of 
illness differ from western beliefs, leading to a preference for traditional 
herbal medicines over western treatments (201-204). Since the help 
sought varies with the believed source or cause of the illness, it includes 
the involvement of faith healers and shamans as well as western 
providers (205, 206). Western medicine is widely mistrusted, and often 
sought only when traditional treatments have failed, frequently delaying 
until it is too late and leading to an association of western medicine with 
death (207). Some believe that surgery upsets the soul and 
LPPXQLVDWLRQHQGDQJHUVDEDE\¶VVSLULWEHOLHIVZKLFKDUHFOHDUEDUULHUV
to accessing treatment (201, 208, 209). 
 
Once help is sought, unfamiliarity with western diagnostic techniques can 
easily lead to a misinterpretation of their function and further 
disillusionment with western medicine. The use of X-ray is given as an 
example: a doctor uses X-ray as a diagnostic tool, but if a patient thinks 
it is a treatment and experiences no cure as a result, it appears that the 
µWUHDWPHQW¶KDVIDLOHG (208, 210).  
 
If patients believe they have different constitutions from whites, western 
dosages can seem inappropriate. Therefore prescriptions do not get 
dispensed, correct dosages are not taken and the patient may stop 
WDNLQJ WKH PHGLFLQH LI KH IHHOV µFXUHG¶ 6LQFH Whe importance of taking 
medicines as prescribed is also not appreciated, their resulting 
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ineffectiveness is attributed to western medicines being inappropriate for 
Asians, and they avoid further encounters with it (201, 204, 209, 211). 
 
Mikhail et al (212) found that the use of home remedies presented other 
significant barriers to health care. Parents in some vulnerable groups in 
the US preferred to use a combination of over-the-counter (OTC) 
preparations and home remedies as the treatment of first resort for 
fever, cough, rashes, diarrhoea and vomiting, rather than seeking 
professional medical care (173, 212). 
 
:HVWHUQ KHDOWK FDUH SURYLGHUV¶ LJQRUDQFH RI VRXWK-east Asian cultures 
leads to problems in delivering health care effectively. As with many 
Refugee populations, poor doctor-patient communications, often resulting 
from inadequate translation services, create barriers to health care 
delivery (213). Lack of cultural awareness can affect non-verbal 
FRPPXQLFDWLRQWRR,QRQHFXOWXUHSRLQWLQJRQH¶VIRRWDWDQRWKHUSHUVRQ
is seen as insulting. Therefore, a doctor trying to create a relaxed 
atmosphere in a consultation by sitting back and crossing his knees may 
unwittingly be insulting a patient if his foot points towards him as a result 
(201). 
 
Misinterpretation of some of the results of south-east Asian medicine has 
also created barriers. Where traditional treatments have included cutting 
or marking the skin, for example, this has been interpreted as self or 
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domestic abuse (201). Refugees have therefore become wary of seeking 
western medicinal help after some traditional medicines have proved 
ineffective, for fear of the law (115, 201, 214). 
 
Cornelius et al (187) found that differences between Latino and US 
culture were identified as a barrier to accessing health care, with some 
Latino parents stating that it was because healthcare staff did not 
understand their culture that they did not take their children for medical 
care (187). 
 
3.7.2.11 Stigma and discrimination  
Stigma 
/LQN DQG 3KHODQ¶V (215) definition of stigma is based on their 
conceptualisation of it as a process whereby stigma can be generated by 
one or more of five interrelated components:  
1) involves labelling and identifying human differences such as 
ethnicity and skin colour, which are significantly noticeable 
in social contexts;  
2)  involves stereotyping, when undesirable characteristics are 
associated with a person or group;  
3) involves separating and setting stigmatised groups apart 
from others in the population; 
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4)  involves the stigmatised groups losing its status and 
experiencing discrimination through exclusion and being 
linked to undesirable characteristics;  
5)  involves the stigmatisation most often associated with the 
exercise of power. Therefore, a reverse stigmatisation will 
be visited on the low-power groups.  
 
 Discrimination 
$FFRUGLQJ WR /LQN DQG 3KHODQ¶V (215), there are three forms of 
discrimination:  
1) Direct discrimination includes the overt refusal to engage 
with ethnic minorities and rejection of their work 
applications;  
2) Structural discrimination is more subtle and indirect for 
example, not providing treatment of stigmatised diseases 
such as schizophrenia in isolated area or dangerous and 
poor neighbourhoods;  
3) Insidious discrimination which includes stigmatising through 
negative labelling, rendering individuals vulnerable to 
accusations of being stupid and less trustworthy than 
others. 
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Individuals who experience these forms of discrimination may avoid 
contact, and act more defensively and less confidently with others. 
Therefore, strained and constricted social interactions may result (216). 
 
Some ethnic groups seeking asylum in the UK may avoid seeking health 
care due to the stigma associated with their refugee status (217). 
 
Cultural and language barriers, in addition to poor experience of 
healthcare professionals treating Refugees as a burden on NHS 
resources, may play a major role in making some Refugees and Asylum 
Seekers feel stigmatised (217). The impact of such attitudes affects the 
extent to which they access health care and reduce the number of their 
visits to GPs or hospitals (217, 218).  
 
A case study in the US by an American psychologist showed the 
perceived stigma attached to mental illness is a potential barrier in 
accessing Western psychological services by some ethnic groups (219). 
For example, south Asian Refugees believe that alternative Asian 
treatment is better than Western health care. Confidence in their 
indigenous treatment and fear of shame induces a reluctance to seek 
healthcare (69, 70, 220-222). 
 
  
109 
Refugees and Asylum Seekers from south Asia show unfamiliarity with 
mental health services (223). Individuals and families from the south 
Asian community in England, for example, have relatively low hospital 
admission rates for mental illness compared with the indigenous 
population (224). This may be because of the perceived stigma of mental 
or emotional illness, leading to reluctance to accept appropriate 
treatment (189, 224, 225). 
 
Reidpath et al (226) indicated in a prospective study that some cultures 
believe that mental illness is inherited. Consequently, such illness in one 
PHPEHURID IDPLO\FRXOGKDYHVHULRXV LPSOLFDWLRQV IRURWKHUPHPEHUV¶
marriageability and damage the family reputation (226). Furthermore, 
some south Asian families believe that the identification of such illness 
might lead to the curtailment, or even cessation, of benefits by the host 
government, and this information may spread through government with 
detrimental effect on their applications to stay in the country (227-230). 
 
The stigma associated with those classed as Refugees creates a 
significant barrier to accessing health care and medicines not only for 
themselves but also for their children (217, 230). These groups of people 
want the attitude of society towards them to change, and for the 
indigenous population to understand the real reasons behind their 
coming to this country instead of assuming they are only coming to get 
free access to treatments and healthcare services (217). Many Refugees 
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expressed the view that non-discrimination, by healthcare professionals, 
allowed them to feel more comfortable with the health system in the host 
country (217).  
 
Good communication between experienced healthcare professionals and 
Asylum Seekers or Refugees by understanding their needs leads to 
improvement in their access, and reduces the stigma that might be 
associated with refugee status (217). More appropriate health-seeking 
behaviour can be achieved by such communication. Furthermore, 
effective mental health services to all ethnic minorities are provided by 
many agencies which mainly reduce the attached stigma and allow 
Asylum Seekers and Refugees to avoid it (230, 231). 
 
Stigma has a significant negative effect on many of life chances. For an 
Asylum Seeker or Refugee stigma may affect access to medicines and 
medical care or an opportunity for employment and housing (215).  
 
Stigma and stress 
Stigma also generates a constant threat to good health outcomes, both 
mental and physical (215). Denying positives and suffering negatives are 
both considered as major sources of chronic stress and other related 
health problems. The fear of some ethnic groups of being labelled with 
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stigmatised diseases such as epilepsy may cause individuals to delay or 
avoid seeking appropriate treatment altogether (232, 233).  
 
3.7.2.12 Isolation 
A study conducted in London which focused on Iraqi Asylum Seekers 
found there was a clear link between poor social support and depression 
(234). Therefore, developing friendships with people and communities in 
the host country, in addition to maintaining contact with other people 
from their own country but elsewhere in the UK, was found to be the best 
way to achieve optimum mental health. However, hostile media 
headlines have sometimes prevented the establishment of such 
relationships and increased the negative feelings towards minority 
groups, leading to racist attacks (120, 234-237).  
 
There are many community and religious organisations supporting 
Asylum Seekers and Refugees. They provide them with useful 
information and orientate them, helping to reduce the isolation which 
many of them are known to experience (120).  
 
3.8 Combating the Problems   
Burnett et al (120) stated several suggestions need to be made as to 
how the situation for Asylum Seekers and Refugees might be improved. 
Local councils, health authorities and voluntary agencies need to co-
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operate to plan and co-ordinate services. An information pack needs to 
be created to include a certificate of entitlement to NHS services, with 
the NHS also providing primary care. The goal needs to be integration of 
these with existing mainstream services, with Asylum Seekers and 
Refugees having the same rights to health care as the rest of the host 
country population. If actioned, all these would contribute significantly to 
removing some of the main barriers to accessing health care. Poor access 
for these minorities to primary health care in the host country may mean 
that many medical conditions will not be treated (120). 
 
3.9  Summary 
The literature review begins to explain the barriers faced by Asylum 
Seekers and Refugees in accessing health care. These are many but 
those of most significance are related to inequality, stigma and 
discrimination. 
 
This inequality is related to place of residence, ethnicity, socioeconomic 
status, culture, language competence, health records, mental health and 
regulations. These widespread factors create barriers which may limit or 
prevent children and their parents within particular groups from access to 
medicines, and deny them optimal treatment (112-114, 238). 
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Thus, strategies for the 21st century need to focus on ensuring that all 
barriers to accessing health care are recognised and removed (31). Only 
then will there be a guaranteed universal healthcare provision for all 
children (239). Social, cultural and behavioural barriers to optimise 
health care need to be eliminated (240). 
 
This review of the literature demonstrates that these minority groups of 
Asylum Seekers and Refugees have significant barriers to health care and 
medicines. Further research is needed, particularly focussing on children 
and their use of medicines, and whether this is affected by their SDUHQWV¶
status and background.  
 
Following the literature review of work covering Asylum Seekers and 
Refugees, chapter 4 similarly reviews the literature on Gypsies and 
Travellers. 
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CHAPTER FOUR 
PROBLEMS OF ACCESS TO HEALTH CARE AND 
MEDICINES FOR GYPSIES AND TRAVELLERS  
 
Review of Literature   
4.1 Introduction  
This chapter reviews the current literature relevant to another group of 
minorities in the UK - Gypsies and Travellers. It will explore the key 
issues and problems that these groups may encounter. 
 
It begins with important background information on Gypsy and Traveller 
history and lifestyle. This considers their way of travelling and their 
experiences, before focusing on childUHQ¶V KHDOWK DQG W\SHV RI EDUULHUV
and difficulties they face in accessing healthcare services. It finally 
presents some suggestions for combating the problems, and conclusions 
based on the review findings.  
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4.2 Method 
Literature searches of computer databases were performed using OVID, 
MEDLINE (data range, 1950-April 2012), EMBASE (data range, 1980-
April 2012), CINAHL and Pub Med search of documents published from 
1995 to 2012, Google Scholar (updated to April 2012), published in 
English, with text and medical subject headings.  In addition, manual 
searches of the reference list of relevant studies were used to identify 
further appropriate papers. 
 
Main inclusion criteria 
The following key criteria were used to refine the search and to identify 
material that would be included in this literature review: 
x Sources covering the last 30 years 
x Evidence-based research 
x Publications, in English, including peer review articles, 
extracts from books, case studies, anecdotal reports, 
government and other reports, and primary researches. 
x Articles relating to the following terms, health care access, 
HWKQLF PLQRULWLHV *\SV\ 7UDYHOOHU FKLOGUHQ¶V DFFHVV DQG
access barriers to health care and/or medicines. 
 
Main exclusion criteria  
x Unrelated abstracts 
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x Duplicate articles 
x Non- English sources 
x Other publications not compatible with the inclusion criteria.  
 
 
 
4.3 Results  
95 abstracts of publications were identified. Duplicates and unrelated 
abstracts were excluded. The resulting publications were then limited to 
papers published in English of which full texts were obtained and 
screened further to exclude studies not compatible with the inclusion 
criteria. Ultimately, 46 published papers relating to access to health care 
and medicines for Gypsy and Traveller groups were included in this 
literature review (Figure 4.1). Some of the articles I have referred to are 
review articles. However to further explain specific points in these review 
articles I have referred back to the original papers mentioned in these 
reviews. This is the reason why my literature review contains references 
to many old papers. The format of these papers is presented in table 
(4.1). 
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Figure 4.1: Flow chart 
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Table 4.1: Format of publications 
 
Format No of papers Percentage 
Review   6   13% 
Case report 10 22% 
Personal  opinion 8 17% 
Study 
(case, prospective,  
retrospective, observational)  
13 28% 
Others 9 20% 
Total 46 100% 
 
 
The results will be presented and discussed in four broad themes which 
have emerged from reviewing the literature. The first section consists of 
WKH GHILQLWLRQV RI µ*\SV\¶ DQG µ7UDYHOOHU¶ ZLWK DQ RYHUYLHZ RI WKHLU
background and history. The second section explores the concept of 
access to healthcare services and medicines for Gypsies and Travellers. It 
evaluates the health status of this community. The third section presents 
DQRYHUYLHZRIWKHLUFKLOGUHQ¶VDFFHVVWRKHDOWKFDUHDQGPHGLFLQHVZLWKD
focus on the immunisation status of those children. The forth section 
presents an overview on specific barriers to accessing health care and 
medicines which mainly relate to the lifestyle of these groups of the 
population.  
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4.4 Overview of Gypsies and Travellers 
4.4.1  Definitions of Gypsies and Travellers 
The legal definition of Gypsies was first introduced in the 1968 Caravan 
Sites Act, which defined "Gypsies" as: 
 µµpersons of nomadic habit of life, whatever their race or origin, 
but does not include members of an organised group of travelling 
showpeople or persons engaged in travelling circuses travelling 
together as such"(241). 
 
Nowadays, Gypsy and Traveller groups are defined together as: 
µµpersons with a cultural tradition of nomadism or living in a 
caravan; and all other persons of a nomadic lifestyle, whatever 
their race or origin including such persons who, on grounds only of 
WKHLU RZQ RU WKHLU IDPLO\¶V RU GHSHQGDQWV¶ HGXFDWLRQDO RU KHDOWK
needs or old age, have ceased to travel temporarily or 
SHUPDQHQWO\¶¶(241).  
 
However, according to the Housing Act 2004 they are defined as: 
"persons with a cultural tradition of nomadism or of living in a 
caravan; and all other persons of a nomadic habit of life, whatever 
their race or origin, including: 
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I. such persons who, on grounds only of their own or their 
IDPLO\
V RU GHSHQGDQWV¶ HGXFDWLRQDO RU KHDOWK QHHGV RU ROG
age, have ceased to travel temporarily or permanently; and 
II.  members of an organised group of travelling showpeople or 
circus people (whether or not travelling together as 
VXFK´(242). 
 
4.4.2  History of Gypsies and Irish Travellers  
4.4.2.1  Gypsies 
Four papers, in the UK (242-245), summarised the history and 
background of Gypsy and Traveller populations. Historically, about 1000 
years ago Gypsies left their country of origin in the northern Indian sub-
continent and headed towards the west.  Over the centuries they were 
thought to have travelled and settled where they were welcomed (242). 
They are thought to have arrived in England during the reign of Henry 
VIII and at that time the indigenous people thought they had come from 
Egypt (242)7KHUHIRUHWKH\ZHUHFDOOHGµ(J\SWLDQV¶7KHQDPHFKDQJHG
RYHUWLPHWRµ*\SWLDQV¶DQGILQDOO\WRµ*\SVLHV¶7KHLURULJLQDOODQJXDJHLV
Romany which has its roots in Hindi but developed over the years as 
influenced by the host language (242, 246). Today, many of them are bi-
lingual which means they speak Anglo-Romany at home. This is the 
reason behind the absorption of some Romany words into English: for 
LQVWDQFHµSDO¶FDQPHDQµEURWKHU¶DQGµPXVK¶FDQPHDQµPDQ¶ (242, 243). 
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4.4.2.2  Irish Travellers 
There were nomads in the UK when Gypsies arrived (242). Irish 
Travellers moved around the country in bender tents and wagons. Until 
the 19th century they were commonly known as Tinkers which came from 
µWLQFHDUG¶ ZKLFK PHDQV µWLQVPLWK¶ LQ WKHLU DQFLHQW SUH-Gaelic language 
(242). This language is called Shelta and some Travellers still use it 
DORQJVLGH (QJOLVK 7KRXJK FDOOHG µ,ULVK 7UDYHOOHUV¶ E\ WKH (QJOLVK WKH\
FDOO WKHPVHOYHV ¶3DYHH¶7KH\FRQVLGHU WKHPVHOYHV to be the indigenous 
population of Ireland like Native Americans in North America and 
Aborigines in Australia. Although there is occasional intermarriage 
between Irish Travellers and English Gypsies, they remain two distinct 
groups (242).  
 
It is difficult to establish accurately the number of Gypsies and Travellers 
in the UK as they typically live in caravans (245). This is because these 
caravans need to be distinguished from other types of caravans or mobile 
homes. The first official count of such caravans was made in 1979 and 
recorded about 8,000 in England. This rose in 2000 to about 13,000 
caravans that are considered to represent about 10,000 families (244).  
Recent estimates of the Gypsy and Traveller population in the UK vary 
widely from 82,000 to 300,000 including those living in bricks and mortar 
housing (244, 245). 
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4.5 Overview of Access to Health Care Services and 
Medicines  
Nine papers (all from the UK ± 72, 74, 247-253) discussed accessing of 
Gypsies and Travellers to healthcare services. Gypsies and Travellers are 
considered the most socially excluded groups in the UK. Despite some 
legal protection, social and cultural differences as well as their travelling 
lifestyle result in poor access to healthcare (74). These issues are often 
consistent with low expectations of access to healthcare (72, 247). 
 
*\SVLHV¶ DQG 7UDYHOOHUV¶ DFFHVV WR KHDOWKFDUH VHUYLFHV KDV EHHQ
researched by Hawes (248) and Jenkins (249). These two case studies 
indicate that, for a wide variety of reasons, Gypsies and Travellers tend 
to make less use of health services than other members of the 
population, despite having greater need of them.  
 
The Scottish Executive found there was little advocacy support for 
Gypsies and Travellers who have difficulties in accessing health services 
(250, 251)%HDFK¶VZRUNRQFKLOGKRRGDFFLGHQWDOLQMXU\UDWHVKDVVKRZQ
that Gypsies and Travellers regularly use A&E departments for treatment 
for their children, since they have no other option (252). As a result of 
being compulsorily moved on, Travellers have to depend increasingly on 
walk-in centres and A&E departments. Follow-up is therefore difficult, 
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especially in the absence of GP registration. This results in interruption, 
delays and discontinuity in medical treatment and care (253).  
 
4.5.1  General health  
The health of Gypsies and Travellers is likely to be worse than the rest of 
the population at large, even when compared with other deprived groups 
and taking socio-economic status into account (254). Arthritis, asthma 
and chest pain were found to be more prevalent in a group of 260 
Gypsies and Travellers than in an age- and sex-matched comparator 
group (254). Chronic cough or bronchitis was more than three times as 
common as in the comparator group. Results also showed a high rate of 
long-term illness and difficulty with mobility in the Gypsy and Traveller 
Group (table 4.2) (254). 
 
Table 4.2: Health status of Gypsies and Travellers (254) 
 
 Gypsies and Travellers Comparator group 
Arthritis 22% 10% 
Asthma 22% 5% 
Chest pain 34% 22% 
Long-term illness 38% 26% 
Difficulty with mobility  25% 15% 
 
Lower exercise levels among Gypsies and Travellers, and a significant 
lack of fresh foods within an overall much poorer diet, were reported in 
an outreach project in Wrexham (255). These groups were compared 
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with a control group from a deprived local area. The project also 
identified much greater self-reported depression and anxiety rates in the 
Gypsy and Traveller group, and risk of early death from heart disease 
among the men (255). 
 
In a survey of 89 Travellers in the south-west of England, 39% admitted 
to ill-health (256). This included chronic liver disease related to 
substance abuse, and other conditions associated in some cases with 
addiction. Ignorance throughout the community, many of whom were 
diagnosed with diabetes, of the risks factors involved or the significance 
of such a diagnosis, was discovered by Saunders (257). 
 
Phal and Vaile (258) found that infant mortality among these 
communities was three times higher than in the population at large. 
Stillbirth and miscarriage rates were also found to be high (258, 259). 
Brack reported that road traffic accidents, regularly related to speeding 
and alcohol abuse, are causes of premature death among young 
members of these groups (260). Road traffic accidents were responsible 
for 16% of deaths among Irish Travellers in a study in Dublin (260).  
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4.6 Overview of Children¶V +HDOWK DQG WKHLU $FFHVV
Barriers to Health Care   
Nine papers (all from the UK - 252, 254, 256, 261-264, 266, 267) 
VXPPDULVHGFKLOGUHQ¶VKHDOWKVWDWXVRI*\SVLHVDQG7UDYHOOHUVDQGWKeir 
barriers to access. Phal and Vaile (261) found Gypsy and Traveller 
children to be suffering higher rates of illness than their peers (261). 
These children not only encounter many of the same barriers as Asylum 
Seekers and Refugees but their traditional nomadic way of life also 
creates barriers of its own that have major implications for health care. 
Such barriers include a lack of safe, healthy sites for their trailers and the 
constant fear of eviction from roadside and illegal sites. In addition, there 
is a constant fear of active hostility from the local population(261, 262).  
 
Where families are living on inadequate sites, a higher accident rate 
among children, especially for under-fives, including burns, scalds and 
lacerations has been reported (252). Road accidents result from living on 
roadsides and in trailers (254). The typical isolation of their 
accommodation sites make it difficult for them to reach minor injuries 
units, immunisation programmes, dentists and opticians (263). 
Furthermore, complicated registration processes have been seen to be 
strong deterrents (264).  
 
Difficulty in obtaining full registration with a GP often leads to incomplete 
immunisations and a lack of medical records and diagnostic screening 
  
126 
(261). This situation is exacerbated by the families frequently living at 
some distance from healthcare facilities (262). The attitude and 
behaviour of some GPs create barriers for Travellers. 'The most common 
problem for Travellers is difficulty in accessing primary care through GPs 
EHFDXVHRI WKH ODWWHU¶V LQVLVWHQFHRQ WKHLUKDYLQJDSHUPDQHQWDGGUHVV' 
(243). Other GPs will only provide temporary registration, thereby 
excluding them from screening and a range of other services. In extreme 
cases registration is allegedly refused altogether. Those who move most 
frequently have the greatest problems (243, 248, 249). 
 
4.6.1  &KLOGUHQ¶VLPPXQLVDWLRQ 
In a highly mobile population, without access to specialist health visitors 
and with only intermittent access to health care, low levels of 
immunisation can pose specific problems (256, 265). This is particularly 
so in a community in which there is already cultural resistance and 
concern over the possible side-effects of immunisation (266).  
 
In a case study by Hollinger et al (267) in 1993, the immunisation rate 
for diphtheria/tetanus and poliomyelitis (64%) was significantly lower for 
Gypsy and Traveller children than for the general population (90%). Lack 
of knowledge and illiteracy, resulting in the inability to read promotional 
literature, were significant factors in compounding the low rates. 
Furthermore, district child health record systems and parental recall 
methods are unreliable for this mobile population (266). Evidence by 
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Feder  suggests that parental choice not to have pertussis vaccines, 
perhaps due to pollution taboos or adverse MMR TV campaigns, still plays 
a significant role in the low figures (246, 266). Other parents have been 
VKRZQ WR EHOLHYH WKDW SHUWXVVLV DQG PHDVOHV ZHUH µQRUPDO¶ RU HYHQ
µVWUHQJWKHQLQJ¶ LOOQHVVHV (267). Many unvaccinated Gypsy and Traveller 
children caught measles in the 2006-7 epidemic, leading to a subsequent 
debilitation in their general health, more permanent disabilities and even, 
in one instance, death (268). 
 
In their East London study, undertaken between July 1988 and February 
1990, Feder et al (266) compared a group of 72 Traveller and Gypsy 
children with a control group of 106 children. Both groups of children 
were aged between 10 months and six years and both were attempting 
to access two GPs and the paediatric A&E department at Queen Elizabeth 
Hospital in east London. The study revealed that Traveller and Gypsy 
children had significantly lower rates for the completion of immunisation 
programmes for pertussis, measles, diphtheria/tetanus and poliomyelitis 
than the control group (table 4.3).  
Table4.3: Percentage of children completing the primary course of 
immunisation(266) 
 
 
Travellers and Gypsies 
n=72 
Controls 
n=106 
Pertussis 15% 71% 
Diphtheria/tetanus 33% 85% 
Poliomyelitis 31% 87% 
Measles/MMR 20% 71% 
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The study also indicated that the low immunisation rates were 
attributable to both poor access to health services and the rejection of 
certain vaccines by the Traveller and Gypsy parents (266). 
 
Parents have the right to refuse immunisation for their children. Such 
refusal may seem a rational choice to an individual in a particular culture 
even if it may not be in the best interests of the whole community. 
Indeed, the rejection of pertussis vaccine may even have become 
symbolic of the boundary between Traveller Gypsies and settled people, 
though evidence also indicates that if access to immunisation were 
improved the uptake would increase (266, 269, 270). 
 
4.7 Overview of Barriers to Accessing Health Care and 
Medicines  
Specific barriers to accessing health care and medicines for Gypsies and 
Travellers have been discussed in 24 papers (all from the UK ± 74, 243, 
247, 248, 254, 261, 262, 271-286). These include inequalities, 
employment experiences, beliefs, cultures and traditions, low health 
expectations, fatalism, fear of death, avoidance, perinatal and maternity 
problems, racism and discrimination, travelling and mobility, 
accommodation, and mental health (table 4.4). 
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Table 4.4: List of barriers to accessing health care and medicines 
 
 
 
 
 
 
 
 
 
 
4.7.1  Inequalities and problems 
Although published research has not covered the inequalities experienced 
by, and familiar to, Gypsies and Travellers and those working with them 
in equal depth, these inequalities are wide-ranging. Cemlyn et al (243) 
highlights many serious, pervasive, and mutually influential difficulties 
and inequalities suffered by the travelling communities. It is possible to 
identify a smaller number of specific areas of concern, though there could 
be said to be others of equal significance (243). 
 
Clark et al (271) in another case study reported that life expectancy is 
lower than for the population at large. The probability of receiving good, 
Barriers to Accessing Health Care  and Medicines  
x Inequalities and problems 
x Employment experiences 
x Beliefs, cultures and traditions 
x Low health expectations 
x Fatalism, fear of death, avoidance 
x Perinatal and maternity problems 
x Racism and discrimination 
x Travelling and mobility 
x Accommodation and sites 
x Mental health 
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continuous health care is less than for the general population despite 
their greater need. While national educational standards in school are 
ULVLQJWKHLUFKLOGUHQ¶VHGXFDWLRQDODFKLHYHPHQWVDUHORZHUDQGIDOOLQJ$V
a result of abusive and discriminatory behaviour on the part of both 
pupils and staff in secondary schools, Gypsy and Traveller children 
frequently leave the education system when still under age, and 
attendance at secondary level is poor. Furthermore, their children and 
young people are often unable to access pre-school, extra-curricular and 
leisure services (271). 
 
The children are perpetually surrounded by intense and public 
antagonism. This results in insecurity and family tension.  Additionally, 
repeated violent removals from campsites may occur. Children are likely 
to have suffered severe psychological damage (272).  
 
The criminal justice system also treats them unfairly at different stages 
(243). This, combined with additional inequality of treatment affecting 
members of these communities, results in a process of faster and 
younger criminalisation and consequently consignment to earlier custody. 
This process includes bypassing alternative processes for resolving 
disputes in favour of Anti-Social Behaviour Orders (ASBOs) which are 
awarded disproportionately (243). Judicial assumptions about the risk of 
the accused absconding, because they are more likely to skip bail, and a 
lack of secure accommodation result in a high use of remand in custody. 
  
131 
The police and the judiciary all exhibit levels of prejudice against Gypsies 
and Travellers within pre-sentence reports, and acute distress resulting 
from perpetual discrimination and separation from their cultures within 
the prison system itself, often leads to suicide (243, 273).  
 
According to the report of Cemlyn et al (243) in 2009 which evaluates 
the available existing evidence on inequalities and discrimination 
affecting Gypsies and Travellers in England, Scotland and Wales, these 
communities are also frequently excluded from community development 
and cohesion programmes, and political structures, initiatives and 
systems designed to promote inclusion and equality.  Furthermore, 
women who are the victims of domestic violence and others in these 
communities who find themselves in similar highly vulnerable situations 
do not have access to support services appropriate for their culture and 
backgrounds. Indeed, since overall their cultural identity is barely 
acknowledged, if at all, there is substantial negative impact on their self-
esteem and sense of self-worth(243, 274). 
 
4.7.2  Employment experiences 
Little research has been undertaken on the employment traditions of 
Gypsies and Travellers. However, what there is reveals that males tend 
towards self-employment (272), preferably in family groups. Employment 
is usually in areas such as market trading, gardening, building, and 
collecting and dealing in scrap metal. One of the most socially 
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marginalised ethnic groups, and with literacy problems stemming from 
their cultural reluctance to access secondary education, Gypsies and 
Travellers find it difficult, if not impossible, to find work (243, 272). 
Consequently, they live in poverty with all its attendant and problematic 
implications for health care for both adults and children (261, 262). 
Poverty is endemic, since few are able to find work, and the 
unemployment situation breeds disaffection leading increasingly to 
substance abuse among the young. Levels of suicide are high in these 
communities (243).  
 
The increase in numbers of incoming eastern European farm workers has 
impacted severely on opportunities for women, who have traditionally 
undertaken harvesting work and such seasonal crafts as making holly 
wreaths (275). They have further been hit by decreasing outlets for 
these crafts, increasingly expensive raw materials and the cost of renting 
market stalls in the face of low sales (243).  
 
4.7.3  Beliefs, cultures and traditions 
Gypsy and Traveller beliefs, cultures and traditions also create barriers to 
health care. The findings of Van &OHHPSXW¶V TXDOLWDWLYH VWXG\ (74) in 
(2007) described important health beliefs and attitudes among Gypsies 
and Travellers. Poor health was directly attributed to social hardship and 
a poor environment, and the distress they caused (74). Considerable 
distress resulted from the feeling of being confined, the erosion of 
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freedom on a site, and the isolation from both extended family and the 
wider Gypsy and Traveller community and culture resulting from being 
housed. The perception that these hardships were imposed by a hostile 
and racist society also caused great distress (247). Negative social 
attitudes and social exclusion were perceived as damaging to health, 
especially mental health, but there was equal dismay at the prospect of 
social assimilation (276).  
 
Perceptions of what constitutes illness, especially chronic illness, stoicism 
in the face of pain and suffering, and the fear of death leading to a 
refusal to acknowledge symptoms that might portend serious illness such 
as cancer, of which there is universal fear, all prevent medical help being 
sought in good time if at all (254). A traditionally relaxed attitude to 
timekeeping results in missed appointments (72).   
 
Stoicism and self-reliance arise from their adverse experiences, and are 
felt as essential for survival for Gypsies and Travellers (254). Commonly 
H[SUHVVHG DV µEHLQJ WRXJK¶ DQG µQRW DGPLWWLQJ RU VXFFXPELQJ WR PLQRU
KHDOWK FRPSODLQWV¶ WKH FKDUDFWHULVWLFV DUH DVVRFLDWHG ZLWK WKH
understatement of chronic ill health especially with men (74). Parry et al  
(254) compared a group of 293 Gypsy Travellers across 5 locations in the 
UK with a control group of 260. Gypsy Travellers were likely to take pride 
in their self-reliance and spoke of their responsibility to share care for 
their elderly or sick extended family members, deploring particularly the 
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idea of a relative going into a care home (254). There are additional 
health problems related to heredity deriving from generations of 
inbreeding, since Gypsies and Travellers traditionally marry within their 
own communities (74). 
 
Self-reliance is also related to a need to retain control, with failure to do 
so causing high stress levels and citing lack of control over their destinies 
under policies that restrict their self-determination, and authorities that 
exclude them in various ways, as real hardships (254). For some the 
impotence results in despair; others resist and fight hard to achieve as 
much control as possible. Gypsies and Travellers express a sense of 
living in a society that has been hostile for generations, seeming to 
reinforce their belief that they should be wary and slow to trust others 
(254). Such lack of trust and low expectations are sometimes manifested 
as stoicism and increased self-reliance (74, 254). 
 
Strict cultural factors, in particular those relating to women, were found 
by Lehti and Mattson (277), in their study of attendance patterns and 
approaches to health care among Gypsy women on the European 
mainland. These factors had a potentially detrimental effect on their 
willingness to attend for treatment. Relationships with opposite sex 
doctors and sensitivities about medical examinations can be influenced 
by strongly held taboos. A woman would, for example, be particularly 
reticent about discussing issues of a sexual or reproductive nature with 
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male health workers. In the UK, Richardson et al (253) found in their 
case study that women living by the roadside in Kent, with similar 
inhibitions with regard to male staff, reported that inability to access 
female staff had a harmful effect on their health. 
 
4.7.4  Low health expectations 
Acceptance and expectation of ill-health is pervasive, and chronic ill-
health is accepted as long as symptoms can be managed. According to 
Van Cleemput (74), some participants from Gypsies and Travellers gave 
a long list of complaints suffered and they did not consider themselves 
unhealthy. This acceptance is consistent with an inverse relationship of 
access to health care in relation to need, though the relevance of some 
symptoms is not always understood (74). 
  
Long lists of complaints are suffered without considering that this makes 
WKHPµXQKHDOWK\¶6WDWHVRIKHDOWKDUHGHVFULEHG LQ WHUPVRIUHVWULFWLRQV
on ability to perform daily tasks. Many Gypsies and travellers in the Van 
Cleemput Study (74)  described inability to obtain relief for 
unmanageable symptoms, and were resigned to low expectation of 
improvement. Many were surprised to learn how poorly their state of 
general health compared with other matched groups (74). 
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4.7.5  Fatalism, fear of death, avoidance 
A qualitative study was undertaken where 27 gypsies and Travellers were 
recruited in an epidemiological survey of health status (74). Participants 
expressed fatalism regarding health problems, but without evidence of 
acceptance of life-threatening diseases or the experience of dying (74). 
Fear of death was associated with a dread of cancer, seen as leading 
inevitably to death. Therefore, they avoided any possibility of hearing 
that diagnosis. Ignorance, low expectations and fear reduce the chances 
of seeking treatment where early detection is most likely to affect 
prognosis (247, 278).  
 
The study of Van Cleemput indicated that bereavement was also feared, 
and the intensity of grief was universally severe and prolonged, with 
conflicting benefits from close family involvement. Close family ensure 
that bereaved relatives are never left alone ± being alone is so unusual, 
it adds to the acute sense of loss - so family members experience added 
grief in witnessing the grief of close relatives (74).  
 
Bereavement grief is seen as a cause of illness and, indirectly, of death. 
Bereavement coping strategies, notably drug and alcohol abuse, were 
recognised as an added cause of ill health(74, 279). 
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4.7.6  Perinatal and maternity problems  
In a study of 150 Gypsy and Traveller women and 141 settled 
comparators, the Gypsy and Traveller mothers had more pregnancies 
and deliveries than the settled group, and experienced significantly more 
miscarriages (29% as opposed to 16%)(280). More (6.2%) had lost one 
or more children than the comparators (0%) with nine reporting one or 
more stillbirths or neonatal deaths. One had undergone multiple 
stillbirths. Difficulties in accessing maternity care and pregnancy 
screening by mothers living in mobile communities who are often not 
registered with GPs are significant barriers to safe deliveries and healthy 
infants(247, 280).  
 
4.7.7  Racism and discrimination 
&HPO\Q¶VUHSRUW(243) in 2009 indicated that, for the most part, racism 
aimed at the majority of ethnic minorities today is more covert and 
widely regarded as unacceptable. However, that targeted at Gypsies and 
Travellers is still everyday, overt and regarded as warranted. The latter 
includes attacks by the media and blatantly racist pronouncements from 
politicians at both town hall and national level. The frequent failure of 
those in authority to challenge any or all of these contributes to the 
bigotry and ignorance of the majority of the population who live in 
permanent housing (243). 
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Despite the mass of anti-discrimination, equality and human rights 
legislation passed in recent years, Gypsies and Travellers continue to be 
targets for hatred just as they have for centuries (271). Many complaints 
of withdrawals of offers of employment and workplace harassment or 
dismissal, in addition to services being refused or provided with grudging 
reluctance, have been made by members of those communities (243). 
 
4.7.8  Travelling and mobility 
Van Cleemput et al (74) demonstrated that, tKHµWUDYHOOLQJZD\¶HPHUJHG
as a central concept for Gypsies and Travellers. Social and cultural issues 
permeated accounts of health and illness. Key issues concerned 
accommodation and travelling. All described their current situations in 
relation to their ability to travel and all had experienced the traditional 
travelling lifestyle at some time. Accommodation difficulties and the 
threat to the travelling lifestyle dominated (74). Many referred to the 
effect of a travelling lifestyle when describing their experiences of health 
and illness, especially the adversity in the limited accommodation options 
open to them. These issues were often described as the perceived 
benefits and disadvantages of the travelling lifestyle (74). 
 
0RELOLW\UHVXOWVLQKDYLQJµQRIL[HGDGGUHVV¶DQGWKHUHIRUHOLWWOHFKDQFHRI
having a bank account, or accessing benefits and postal services. This 
means Gypsy and Traveller patients cannot be contacted for 
appointments, and miss appointments made orally (and therefore 
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treatment) since reminder letters are not received; while tests may be 
duplicated unnecessarily, due to a lack of patient-held medical records 
(243, 248). 
 
It also means that any local unskilled employment that may be found is 
lost as the community moves on. Mobility also accounts for a lack of 
primary school continuity, while the traditional resistance to secondary 
education in preference to work compounds illiteracy. This means 
training places cannot be accessed or maintained and workplace 
qualifications achieved, all of which leads to the poverty that results in ill 
health impacting on the whole family (266, 281, 282). 
 
Geographical barriers are also considerable for Gypsies and Travellers, 
particularly given their nomadic way of life, since they are constantly 
being  moved on from wherever they may be encamped regardless of 
how far this may move them from healthcare facilities (72, 74, 262).  
 
4.7.8.1  Health-related benefits of travelling 
For some participants there are health-related benefits from the 
travelling lifestyle, including freedom, choice and the ability to live 
among extended family in a hostile world ± important psychologically and 
for support and security (74). Strong regret was expressed by a group of 
Gypsy and Traveller participants that fresh air was lost when they had to 
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move into housing. The ability simply to move on if housed neighbours 
were hostile was stated as important, and  some of these Travellers had 
moved back into trailers for this reason (74). 
 
4.7.8.2  Health-related negative effects of travelling 
Some of the Gypsies and Travellers interviewed by Van Cleemput stated 
that, a diminishing choice of safe stopping places, and lack of basic 
amenities such as running water on unauthorised or poorly serviced 
sites, impact negatively on their health (74). There are also healthcare 
concerns about conditions on official rented sites, which are often in 
hazardous environments. Psychological effects such as a feeling of 
imprisonment on some rented sites are related to the loss of freedom to 
travel and the stress of being forcibly moved on from unofficial sites 
(74). Elderly Participants indicated that wet and damp conditions endured 
over the years results in arthritis and chest complaints (74).  
 
For some participants in the study cited above, poor health has led to a 
move into housing; but the psychological effect and culture shock of 
relinquishing travelling cited above were seen by these respondents as 
counter benefits (74). 
 
Gypsies and Travellers¶ valued travelling lifestyle is perceived as 
increasingly denied. Lack of choice of accommodation and poor site 
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FRQGLWLRQVDUHVHHQDVLQGLFDWLRQVRIVRFLHW\¶VQHJDWLYHYLHZRI7UDYHOOHUV
(74, 247). 
 
4.7.9  Accommodation and sites  
Many of the inequalities experienced by Gypsy and Traveller communities 
commonly derive from a lack of appropriate and safe sites (243). 
Whereas previously, planning policy favoured publicly owned sites under 
the control of the local authority, this has now given way to the practice 
of these communities providing their own sites (243). However, 
opposition from local residents, which is frequently overtly racist in 
language, repeatedly results in the refusal of planning permission to 
develop sites they have bought and own, though appeals against such 
decisions are often upheld (243). 
 
Housing authorities are now required to undertake formal inspections of 
accommodation for Gypsies and Travellers (243). Hence, there is now 
hard evidence VXFK DV YDULDELOLW\ RI DXWKRULWLHV¶ DFFHVV WR JUDQWV IURP
the government, of the extent of under provision and deprivation in this 
area, in particular the paucity of residential and transit sites for those 
preferring not to settle in traditional housing. Although there are some 
good sites these are comparatively few. The majority are in 
unsatisfactory and unhealthy locations, such as under motorways or 
adjacent to sewage treatment plants. On these sites vermin, poor or no 
sanitation, leaking sewage and water pipes, and a lack of clean water, 
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waste disposal facilities, hygiene facilities and fire safety precautions 
pose real dangers to health (243, 271).  
 
Given the shortage of legal sites Gypsies and Travellers are faced with 
the only other option ± namely that of illegal encampments and 
developments (243). This may result in repeated eviction processes 
frequently actioned by private companies (243). This inevitably disrupts 
FKLOGUHQ¶VHGXFDWLRQRSHQLQJVIRUDGXOWHPSOR\PHQWDQGDFFHVVWRKHDOWK
care and, together with the habitual daily trauma of relentless instability 
and lack of facilities, results in deteriorating health (243). 
 
To escape from the endless round of evictions and/or to take advantage 
of essential services, accepting social housing is now becoming the 
reluctant option for many families (271). However, by taking this option 
they have to dislocate from their wider family circle and community, their 
culture and their support systems. They also typically find themselves in 
the most deprived and environmentally disadvantaged housing estates 
and the targets of hostility from equally disadvantaged neighbours 
towards their race and lifestyle (243, 274). Those who have moved into 
settled housing suffer from cultural deprivation arising from the loss of 
their traditional way of life, leading to mental illness (247, 282) 
 
$FFRUGLQJWR1LQHU¶VUHWURVSHFWLYHVWXG\(283), too often accommodation 
that takes into account the cultural needs of specific groups, mainly 
  
143 
Gypsies and Travellers, is unavailable. Consequently, those groups have 
to resort to unauthorised pitching on sites lacking even the most basic 
living requirements. The dearth of educational opportunities and access 
to health care inevitably result in continuous social exclusion (283).  
 
These disparities with the rest of the population in educational 
opportunity and health care were emphasised in a report from the 
Institute for Public Policy Research (IPPR), (281). This called for a 
Traveller Task force to advise on the development of a high-level unit 
and supervise the provision of appropriate sites. Such sites were to come 
under the auspices of local development structures and conform to the 
new planning regulations currently being enforced. Only when such 
appropriate accommodation is provided will the struggle for the basics of 
civilised living, such as clean water, sanitation and emergency health 
care, and the stress of continual insecurity recede, enabling these 
communities to operate and acclimatise positively(243). 
 
4.7.10 Mental health 
Gypsies and Travellers are regularly subjected to a range of stress-
inducing factors including unemployment, racism, bereavement, and 
discrimination - by both public services and the public at large ± as well 
as  chronic accommodation issues (284). Parry et al (247)in an 
epidemiological survey recorded almost three times as much anxiety as 
in other communities, with just over twice the incidence of depression. 
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The feeling that there is no escape from a very poor campsite can lead to 
long-term ill-health, especially in women (247). There are comparatively 
few legal sites nationally, following the removal in 1994 of local 
DXWKRULWLHV¶ OHJDO REOLJDWLRQ WR SURYLGH SHUPDQHQW VLWHV IRU 7UDYHOOHUV¶
trailers (243). This has produced constant anxiety over eviction from 
illegal sites, which affects the physical and mental health of the whole 
community, and coping strategies involving heavy smoking and alcohol 
and drug abuse(247, 266). 
 
Depression and anxiety can also be linked to a move into permanent 
housing, reflecting and resulting from attendant experiences of 
discrimination and racism and a sense of bereavement from losing the 
community life (243, 285). Similarly Richardson et al (253) 
demonstrated that, where the law has affected their right to live on a 
site, or where they have moved to escape violence, in common with 
traditional Gypsies and other Travelling people, new Travellers, also 
reported symptoms of anxiety and depression (253). 
 
The housing charity Shelter, which also took part in the consultation of 
experience of working with Gypsies and Travellers, recorded a need for 
research to be carried out among housed Travellers into the effects of 
permanent housing on their mental health (243). A specialist Traveller 
WHDPUHIHUUHGWR³7UDYHOOHUV¶SV\FKRORJLFDODYHUVLRQWRKRXVLQJDQGKRZ
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KRXVLQJ FDQ LPSDFW RQ 7UDYHOOHUV
 PHQWDO DQG SK\VLFDO KHDOWK´ (243, 
286).  
 
4.8 Combating the Problems  
Cemlyn et al (243) reported some suggestions to combat gypsy and 
Traveller problems. Far from simply waiting for others to address their 
problems and assert their rights, many Gypsy and Traveller organisations 
are proactively striving, together with both voluntary organisations and 
statutory bodies on occasion, to introduce and promote initiatives. The 
aim is to ensure their access to health and social care services, enable 
their children to enjoy a higher standard of education and develop 
opportunities for training, thereby improving their chances of 
employment. They also work to enable their participation in satisfying 
and worthwhile leisure activities and keep their cultural heritage and 
identity alive, as well as encouraging political and community 
involvement (243).  
 
Some have cooperated with local authorities in an effort to reduce the 
ubiquitous hostility by combating the ignorant, inaccurate and negative 
propaganda through the circulation of true information about their needs 
and culture. Furthermore, those Gypsies and Travellers who have 
assimilated into the wider community, perhaps by winning seats on local 
and county councils or playing active parts in national or international 
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organisations, are able to use their positions to raise awareness of the 
needs of their difficulties. This can only be for the good of all (243).  
 
It will take concerted urgent action by the range of organisations, both 
public and private, and the various authorities with whom Gypsies and 
Travellers interact, in addition to the public at large, before those 
minority groups can enjoy the same rights, and access services on the 
same terms, as everyone else. All branches of the media have a part to 
play here, too, not only through proactively speaking out against racism 
and discrimination but also by taking stock of the way they address 
Gypsy and Traveller news stories and attendant issues in their own 
outlets. Until then, the quality of life of Gypsies and Travellers will 
continue to suffer enormous damage as a direct result of the problems 
outlined (243). 
 
4.9 Summary  
Essential work needs to be undertaken to remove the barriers and 
improve access to healthcare services for Gypsies and Travellers in ways 
that are compatible with their traditional lifestyle. Furthermore, their 
particular beliefs and circumstances need to be fully understood and 
appreciated when designing services to improve their health(74).  
The literature reviews in Chapters 3 and 4 have focussed RQ WKHVH ³DW
ULVN´JURXSV and described how the data for the previous research was 
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collected and used. Chapter 5 explains the method and methodology 
involved in research for this thesis.
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CHAPTER FIVE 
&+,/'5(1¶6$&&(66720(',&,1(6 
METHODOLOGY 
 
 
5.1  Introduction 
This chapter will highlight the research methods that were used in order 
to achieve the aims and answer the questions of this study. This will help 
WR LGHQWLI\ LI WKHUH DUH DQ\ SUREOHPV LQ UHODWLRQ WR FKLOGUHQ¶V DFFHVV WR
PHGLFLQHVLQVHYHUDOGLIIHUHQWµµDWULVN¶¶JURups involving Asylum Seekers 
and Refugees, and Gypsies and Travellers respectively in the East 
Midlands region of the UK. It will clarify the research strategy and design, 
the method of data collection and the reasons for choosing them. This 
chapter will also describe the procedure of ethical approval. It will end by 
describing the method of data analysis.  
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5.2  Aims 
The aims of the study were: 
I. to determine the average number of medicines used by 
children over the last month and the last six months by 
means of a semi-structured interview; 
II. to compare the number of medicines received by children 
IURPGLIIHUHQW³DWULVN´JURXSV± children of Asylum Seekers 
and Refugees (Group A), Gypsy and Traveller communities 
(Group B) with a control group of children; 
III. to explore diversity in attitudes towards receiving treatment 
IRU FHUWDLQPHGLFDO FRQGLWLRQVE\SDUHQWV RI WKHVH ³DW ULVN´
groups. 
 
5.2.1 Primary objective 
The primary endpoint of the study is to compare the number of 
PHGLFLQHV UHFHLYHG E\ FKLOGUHQ LQ WKH ³DW ULVN´ JURXSV ZLWK D FRQWURO
group of children to determine any differences in the number of received 
medicines and whether they related to differences in their access to 
health care or attitudes towards treatment. 
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5.2.2 Secondary objective 
The secondary endpoint of the study is to explore whether attitudes 
WRZDUGVWUHDWPHQWDUHGLIIHUHQWEHWZHHQSDUHQWVRI³DWULVN´JURXSVDQG
the control group. 
5.2.3 Hypotheses  
This study is guided by three hypotheses:     
1. &KLOGUHQ IURP ³DW ULVN´ JURXSV are likely to receive fewer 
medicines than other children. 
2. Problems in accessing health care influence the number of 
medicines children receive. 
3. Diversity in parental attitudes towards certain medical 
conditions, such as epilepsy, may influence the number of 
medicines children receive. 
 
 
5.3  Theory of Research Methodology 
5.3.1  Introduction 
The methodology which was used in this research involved both 
quantitative and qualitative methods. Quantitative methods are used to 
compare the number of prescribed mHGLFLQHV UHFHLYHG E\ WKH ³DW ULVN´
groups with the control group over the past month and six months. The 
qualitative element is aimed at exploring and describing parental 
attitudes and whether they affect the treatment given. Johnson & 
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Christensen (287) reported that µµqualitative research seeks a deeper 
understanding of the given research problem or of a phenomenon from 
the perspectives of the study sample¶¶. Different issues can be considered 
in qualitative research, such as the values, opinions, behaviours and 
social contexts of the research sample. This means that the qualitative is 
different from the quantitative, as it searches for a deeper explanation of 
the research questions or phenomena rather than searching for the 
relationship between cause and effect (287).  
  
Quantitative and qualitative research methods differ fundamentally in the 
epistemologies from which they derive and type of information they can 
deliver (288). Each has its applications and limitations, and while one or 
the other may be clearly more appropriate for data collection in some 
research projects, that data collection in others benefits from the use of 
both. It is therefore necessary for researchers to understand fully the 
strengths and limitations of each in order to select the appropriate 
method for their own work (289, 290). Since both qualitative and 
quantitative methods have been used in this study in order to increase 
the robustness of the data, the fundamentals of both methods are briefly 
outlined below. 
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5.3.2  Quantitative Research 
The quantitative method, which may be regarded as traditional, positive, 
experimental or empirical, relies on statistics, measuring and analysing 
not the processes between variables but the causal relationships between 
such variables (291). 
  
Enabling numerical results and findings to be presented visually in tables 
and graphs, it conveys the major attraction of a sense of scientific 
respectability and staunch, independent objectivity (291). Furthermore, 
areas which have already been researched by others, and in which there 
are already existing theories, known variables and an established body of 
literature, may be re-examined (292). 
 
Data is often gathered through questionnaires, by setting up equipment 
and experiments and working with selected comparative groups or 
variables, all of which is, however, time-consuming to prepare and 
operate (293). 
 
In this study, the demonstration of causal relationships between 
identifiable and measurable variables plays a critical role; and 
quantitative forms of presentation, such as graphs and tables, will be 
used to present some of the research findings. 
  
153 
 
5.3.3  Qualitative Research 
A universal definition of qualitative research is far more elusive, since it 
relies on no distinctive theory or paradigm. As described by Denzin et al 
(294), it is widely interdisciplinary. Unlike quantitative research, it may 
be described as interpretative, exploratory, without a single methodology, 
and a field of enquiry in its own right in which, though the variables are 
often unknown, context is of great importance. According to Banister et 
al (295), it aims to identify and encapsulate what it is within us that 
OHDGVXV WR VD\ZKDWZHGRDERXWRXUDFWLRQV ,W LQYROYHV µH[SORUDWLRQ 
elaboration and systematisation of the significance of an identified 
phenomenon and the illuminative representation of the meaning of a 
GHOLPLWHG LVVXH RU SUREOHP¶ DQG LGHQWLILHV SUREOHPV DQG GHILQHV
situations through human beings rather than scientific instruments (296).  
 
5.3.4  Strengths and weaknesses    
There are strengths and weaknesses in both qualitative and quantitative 
methods of research. A number of these strengths and weaknesses in 
both methods were classified by Johnson and Onwuegbuzie (297).  
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5.3.4.1 Quantitative Research 
Strengths 
Quantitative Research according to Johnson and Onwuegbuzie (297) can: 
x test and validate theories of how and why phenomena occur; 
x test hypotheses that existed prior to the data collection; 
x generalise research findings when data are based on an 
adequate number of randomised samples; 
x generalise a research finding when it has been replicated in 
many different populations and subpopulations; 
x provide precise, quantitative, numerical data; 
x lead to data analysis that is relatively less time consuming 
(using statistical software); 
x produce research results that are relatively independent of 
the researcher. 
 
 
Weaknesses 
In Quantitative Research the researcher might inadvertently (297): 
x use categories and theories that  may not reflect local 
FRQVWLWXHQFLHV¶XQGHUVWDQGLQJV 
x miss out on phenomena occurring because of the focus on 
theory or hypothesis testing rather than on theory or 
hypothesis generation (called the confirmation bias); 
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x produce knowledge that may be too abstract and general for 
direct application to specific local situations, contexts, and 
individuals. 
 
5.3.4.2 Qualitative Research  
Strengths 
Qualitative Research according to Johnson and Onwuegbuzie (297) can: 
x EDVH WKH GDWD RQ WKH SDUWLFLSDQWV¶ RZQ FDWHJRULHV RI
meaning; 
x be useful for studying a limited number of cases in depth; 
x be useful for describing complex phenomena; 
x provide individual case information; 
x SURYLGHXQGHUVWDQGLQJDQGGHVFULSWLRQRI SHRSOH¶V SHUVRQDO
experiences of phenomena; 
x describe, in rich detail, phenomena as they are situated and 
embedded in local contexts; 
x allow the researcher to identify relevant contexts and 
settings; 
x produce data which lend themselves to the exploration of 
how and why phenomena occur. 
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Weaknesses 
In Qualitative Research the researcher might (297): 
x produce knowledge specific to a few that may not relate 
generally to other people or other settings. That is, findings 
may be unique to the relatively few people included in the 
research study; 
x find it difficult to make quantitative predictions; 
x find it more difficult to test hypotheses and theories;  
x take more time to collect the data as compared to 
quantitative research; 
x find data analysis time consuming; 
x inadvertently reach conclusions more easily influenced by 
his own personal biases and idiosyncrasies. 
 
It has been necessary to adopt both quantitative and qualitative methods 
DQG DQ LQWHUSUHWLYH SDUDGLJP DV WKH EDVLV IRU WKLV VWXG\¶V UHVHDUFK
methodoORJ\ WR FDSWXUH WKH EUHDGWK DQG ULFKQHVV RI SDUWLFLSDQWV¶
experience in a natural context (298). 
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5.4  Research Methods  
5.4.1  Interviews  
5.4.1.1  Introduction  
An interview is a structured conversation, designed to produce a certain 
outcome, between the interviewer and interviewee(s) (294, 296). 
Though they may be time-consuming to undertake and subjective in 
nature, and the responses difficult to analyse and evaluate, interviews 
may produce rich results for the researcher (299). Interviewees have the 
opportunity to express themselves using their own words, from their own 
viewpoints and in the language which is most natural to them (300, 301). 
This is more likely to reveal the detailed information being sought. 
Interviews are prepared with a view to constructing knowledge between 
the participants in order to generate rather than collect information(302). 
 
The personal interview is a highly valuable way in which to amass in-
depth data for both qualitative and quantitative research (300). 
Participants may have individual biases, or uncertain recall, resulting in 
errors at times (303). The exact wording of questions and the order in 
which they are asked may likewise influence their responses, and 
therefore the results of the research (304). However, the participation 
rate tends to be higher than for questionnaires requiring self-completion, 
since respondees are likely to feel more involved in, and therefore 
motivated by, the process (303). Furthermore, if interviews are 
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conducted in comfortable, familiar surroundings, participants are more 
likely to express their views and feelings more freely (305).  
 
5.4.1.2  Semi-Structured Interviews 
In both qualitative and quantitative research, interviews may range from 
structured to semi-structured and highly structured, depending on their 
purpose and context (300, 304). Many varied types of interview may be 
used ranging from the highly structured formal interview, offering little if 
any scope for flexibility in either sequence or content, to informal 
conversations allowing the interview to develop and adjust during the 
interview process (300, 306).  
 
The semi-structured interview, standing as it does between the 
structured and unstructured, and containing elements of both, is 
fundamentally a set of fairly well structured questions predetermined by 
the interviewer. The exact wording of each question and/or the overall 
order in which questions may be asked may vary for each participant. 
The line of enquiry, however, will be the same for all (303). This 
structure permits similar data to be collected systematically from each 
interviewee, while allowing an interview to be flexible and adapted to 
each participant or workplace, thereby enabling individual issues and 
insights to be explored as they arise (302, 304). 
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5.4.1.3  Defining semi-structured interviews 
Individual interviews, defined by Wilson and Goodall (307) DV ³a 
communication process in which two or more people interact within a 
relational context by asking and answering questions designed to achieve 
a specific purpose,´ ZHUH FHQWUDO WR WKH GDWD-gathering process in this 
project. Anderson (308) defines semi-VWUXFWXUHG LQWHUYLHZLQJ DV ³a 
specialized form of communication between people for a specific purpose 
associated with some agreed subject matter´%U\PDQ(305), recognising 
the need for flexibility within the research process, defines the semi-
stUXFWXUHGLQWHUYLHZDV³a context in which the interviewer has a series of 
questions that are in the general form of an interview schedule but is 
able to vary the sequence of the questions´ 
 
³Displaying empathy and acceptance, conveying respect and creating an 
ethos of trust´ LV DFFRUGLQJ WR %XUQV (301), essential for successful 
interviewing. Creating a relaxing atmosphere encourages the interviewee 
to trust and relate to the researcher, and talk openly and uninhibitedly 
about how he/she feels. For interviewees who might not feel very 
confident in the interview process, such an approach might well reduce 
any negative impact such feelings might have on the interview (309).  
 
The interviewer should take the role of listener rather than that of leader 
in what he/she intends to be relaxed conversations, gently guiding the 
discussions as might be necessary to ensure that all the main issues had 
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been included. While interviewees are able to ask the researcher to 
explain any questions which they may not fully understand, the 
researcher can explore answers more deeply and invite participants to 
amplify their replies ± all of which is advantageous for the accumulation 
of detailed data (310). According to Hutchinson (311)³Interviews permit 
researchers to verify, clarify or alter what they thought happened, to 
achieve a full understanding of an incident and to take into account the 
µOLYHG¶H[SHULHQFHRISDUWLFLSDQWV´(311).  
 
5.4.1.4  Benefits of using a semi-structured interview 
A semi-structured interview aims to collect rich data clarifying 
SDUWLFLSDQWV¶ EDFNJURXQGV DQG SHUVSHFWLYHV DQG GUDZLQJ RXW DFFXUDWH
information about their experiences and views.  
 
The interviewer is required to ensure comparable findings through the 
use of identically worded questions. Yet he also needs to include more 
open questions allowing in-depth exploration of his subject. The semi-
structured interview can exploit the best features of both structured and 
unstructured interviews, while incorporating further important features 
that distinguish them and increase their suitability for this type of 
research (305, 309, 312). 
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With a semi-structured interview, the interviewer predetermines the 
WRSLFVWREHFRYHUHGDQGSUHSDUHVDOLVWRITXHVWLRQVRUµLQWHUYLHZJXLGH¶
(305). Since this gives the interview structure and direction while still 
allowing for flexibility,  it is recommended by Patton (313). The flexibility 
WKDWSHUPLWV WKHUHVHDUFKHUWRUHVSRQGKLPVHOI WRDSDUWLFLSDQW¶VUHplies 
by posing additional questions for clarification, and to explore and 
expand on any new and relevant ideas that might emerge, is perceived 
by Merriam (314) as a core advantage.   
 
5.4.1.5  The limitations of using semi-structured interviews 
To help to ensure that the information gathered from using a particular 
research method is both valid and ethical, its limitations, many of which 
are outlined in the relevant literature and relate to the process of 
conducting the interviews, should be understood.  
 
One of the weaknesses identified by Patton (313) is the danger that, in 
the ebb and flow of the interview itself, significant topics, and therefore 
important information, may be omitted. To gain the confidence to access 
the rich data offered by interviewees the researcher has to appreciate the 
necessity of following the interview schedule in moving through the 
questions. However, the flexible interview structure enables a variety of 
approaches to be taken in devising and sequencing an interview, which 
may in turn lead to widely differing responses and a reduction in their 
comparability. Although generalisations are not a key feature of 
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qualitative research, the responses of the parents in these groups were 
compared and contrasted as the researcher sought to analyse and 
categorise their experiences (313). 
 
A further shortcoming of the semi-structured interview that might prove 
challenging to both researcher and participant is that it inevitably 
depends on the language skills of the interviewee (315). For instance, 
participants may not be sufficiently articulate in their own or another 
language to able to describe their perceptions adequately, or they may 
interpret or understand individual words and concepts differently from 
the interviewer. Not all individual participants may have the intellectual 
capacity for critical thought (315).  
 
This research was planned to encourage the participants involved in this 
study to explore their experiences and develop their understanding of 
them. The aim of the interviews was to find out about their ideas and 
perceptions of access to medicines and health care for their children over 
two time scales (the last month and the last six months).  
 
5.4.2  Ethical Considerations 
Both before a qualitative research project can begin, and throughout its 
whole process, the researcher has to address a number of ethical 
considerations and design the project to take into account the well-being 
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and interest of those taking part (316). Each researcher has to take 
responsibility for the ethics within his/her research, and should not 
ignore the importance of ethical consideration (314, 317).  
 
 5.4.2.1  Informed Consent 
No study-specific interventions will be undertaken before informed 
consent has been obtained. The process for obtaining participant 
informed consent or assent and parent / guardian informed consent 
should be in accordance with the Research Ethics Committee (REC) 
guidance, Good Clinical Practice (GCP) and any other regulatory 
requirements that might be introduced. The investigator or their nominee 
and the participant or other legally authorised representative shall both 
sign and date the Consent Form before the person can participate in the 
study. 
 
Informed consent, the most basic of ethical principles and one which 
GHULYHVIURPSDUWLFLSDQWV¶ULJKWWRIXOOFRQWURORYHUWKHLURZQOLYHVDQGWKH
way they live them (300), rules that they must freely agree to take part 
without pressure of any kind, and in full knowledge of the nature of the 
research, why it is being undertaken and its risks, benefits and aims (301, 
318, 319). 
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5.4.2.2  Voluntary participation 
It is essential that those taking part should be aware that not only must 
their participation be entirely of their own freewill, but also that should 
they wish to withdraw their cooperation at any point, they are entirely 
free to do so (320).  
 
There should be no criticism of any who either withdrew or declined to 
participate in the first instance. The investigator should inform the 
participant of any relevant information that emerges during the course of 
the study, and should discuss with them whether they wish to continue 
with the study. If necessary they will be asked to sign revised consent 
forms. If the consent form is amended during the study, the investigator 
should follow all applicable regulatory requirements pertaining to 
approval of the amended consent form by the REC and use of the 
amended form (including for ongoing participants)(320). 
 
5.4.2.3  Privacy and confidentiality 
Bishop and Glynn (321) consider it essential to protect the identity of all 
participants in research projects. As Anderson (318) indicates, an 
understanding between researcher and participant that guarantees 
confidentiality and anonymity is of paramount importance. The 
researcher is bound to design the project in such a way that this 
guarantee can be honoured (318). Though the researcher himself might 
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be able to identify participants from the data given, not only does he 
have to keep this information completely confidential but he also has to 
present it in such a way that it is impossible for any subsequent reader to 
make the same connection (300, 318).  
 
5.5  Methodology of Project 
5.5.1  Introduction  
The difficulties associated with interviewing parents from the identified 
µµDW ULVN¶¶ groups such as their communities to which access in difficult 
without using a specific support group, language communication 
problems and a reluctance to give information due to their precarious 
status are well recognised. This study, however, specifically focussed on 
these groups to determine whether or not their access to drug therapy 
was sub-optimal.  
 
In the East Midlands there are two key organisations, Refugee Action and 
Derbyshire Gypsy Liaison Group, involved with Refugees and Asylum 
Seekers, and Gypsies and Travellers respectively. Both support groups 
were contacted by the main investigator (my supervisor) to discuss with 
them the project and to ensure that they were fully supportive. Both 
organisations were keen to collaborate with the research.   
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)DPLOLDULW\ZLWKDQ LQWHUYLHZHH¶VEDFNJURXQGDQGFXOWXUH LV IXQGDPHQWDO
to the effective collection and interpretation of social data. It is therefore 
essential for the research group to verse themselves in the lifestyle, 
health history and cultural norms of each participant (322). Refugee 
Action sugJHVWHG DQG RUJDQLVHG D IXOO GD\¶V WUDLQLQJ RQ UHIXJHHV DQG
asylum seekers.  Alongside other members of the research group, I 
attended the training before attempting to approach parents. This course 
gave an overview on Asylum Seeker and Refugee cultures, backgrounds, 
languages, and on the legal differences between Asylum Seekers and 
Refugees. I found the course was very useful and made me familiar with 
the problems faced by Refugees in order to understand their needs.  It 
helped me overcome some of the issues we faced in our research during 
the interviews. For example, some of the potential participants were 
unhappy about providing any information due to their refugee status or 
their enclosed community until I explained the purpose of the study and 
its importance to them in great detail.    
 
The research group also had extensive discussions with Derbyshire Gypsy 
Liaison Group. It is clearly impossible to undertake interviews with 
Asylum Seekers and Refugees, and Gypsies and Travellers without the 
involvement of such organisations, and their support and comments have 
been incorporated into the questions included in the interviews. These 
two organisations were heavily involved in assisting the researchers to 
PDNH FRQWDFWZLWK WKH SDUHQWV RI FKLOGUHQ IURP WKHVH ³DW ULVN´ JURXSV
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They assisted in providing an initial contact point for these parents and 
helped facilitate interviews.  
 
5.5.2 Terminology  
For the purpose of this study, the terms Asylum Seekers and Refugees 
are used interchangeably (i.e. Refugees denotes Asylum seekers and 
Refugees groups). The terms Gypsies and Travellers are used 
interchangeably as well despite differences between these categories (i.e. 
Travellers denotes Gypsies and Travellers groups). 
 
5.5.3  Interview schedule and guide    
In preparation for the study, the semi-structured interview schedule was 
revised with the research group and clinical psychologists from the NHS 
who were experienced in this kind of research. Comments were also 
obtained from both Refugee Action and Derbyshire Gypsy Liaison Group. 
 
The interview determines accessibility to health care and also attitudes 
towards receiving treatment for the following medical conditions: 
epilepsy, asthma and pain. It also records medicines actually 
administered to the children by parents over the past month and six 
months. Furthermore, difficulties in relation to obtaining medicines were 
explored. 
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The aim of this study was to explore the way in which individuals 
perceived their access to health care and, most importantly, to learn 
IURPHDFKLQGLYLGXDO¶VH[SHULHQFH   
 
The schedule of interview for groups of participating parents contained 
both types of question: closed and open-ended questions. It consisted of 
43 questions divided into five parts (see Appendix A1).  
The first part consisted of questions eliciting socio-demographic 
information including details of:  
 family structure  
 country of origin  
 employment status  
 number of years in the present accommodation and current 
locality   
 link with local community. 
 
The second part asked about: 
 GP registration  
 SDUHQWV¶KHDOWK 
 FKLOGUHQ¶VKHDOWK 
  immunisation status. 
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The third part asked about: 
 the number of illnesses and medicines received by the 
children during the past month 
 the prescriber of such medication  
 any barriers experienced in obtaining such medication  
 whether any home remedies such as herbal medicines were 
used.  
 
The fourth section examined aspects covered in the third part, but during 
the past six months. 
 
The fifth part concerned general parental attitudes towards the treatment 
of certain medical conditions such as pain, asthma, and epilepsy, and 
whether those attitudes affect the treatment given. These health 
conditions were chosen because they are common problems in children 
and require medicines. 
 
All these questions were designed to assess barriers to the accessibility 
and affordability of health care and medicines. 
 
5.5.4  Conduct of interviews  
Semi-structured interviews were used for the parents of children of 
different ages. The interviews were performed in accordance with the 
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Qualitative Research Review Guidelines ± RATS (127) (see Appendix B). 
The data assembled for this research comprises information drawn from 
these semi-structured interviews. The same interviews and procedures 
were used for all the participants in this research.  
 
Semi-structured interviews enabled the participating parents to describe 
their experiences in accessing health care services. The interviews 
allowed me as a researcher to gain a better understanding of the cultures, 
EHOLHIV DQG FRQWH[WXDO EDFNJURXQGV WKDW LQIOXHQFHG WKH LQWHUYLHZHHV¶
thoughts on access to medicine and health care. 
 
5.5.5  Participants 
This study aimed to include 50 parents in each of the three groups. This 
number was felt to be achievable based on the discussions with 
Nottingham Refugee Action and the Derbyshire Gypsy Liaison Group.   
This study included:  
I. parents who applied for asylum and those parents who got a 
decision on their asylum claim as refugees; 
II. parents from Gypsy and Traveller communities;  
III. parents from a random control group who volunteered in a 
local shopping centre to take part in the research. 
 
However, the following were excluded:  
  
171 
I. those resident illegally; 
II. those who refused or withdrew consent; 
III. those with mental incapacity, unable to give valid consent;  
IV. those who did not match the inclusion criteria.  
 
Participants were recruited from November 2010 till January 2012. I 
initially focused on the recruitment of Refugees and Asylum Seekers.  
This was done through close collaboration with Refugee Action in 
Nottingham. The initial approach was from a member of Refugee Action. 
Parents from this group routinely visit the office of Refugee Action in 
Nottingham to be advised in many aspects of their daily lives. At the 
office, once they came to the reception desk they were given general 
information about the study and asked if they would be happy to be 
involved. I was then introduced to the parents as a researcher, and 
provided more details about the study both verbally and by giving them 
an information sheet. For those who could not read, I read to them both 
the information sheet and the consent form to clarify everything before 
we started the interviews. If the parents gave consent, I then conducted 
the interview in a private room within the offices of Refugee Action.   
 
Many significant difficulties were encountered during this stage of 
research which consumed much time and effort. I had to go from Derby 
to Nottingham at least twice a week to do the interviews with 
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participating parents. However, many times I went there and spent all 
day and none of the parents who came to the Refugee Action office was 
happy to be involved. Furthermore, recent funding cuts by the 
government led these charities to close their offices in Nottingham and 
Derby and move them to Leicester. Due to this situation, I decided to 
approach Asylum Seekers and Refugees through a Muslim community 
centre in Derby where some participants were recruited. All these factors 
made this stage of the data collection very difficult and it consequently 
took longer than we expected. This part of our study took about one year 
to be completed since we started in November to 2010 and finished in 
November 2011.            
 
Once I had completed all the interviews with Refugees, I then focused 
my attention on recruiting Gypsies and Travellers. This was done in 
conjunction with Derbyshire Gypsy Liaison Group. I had several meetings 
with members of this group and it was agreed that they would introduce 
me and the other researcher to parents of traveller children. This was 
done by visiting campsites throughout Derbyshire. All the interviews took 
place in their caravans. Many of the traveller communities are wary of 
men approaching the female members of the community. In view of this, 
I had to interview the female parents alongside the female research 
nurse. I am pleased to say that during the course of the interviews with 
the women of the traveller community, they accepted me as an honest 
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and conscientious researcher. Recruitment of this group took about four 
months to be completed, from October 2011 to January 2012.  
 
In order to interview the control group, the head office of the local 
shopping centre in Derby (Westfield) was contacted by the main 
investigator to obtain approval for recruiting parents from people 
shopping in this centre. By arrangement with the managers of the 
Westfield, the interviewers (I and the research nurse) randomly 
questioned passers-by in a designated area. Interviewers were identified 
by wearing T-shirts with the University of Nottingham logo and carrying a 
distinctive poster (see Appendix A2).   
 
A 1:1 case-control study was conducted. An appropriate control was 
selected carefully to match each case to minimise any bias that may 
influence the results. Therefore, 50 control parents were selected from 
67 participants who were interviewed as potential controls. The control 
group of parents was selected randomly from parents who volunteered to 
participate in this study. They were selected from white British subjects 
in order to assess the effect of cultural and ethnicity differences in 
parental pattitudes towards treatment of asthma and epilepsy. The 
interviews were carried out using the same procedures as those of other 
groups. The children of the control group  had a similar age distribution 
WRWKRVHRIWKHµ
DWULVN
¶JURXS 
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5.5.6  Ethical Considerations  
This section identifies and addresses the ethical considerations specific to 
this research project and highlights the particular areas that need to be 
addressed when conducting research into vulnerable populations.  
 
The UK has strict ethical regulations for researchers, especially where 
children are involved, so before anything else I had to apply for ethical 
approval to conduct this study. Approval was obtained from the Medical 
School Research Ethics Committee at the University of Nottingham (see 
Appendix A3). The committee required an undertaking that participants 
were to be assured that anonymity would be observed through the report; 
that they should be informed of the overall aims of the project and that 
completed interview schedules would be securely retained at the 
University of Nottingham.  
 
Discussions were held with the Medical School Research Ethics 
Committee in relation to where the control group should be obtained. The 
Medical School Research Ethics Committee originally suggested that 
parents should be recruited from outpatient clinics. Unfortunately, in 
order to recruit parents from an NHS outpatient clinic, we would have 
had to submit a separate ethical application to the NHS Ethics Committee. 
It was therefore agreed with the Medical School Research Ethics 
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Committee that it would be more appropriate to obtain a control group 
from a local shopping centre.   
 
5.5.6.1  Informed consent 
The participants were fully informed of the purpose of the project in 
which they would be involved initially by members of the relevant 
charities and then by the researcher. The information sheet which was 
given at the beginning by the researcher provided a brief introduction to 
the research topic and indicated what a participant might expect during 
the interview (see Appendix A4). It was felt that this approach would not 
only reassure interviewees and reduce any anxiety they might have 
concerning the project, but also encourage them to start thinking about 
what they might want to say in the interview, which was intended to be 
relatively informal and a positive and enjoyable experience for all 
involved. I consistently tried to make sure that they understood all the 
relevant information given to them either verbally or in the information 
sheet and asked the interpreter to explain everything to those who did 
not speak English. 
 
When satisfied that all fully understood the implications of participating, 
those willing to take part on these terms indicated their informed consent 
by signing a short statement to that effect (see Appendix A5). The 
consent form was signed and dated by the participant before he/she 
entered the study. One copy of this was given to the participant and 
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another was kept by the investigator. The consent form confirmed in 
writing the agreement to participate. I reassured participants of the 
importance of the research and that any information provided would be 
handled professionally and treated in strict confidence by the research 
team at the University of Nottingham.  
 
5.5.6.2  Voluntary participation 
It was made clear from the beginning, by the researches, that 
participants could ask questions and raise concerns at any time during 
their participation in the project. They were informed of their right to 
withdraw at any time up until the writing of the first draft of the report 
without need for explanation. It was explained to them that their entry 
into the study was entirely voluntary. They were made aware that they 
could withdraw at any time without affecting the quality or quantity of 
their future medical care, or loss of any benefits to which they would 
otherwise be entitled. 
 
5.5.6.3  Privacy and confidentiality 
In this project, to maintain anonymity each participant was given an 
identity code for all information recorded. Therefore, the investigators 
are confident that the guarantees of privacy and confidentiality given to 
the participants have been honoured and maintained throughout the 
research process. All papers from the study were and will be held 
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securely, in a locked cupboard or cabinet. Access to the information was 
limited to the investigators and any relevant regulatory authorities. All 
data, including the study database, was stored on a secure dedicated 
computer and access was restricted to investigators by user identifiers 
and passwords. The timeline of the research is described in figure 
5.1(below). 
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Figure 5.1: Timeline of the research 
 
 
 
 
Semi-structured interviews were used with the intention to allow new 
viewpoints to emerge freely. We (I and research nurse) first introduced 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jan 2010 
June2010 
Nov 2010 
Oct 2011 
Nov 2011 
Phase1: 
Developing the 
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ourselves to the interviewees as researchers in the Academic Division of 
Child Health at the University of Nottingham, undertaking a study on the 
LVVXHVWKDWPLJKWDIIHFWFKLOGUHQ¶VDFFHVVWo medicines.   
 
All potential interviewees were initially contacted face to face, so that the 
nature and purpose of the study could be explained. Two researchers 
(the research nurse and I) were always present during the interviews. 
The questioning was undertaking by one investigator and the other took 
the role of writing. The responses to each question were written down 
immediately to make sure that all answers were fully understood and 
documented properly. We also explored the responses to questions to 
check that we had accurately interpreted the answers.  Interviews lasted 
from 15 to 35 minutes, and all were transcribed verbatim. Interviews 
were undertaken orally in the language of the participant. If the Asylum 
Seeker and Refugee parents did not speak English as their first language, 
an interpreter was present throughout the interview. Translator services 
at the office were available to assist with discussion and to explain the 
participant information sheets and consent forms. For those who speak 
Arabic I took the role of translator as my first language is Arabic. 
Consent forms and information sheets were also available in other 
languages such as Arabic and French.  
 
The location of the interviews depended upon the group, and preferences 
of the parents. The majority of the interviews took place in the offices of 
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the support groups, community centres and a local shopping centre 
(controls) . Parents were approached at the offices of one of the support 
groups and given the choice of participating in the interview in the office 
or at home. Control parents were randomly questioned in a designated 
area in the Westfield mall in Derby.  
 
5.5.7  Data entry and analysis 
,VFUXWLQLVHGWKHLQGLYLGXDOSDUHQWV¶VHPL-structured interview transcripts 
carefully to make sure that all questions were properly answered. The 
data from the semi-structured interview transcripts for the individual 
parents were read through several times. Then, substantive parts that 
related to the research questions were analysed and classified into 
different categories.    
 
The analysis started with coding. Numbers were used to code the 
participants, while SPSS (Statistical Package for the Social Sciences) 
software (version 17.0) was used to analyse the data. Statistical 
comparisons between groups were conducted using an independent 
sample t-test and nonparametric tests such as Mann-Whitney and Chi-
square tests. The t-test was used to compare the continuous data such 
DV WKH SDUHQWV¶ DJHV KRZ ORQJ WKH\ KDG EHHQ LQ WKHLU SUHVHQW
accommodation and number of days since their last visit to a GP. The 
Mann-Whitney test was used for categorical data such as gender, 
occupation and health status. The Chi-square test was used to determine 
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the frequency of illnesses they had suffered and medicines used during 
the last month and six months. These tests were used as appropriate 
tests to GHWHUPLQHZKHWKHUGLIIHUHQFHVH[LVWHGEHWZHHQWKH³DWULVN´DQG
control groups in their access to health care and medicines. 
 
These statistical tests were used for the categorical answers in the semi-
structured interviews. Once I had established the themes for quantitative 
and qualitative answers descriptive statistics were used around these 
themes.   
 
5.6  Summary 
The purpose of this methodology was to provide a clear framework for 
the research process involved and to outline the procedures used to 
gather information within the research. This chapter has also been 
concerned with outlining data collection and analysis. It has highlighted 
and addressed the ethical considerations relevant to this research and 
followed diligently to ensure the rights and safety of participants.  
 
Following the description of the method and methodology used for this 
thesis, the next chapter describes the findings of this study with regard 
to Asylum Seekers and Refugees.  
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CHAPTER SIX 
RESULTS AND DISCUSSION   
Asylum Seekers and Refugees 
6.1 Introduction 
7KLV FKDSWHUSUHVHQWV WKHNH\ ILQGLQJV UHODWLQJ WR WKHDFFHVVRI WKH ³DW
ULVN´JURXSFRPSULVLQJ$V\OXP6HHNHUVDQG5HIXJHHVWRKHDOWKFDUHDQG
medicines in the East Midlands region of the UK. The intention of this 
chapter is to analyse, collate and discuss the responses from the two 
participant groups of parents. 
 
The presentation of the findings is divided into three sections. The first 
section addresses the sociodemographic characteristics of the 
participating parents. The second section addresses the chLOGUHQ¶VKHDOWK
status and their use of health services. The third section presents the 
SDUHQWV¶ DWWLWXGHV WRZDUGV KHDOWK FDUH DFFHVV DQG WKH WUHDWPHQW RI
certain medical conditions (pain, asthma, and epilepsy). The discussion 
then considers the key findings.      
 
  
183 
6.2 Participants 
6.2.1 Sociodemographic characteristics 
One hundred and thirty seven families were invited to participate. 100 
families agreed to participate in this part of the study. For each family, 
one parent was interviewed. A total of 37 parents declined to participate 
in the study. The majority of the interviewed parents were females (56) 
and 44 were males. Their median age was 35 years (range 19±58 years). 
Fifty parents formed the group of Asylum Seekers and Refugees, and the 
other 50 parents formed the control group. The 100 families had a total 
of 216 children who were also involved in this part of the study. One 
KXQGUHG DQG VHYHQWHHQ RI WKHVH FKLOGUHQ ZHUH LQ WKH µµDW ULVN¶¶ JURXS
(Asylum Seekers and Refugees), and 99 children were in the control 
group. Most of the children (211) lived with both parents; as for the 
remaining five children, the mother or the father was the primary 
custodian for them. 
 
6.2.2 Asylum Seekers and Refugees  
7KH IDPLOLHV IURP WKH ILUVW µµDW ULVN¶¶ JURXS RI WKH VWXG\ FRPSULVHG 
parents of Asylum Seekers and Refugees. The majority were male (38). 
Sixteen parents declined to participate in the study. Those who 
participated were predominantly Iraqi, Pakistani, Nigerian, and Afghani. 
The rest were from various different countries, specifically Ethiopia, 
Zimbabwe, Somalia, Vietnam, Tunisia, Iran, Sudan, Kenya, East Africa, 
The Gambia, and Zambia (table 6.1). 
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Table 6.1: Country of origin RIµµDWULVN¶¶JURXS$V\OXP6HHNHUVDQG5HIXJHHV 
       Country of Origin                    No. of Participants 
 
Iraq      20 
Pakistan 6 
Nigeria 4 
Afghanistan 4 
Ethiopia 2 
Zimbabwe 2 
Somalia 2 
Not stated 2 
Others 8 
 
 
 
The youngest Refugee parent was 24 years old, and the oldest was 58 
years old. The median age of the parents was 36 years, and all were 
born outside the UK. The foreign-born parents had lived in the UK for a 
median of 6.25 years. Only 18 were authorised residents as refugees. 
Seventeen did not state their status of residency. Fourteen had stated 
that their cases were under consideration, and one had received a refusal 
and lodged an appeal. Only 11 of the parents said they spoke English 
poorly and five said they did not speak it at all. Participants were asked 
about the reasons for leaving their country of origin.  
  
The majority of them indicated that they left their country of origin for 
VHYHUDO UHDVRQV7KHPRVW FRPPRQ UHDVRQZDV µµXQVDIH¶¶ZLWK WKHQH[W
mRVWFRPPRQUHDVRQEHLQJµµSROLWLFV¶¶ILJXUH 
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            Figure 6.1: Reasons for leaving country of origin 
 
 
 
The majority of the participating parents (32) were normally fit and well. 
However, more than one third of these parents (18) reported that they 
had chronic illnesses (four chronic severe back pain, four depression, two 
diabetes, two disabilities, and six different illnesses).  
 
The employment status report showed that over half (27) the parents 
were currently unemployed, 18 were employed, and five did not state 
their occupation. The median number of years in the present 
accommodation and current location were 2.25 and 4.75 years, 
respectively. The level of links with locality was relatively high (92%) 
table (6.2). Most of them stated that they had good links with neighbours 
and friends in their local area. Only four had moved recently to a new 
Unsafe 
17 
Politics 
10 
Not stated 
16 
Other 
reasons 
7 
Reasons for leaving  
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area and thus had poor links with the locality. The demographics of the 
participants are detailed in table (6.2).  
 
6.2.3 Control Group  
Fifty families agreed to participate in the control group. For each family, 
one parent was interviewed. The majority were females (44). Twenty one 
parents declined to participate in the study. All the parents who 
participated in the control group were British citizens who have at least 
one child and live in the East Midlands area. Their ages ranged from 19 
to 46 years with a median age of 34.5 years. Most of the participating 
parents (45) were normally fit and well. However, five of the parents in 
the control group reported health problems (three asthma and two stress 
and depression). Over half the participants (26) in this group were 
employed and 24 were housewives. 
 
The median number of years in the present accommodation and current 
location was relatively high (7.4 and 17.5 years, respectively). This 
finding reveals the high rate of links and contacts with the local 
community (table 6.2). 
 
 
 
 
  
187 
   
Table 6.2: Sociodemographics of parents 
 Refugees (A-Group) 
N=50 
Control (C-Group) 
N=50 
P-value 
Gender 
            Male 
            Female 
 
              38     (76%)  
 12             
 
                   6         (12%) 
 44 
 
.000 
Age (Y) 
        Median  
        Range  
 
36 
24-58 
 
34.5 
19-46 
 
.121 
3DUHQWV¶+HDOWK 
 (fit and well)/ Yes 
                     No         
 
 32      
               18     (36%) 
 
                   45         
                    5        (10%) 
 
.002 
Occupation 
Work 
None 
Not stated 
 
               18     (36%)     
 27 
  5 
 
                  26        (52%) 
24 
0 
 
.244 
Median No. of 
Years in Present 
Accommodation 
2.25 7.4 .000 
Median No. of 
Years in Current 
Locality  
4.75 17.5 .000 
Links with Locality  
Yes 
No 
Not stated 
 
              46      (92%) 
4 
0 
 
                47        (94%) 
1 
2 
 
.186 
 
 
The results showed no significant difference between the control group 
DQGWKH5HIXJHHSDUHQWV LQWHUPVRIWKHSDUHQWV¶DJHVW-Test (p=0.12; 
table 6.2).  
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The Refugee and control groups showed a significant difference in the 
number of male and female parents, with the Refugee group having 
fewer participating female parents, Mann-Whitney Test (p WDEOH
6.2). However, the number of working and non-working parents in both 
groups was not significantly different, Mann-Whitney Test (p=0.24; table 
6.2). 
 
Overall, 77 of the parents from both groups were well and in good health. 
Refugee parents were more likely to have health problems, Mann-
Whitney Test (p=.002; table 6.2). Of the 18 Refugee parents who were 
unwell, four were patients suffering mental health problems mainly 
chronic depression as they referred this to their refugee status. All four 
were on antidepressant treatment. Others, however, said they had had 
depression prior to the study.  
 
Male Refugee parents were more likely to report good health compared 
WRIHPDOH5HIXJHHV,QFRQWUDVWWKHFRQWUROJURXS¶VIHPDOHSDUHQWVZHUH
in better health than the male parents. 
 
As anticipated, the Refugees had lived for a significantly shorter duration 
in their present accommodation and current locality compared to the 
control group, t-Test (p=WDEOH.2). However, the groups did not 
differ in terms of their links with their surrounding community.  
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6.3 Access to Health Care and Medicines 
The parents were asked about their experiences with the health care 
system in the UK during the past month as well as during the past six 
months. Two main themes emerged from the data collected, which were 
subjectively organised into the following areas: general access to health 
FDUHDQGPHGLFLQHVFKLOGUHQ¶VKHDOWKDQGDWWLWXGHVWRZDUGVWUHDWPHQWRI
some medical conditions such as pain, asthma, and epilepsy.  
 
6.3.1 General Access to Health care and Medicines  
 6.3.1.1 Asylum seekers and Refugees 
The results showed that 14 was the median number of days since their 
last visit to the GP (either UHJDUGLQJWKHLURZQKHDOWKRUWKHLUFKLOGUHQ¶V). 
Only one family had not visited the GP during the past month or the past 
six months. None of them claimed to face any difficulty registering with 
the GP. However, nine of them experienced difficulties while visiting the 
GP or hospital and while obtaining medicines. Specifically, they claimed 
to have problems with communication (language) or affording the travel 
costs to access the healthcare services. Most of them (45) did not pay for 
prescribed medicines for their children. Four stated that they purchased 
OTC medicines directly from a chemist. Nearly one third (16) of the 
participants reported that they normally used a home remedy for their ill 
children. These home remedies were either prepared at home (such as 
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boiling herbs, honey with ginger mixed in warm water, etc.) or given by 
friends and relatives. Some of the other supplemental preparations that 
they reported using included vitamins, cod liver oil, and gripe water, 
which are all available on shelves at local chemists. Parents indicated 
that they most often took their ill children to GPs or to walk-in centres, 
but rarely to hospital emergency department (table 6.3). 
 
6.3.1.2 Control group 
The results showed that 15 was the median number of days since their 
last visit to the GP (either UHJDUGLQJWKHLURZQKHDOWKRUWKHLUFKLOGUHQ¶V). 
Five families had not visited the GP during the past month or the past six 
months.  
 
None of the participants mentioned that they experienced any difficulty 
accessing health care and medicines. About half of them (24) indicated 
that they would prefer to purchase analgesics directly from chemists 
rather than go to the GP to get a prescription. Eleven parents indicated 
that they often give their children home remedies at home or provide 
them with other products they bought from the supermarket or chemist 
(such as Calpol and vitamins). They preferred to contact their GPs or use 
NHS Direct when their children became ill (table 6.3).  
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Table 6.3: General access to health care and medicines  
 Refugees (A-Group) 
N=50 
Control (C-Group) 
N=50 
P-value 
Registration with 
GP 
             Yes 
  No 
 
                50   (100%) 
0 
 
                 50         (100%) 
0 
 
1.000 
No. of Days Since 
the Last Visit to 
GP 
Median 
Range  
No. of families 
visited GP 
 
 
 
         
 
14 days 
1- 200 days 
49 
 
            
 
 15 days 
1- 730 days  
45   
 
 
 
.079 
Difficulties 
Yes 
No  
Not stated 
 
                 9   (18%) 
                41 
                 0 
 
0 
41 
 9 
 
.008 
Recently 
Purchased OTCs 
Yes 
No  
Not stated  
             
             4    (8%) 
45 
  1 
                      
                24           (48%) 
15 
11 
 
.000 
Home Remedy 
Yes 
No 
Not stated 
  
                  16   (32%) 
 34 
 0 
 
                     11           (22%) 
 38 
  1 
 
.288 
 
 
The Refugee and control groups did not differ in terms of having 
registered with a GP or use of homeopathic or herbal medicine at home 
for their ill children. In addition, the groups did not show any significant 
difference in the number of days since their last visit to a GP (either by 
themselves or with their children) table (6.3).  
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Refugee parents were more likely to report difficulties with accessing 
health care compared to parents in the control group, Mann-Whitney test 
(p=.008; table 6.3). Specifically, the former indicated that they 
experienced some difficulties while obtaining medicines, such as 
language barriers, travel costs to the hospital and detention of parent by 
immigration authorities. In contrast, none of the control parents 
mentioned any difficulty while accessing health care or obtaining 
medicines.  
  
Parents in the control group were more likely to purchase OTC drugs 
such as analgesics from local chemists compared to parents in the 
Refugee group, Mann-Whitney Test (p=WDEOH.3).  
 
6.3.2 &KLOGUHQ¶VKHDOWK  
6.3.2.1 Asylum Seekers and Refugees  
The total number of children in the Asylum seekers and Refugees group 
was 117, with a median number of two children per family. Their ages 
ranged from 0.2 to 18 years with a median age of five years.  
 
Most of the Refugee children (113) were in good health. Only four 
children had chronic medical conditions such as congenital heart disease, 
asthma, cancer, and poor growth. The results also revealed that most of 
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the children (116) were up-to-date with their immunisations according to 
the information obtained from parents (table 6.4). 
  
6.3.2.2 Control group  
There were 99 children in the control group, again with a median of two 
children per family. Their ages ranged from 0.2 to 15 years with a 
median age of four years.   
 
Most of the children in this group (92) were normally fit and well. Seven 
children had a chronic health condition. Four children had asthma, one 
had epilepsy, one had ADHD, and one had arthritis.  
 
All the control children were fully immunised. All parents were aware of 
and understood the importance of their child being immunised (table 6.4). 
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Table 6.4: Data for the children 
 Refugees (A-Group) 
N=117 
Control (C-Group) 
N=99 
P-value 
Median No. of 
Children/Family 
2 2 .224 
Age (Y) 
Median 
IQR 
Range 
 
5 
2.25-8 
0.2-18 
 
4 
1.9-8 
0.2-15 
 
.130 
&KLOGUHQ¶V+HDOWK 
 (fit and well)/Yes 
                      No 
 
                 113        
                  4      (3.4%) 
 
92             
                   7           (7%) 
 
 
.225 
Child 
Immunisation 
                  Yes 
                  No  
 
          
            116      (99%) 
              1        (1%) 
 
                     
                    99        (100%) 
  0 
 
 
.358 
  
The Refugee and control groups did not significantly differ in terms of 
number of children. Furthermore, children of both groups did not show 
DQ\ VLJQLILFDQW GLIIHUHQFH LQ WKH FKLOGUHQ¶V UHSRUWHG KHDOWK DJH DQG
immunisation status (table 6.4).  
 
6.3.2.3 Number of illnesses and medicines in the last month  
Of the 117 children from the Refugee group, 33 (28%) experienced a 
total of 34 illnesses during the last month. The median number of 
illnesses reported was one illness per child (range of 1-3 illnesses).  
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A total of 46 medicines were prescribed to 30 of the 33 children who 
experienced illnesses in the last month (median 1 medicine/child) (table 
6.5). Thirty seven (80%) of the 46 medicines were prescribed by a 
doctor either from a GP or A&E department at the hospital and the 
remainder were OTC medicines (table 6.6). 
 
Thirty-five children from the control group (35%) experienced illnesses in 
the last month.  A total of 53 medicines were taken by 30 of these 
children (median 1 medicine/child) table (6.5). Twenty one (40%) of the 
53 medicines were prescribed by a doctor either from a GP or A&E 
department at the hospital and the remainder were OTC medicines (table 
6.6). 
 
Table 6.5: Number of illnesses and medicines in the last month  
 No. of Children 
with an Illness 
Total No. of 
Illnesses  
Total No. of 
Medicines  
No. of Medicines/ Ill Child 
Median IQR Range 
Refugees 
(A-Group) 
33 34 46 1 1-2 1-3 
Control  
(C-Group) 
35 35 53 1 1-2 1-4 
P-value  .458 .638    
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There was no difference in the number of illnesses reported by the 
Refugee children over the past month compared to the control children, 
Chi-Square Test (p=0.45; table 6.5). 
 
Additionally, there was no difference in the number of medicines used by 
the Refugee children during the past month and the control children, Chi-
Square Test (p=0.63; table 6.5). Children in the control group, however, 
were more likely to receive OTC medicines with regards to types of 
received medicines, while the Refugee children were more likely to 
receive prescribed medicines (p WDEOH.6).  
 
Table 6.6: Medicines in the last month 
                                               Prescribed Medicines                     OTC Medicines 
Refugee Group  37 (80%)                   9 (20%) 
Control Group 21 (40%)                     32 (60%) 
P-value .000                  .000 
 
Analgesics/antipyretics were the group of medicines most likely to be 
used in both groups of children over the last month (Figure 6.2).   
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            Figure 6.2: Medicines in the last month 
 
 
 
6.3.2.4 Number of illnesses and medicines in the last six 
months 
Twice as many children experienced an illness in the past six months 
(154) than over the past month (68).  
 
Eighty-five (72%) of the 117 children from the Refugees group 
experienced a total of 100 illnesses (15 experienced at least two 
illnesses). The results also showed that not all ill children received 
medicines. Sixty-six of the 85 children who experienced illnesses 
received a total of 91 medicines (table 6.7). Seventy four (81%) of the 
91 medicines were prescribed by a doctor either from a GP or A&E 
department at the hospital and the remainder were OTC medicines (table 
6.8). 
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Sixty-nine (69%) of the children from the control experienced a total of 
85 illnesses (16 experienced at least 2 illnesses) in the last six months. 
Sixty-one of these children received a total of 86 medicines (table 6.7). 
Thirty three (38%) of the 86 medicines were prescribed by a doctor 
either from a GP or A&E department at the hospital and the remainder 
were OTC medicines (table 6.8). 
 
   Table 6.7: Number of illnesses and medicines in the last six months   
 No. of Children 
with an Illness 
Total No. of 
Illnesses 
Total No. of 
Medicines  
No. of Medicines/Ill child 
Median IQR Range  
Refugees 
(A-Group) 
85 100 91 1 1-2 1-3 
Control  
(C-Group) 
69 85 86 1 1-2 1-3 
P-value  .424 .951    
  
 
There was no difference in the number of illnesses reported by the 
Refugee children over the past six months compared to the control 
children, Chi-Square Test (p=0.42; table 6.7).  
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Similarly, there was no difference in the number of medicines used by 
the Refugee children during the past six months and the control children, 
Chi-Square Test (p=0.95; table 6.7). Children in the control group were, 
however, more likely to receive OTC medicines with regards to types of 
received medicines, while the Refugee children were more likely to 
receive prescribed medicines (p=WDEOH.8).   
 
         Table 6.8: Medicines in the last six months 
                                             Prescribed Medicines                      OTC Medicines 
Refugee Group  74 (81%) 17 (19%) 
Control Group 33 (38%) 53 (62%) 
P-value .000 .000 
 
 
Analgesics/antipyretics were the group of medicines most likely to be 
used in both groups of children over the last six months (Figure 6.3).  
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           Figure 6.3: Medicines in the Last Six Months 
 
 
 
 
6.3.3 Attitudes 
The third main theme is the attitudes of participating parents towards the 
treatment of three medical conditions: pain, asthma, and epilepsy. 
 
6.3.3.1 Attitudes towards pain (earache) 
 
Attitudes towards pain were different between the two groups. Most of 
the control parents (44) reported that they would give a medicine (such 
as an analgesic) for earache. In contrast, only 22 Refugee parents would 
give a medicine. 7KLVGLIIHUHQFHLQWKHSDUHQWV¶DWWLWXGHVWRZDUGVHDUDFKH
was statistically significant, Mann-Whitney Test (p WDEOH 
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    Table 6.9: Attitudes towards medical conditions   
 Refugees (A-Group) 
             N=50 
Control (C-Group) 
               N=50 
P-value 
Give Rx for  
Earache        
 
Yes 
 No 
            22             44          .000 
            28              (56%)               6              (12%)  
Know about  
Epilepsy 
 
Yes            48           (96%) 50        
 
    (100%)    .155 
 No               2   0  
Happy to Treat 
 Epilepsy 
 
Yes            50           (100%)   50   (100%) 1.000 
 No                0     0  
Happy to Tell  
Family & Friends 
 
Yes             33            (66%)     50   (100%) .000 
 No              17       0  
Happy to Tell  
School 
 
Yes             43   (86%)       50   (100%) .08 
 No               7         0  
 
 
Parents from both groups who expressed their willingness to give 
analgesics such as paracetamol and/or ibuprofen indicated that they 
would start by exploring the possible causes, such as foreign bodies, 
and/or put a few drops of olive oil in the ear, then give pain relief.   
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Twenty-eight of the Refugee parents reported that they would prefer to 
see their GP before giving any treatment. Parents, who said they would 
prefer not to start giving medicine at home, would try first to get a 
medical opinion by contacting their doctors or ringing NHS Direct. They 
would prefer to see the doctor first to diagnose the problem before giving 
treatment. However, a few of them said that they would prefer to try 
other options before they contacted their GPs. They would first try a 
warm bandage or breast feeding, and then they would take the child to 
A&E or see a GP.   
Common responses of Asylum Seeker and Refugee parents are 
summarised in tables 6.21, (see Appendix D1) and those belonging to 
the Control group are summarised in table 6.24, (see Appendix D2). 
 
6.3.3.2 Attitudes towards asthma 
Parents in both groups held a variety of views regarding the condition of 
asthma. Thirteen parents from the control group reported that they were 
aware of the risks involved in asthma and understood the importance of 
medication. Eight of the Refugee parents expressed their awareness of 
asthma. Some of them already had experience, since a member of the 
family had asthma and they would know what to expect. Therefore, they 
would not panic or feel too worried about it.  
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Thirty Refugee parents and 28 control parents expressed their willingness 
to follow the instructions of doctors by giving inhalers for asthma. All 
these parents from both groups indicated that they would use inhalers 
for asthma if the medicines helped theiUFKLOG¶VFRQGLWLRQ7ZHOYH5HIXJHH
parents and nine control parents showed concern. They said that they 
would be worried and anxious about the health risks of this condition, so 
they would seek advice on how to control it in the case of a severe attack 
or LILWDSSHDUHGWREHKDUPLQJWKHLUFKLOG¶VKHDOWK 
 
In general, there was no noticeable difference between the attitudes of 
the parents in either group towards the treatment of asthma. Common 
responses of Asylum Seeker and Refugee parents are summarised in 
tables 6.22, (see Appendix D1) and those belonging to the Control group 
are summarised in table 6.25, (see Appendix D2). 
 
6.3.3.3 Attitudes towards epilepsy 
Most of the parents in both groups (98) possessed good knowledge of 
the condition of epilepsy and the importance of treatment. Only two 
participants, who were both female Refugee parents, reported that they 
had not heard of the condition of epilepsy (fits and seizures). All parents, 
irrespective of their group, reported that they would consult a doctor if 
their child were to develop epilepsy and would give regular treatment.  
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Generally, results indicated that parents from both groups were aware of 
the importance of treatment, so they would not hesitate to give 
medicines or to see the doctor regularly when recommended. Therefore, 
they did not show any significant difference in their attitude towards 
treatment of epilepsy, Mann-Whitney Test (p=0.15; table 6.9). However, 
a few of them mentioned that they would be concerned about this illness, 
which would affect them emotionally. Their emotions, however, would 
not prevent them from giving the recommended treatment. Common 
responses of Asylum Seeker and Refugee parents are summarised in 
table 6.23, (see Appendix D1) and those belonging to the control group 
are summarised in table 6.26, (see Appendix D2). 
 
Seventeen of the Refugee parents (12 males and 5 females) said that 
WKH\ZRXOGQRW LQIRUP IULHQGVDQG UHODWLYHVDERXW WKHLU FKLOG¶VHSLOHSV\
In contrast, none of the control parents said they would do so. This 
GLIIHUHQFH LQ WKH SDUHQWV¶ DWWLWXGHV WRZDUGV HSLOHSV\ ZDV VWDWLVWLFDOO\
significant, Mann-Whitney Test (p=WDEOH.9).  
 
There was a trend for Refugee parents to be less likely to inform the 
VFKRRORIWKHLUFKLOG¶VHSLOHSV\FRQGLWLRQFRPSDUHGWR the control group. 
1HYHUWKHOHVVWKLVGLIIHUHQFHLQWKHSDUHQWV¶DWWLWXGHVZDVQRWVWDWLVWLFDOO\
significant, Mann-Whitney Test (p=0.08; table 6.9). It is worth noting 
that some of those Refugee parents who were happy to tell the school 
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indicated that they preferred to tell only the head teacher or the class 
WHDFKHUDERXWWKHLUFKLOG¶VFRQGLWLRQ 
 
Overall, the parents of the Refugee children were less likely to inform 
IULHQGV DQG VFKRRO DERXW WKHLU FKLOG¶V HSLOHSV\ 7KLV GHFLVLRQ PD\ DULVH
from concerns over stigma or from different cultural beliefs.   
 
6.4 Discussion 
The investigations detailed in this chapter revealed some interesting 
comparisons between both parents and children in the Refugee and 
control groups. Overall the Refugee parents were more prone to health 
problems, especially depression, than the control group.  
  
The Refugee group did not show any significant difference in terms of 
SDUHQWV¶DJHDQGWKHLURFFXSation compared with the control.  
 
 Accommodation and current locality 
Widespread dissatisfaction among Refugees over the location of housing, 
which was concentrated wherever local authorities have made it available 
rather than near others from the same or similar ethnic or cultural 
backgrounds has been previously reported (119). Refugees have been 
dispersed to places away from London and the south-east with no 
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influence in the choice of where they were sent by either themselves or 
the local people in the new places, which created resentment(146). 
 
My group of Refugees parents had lived for shorter periods of time in 
their present accommodation and current locality than those in the 
control group. Refugees may be itinerant as they may be required to 
relocate from one area to another depending on their individual 
circumstances or they may not have been in the UK so long. Those 
Asylum Seekers who did not have Refugee status yet, or those awaiting 
the outcomes of appeals, had no rights to housing by local authorities. 
These could be reasons for their enforced mobility and shorter stays in 
accommodation and localities compared with the control group.  
 
However, though the length of time Refugees had been in their current 
locality tended to be shorter than that of the more settled control group, 
both groups described similarly positive links with their local communities. 
My group had links with the local community and they were already in 
contact with Refugee Action. This would explain their good links despite 
the length of their stay in present accommodation and current locality as 
they had taken time to seek out the local group.  
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Parental health   
Asylum Seekers and Refugees may be at higher risks of health problems 
since most of them come from countries where there is upheaval and 
violent conflict (188, 191). Depression and PTSD are more common. 
These conditions are known to be consequences of political oppression, 
torture, bereavement and separation from families, friends, social 
environment, locality and homeland. Additionally, anxiety about their 
future contributes to the high incidence of mental illness (119). Previous 
VXUYH\VRQ$V\OXP6HHNHUV¶DQG5HIXJHHV¶KHDOWKLQWKH8.have found a 
high rate of mental health problems such as anxiety and stress. These 
health problems are severe enough to impact on them for life(120, 161).   
 
As anticipated parents from the Refugee group, in my sample, were more 
likely to have health problems than those in the control group. The 
former reported a variety of health conditions as before in addition to a 
range of disabilities. Parents who reported feeling depression and stress 
referred this to both their refugee status and issues they often encounter 
in their daily lives.  
 
Registration with GPs   
Difficulties in obtaining full registration with a GP, and the entitlement to 
benefits this brings, are identified as major barriers to accessing health 
care, treatment and medicines for Asylum Seekers and Refugees (119). 
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Previous studies indicate difficulties in obtaining GP registration in the UK 
(150, 178, 194, 323). These studies have suggested that full registration 
with a general practice would enable Asylum Seekers and Refugees to 
access all mainstream services and to benefit fully from the UK 
healthcare system.  
 
The literature also revealed that Asylum Seekers and Refugees from 
countries with no developed system of primary care will often have a 
poor knowledge of the UK health care system especially if they do not 
have any guidance (120). They therefore expect hospital referral for 
some medical conditions that in the UK are normally treated in primary 
care. Minority group children in some developed countries are affected 
GLVSURSRUWLRQDWHO\E\ WKHLUSDUHQWV¶ ODFNRINQRZOHGJHRI WKHKHDOWKFDUH
system in the host country and how to access healthcare services (31, 
43). A national survey in the US indicated that certain ethnic minority 
groups encounter particular barriers to health care arising from a lack of 
information about, and familiarity with, the services available (156).  
 
Based on the results of this study, parents from the Refugee group who 
took part in the study expressed a good basic understanding of the 
English health system. None of the parents, in both the Refugee and the 
control groups, experienced any difficulty in registration with GPs. 
Neither did they differ in terms of the median number of days since their 
last visit to a GP (either by themselves or with their children) or use of 
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homeopathic and herbal medicines at home for their ill children. This 
positive knowledge of my study group might be related to, their links 
with the Refugee Action.  
 
Homeopathic and home remedies  
Previous studies also found that the use of home remedies presented 
other significant barriers to health care (210, 324). A high percentage of 
the population from Asian and African countries depends on traditional 
medicines for their health care and herbal medicines are the most 
common form. Parents in some vulnerable groups in the US, for example, 
preferred to use a combination of OTC preparations and home remedies 
as the treatment of first resort for fever, cough, rashes, diarrhoea and 
vomiting, rather than seeking professional medical care (210). 
 
However, the Refugee parents in this study did not show any difference 
in terms of using homeopathic or herbal medicines compared with control 
group.  
 
Difficulties in accessing health care and medicines  
Previous studies reported that, though Asylum Seekers and Refugees 
may have free access to NHS services in theory, in practice language 
barriers in consultations may make these very hard to access (146, 170, 
171). Language communication barriers are encountered when trying to 
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travel to healthcare facilities, at the reception desk and when trying to 
make appointments, as well as in the consulting room (119). Similar 
conclusions were reached by another study in the US, showing that 
parents from Latino immigrants indicated language problems as the 
greatest barrier to accessing health care both for themselves and their 
children. Many of them who  spoke English, either not very well or not at 
all, did not bring their children for primary or emergency health care 
(186, 324). Others said that, because of poor communication with health 
professionals due to language problems, their children received poor 
medical care resulting from misdiagnosis and inappropriate 
medication(187). 
 
Similarly, while all participating parents in this study reported that the 
NHS met their needs, especially in registering with GPs, some factors 
impacting on their access were mentioned. These included language 
problems and a lack of financial resources.  
 
Only nine out of the 50 Refugee parents were more likely to report 
difficulties in accessing health care and obtaining medicines than parents 
in the control group. Specifically, the former indicated that they 
experienced problems such as language barriers when they contacted the 
GP. Six parents had difficulty in speaking English and expressed their 
need for an interpreter during the interviews. On arrival in a new country, 
Refugees often have communication difficulties due to language problems 
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with health workers. They are often unable to give an adequate medical 
history and this may prevent or delay appropriate treatment. 
 
Access to health care and medicines is also affected by poverty, and 
many Refugees live below the poverty line (126). Asylum Seekers are 
forbidden from working and therefore prevented from supplementing 
their income. As a result they are trapped in poverty. Absolute 
dependence is likely to have serious consequences for their health and 
access to health (147). An American study indicated that large numbers 
of children from the Asylum Seekers and Refugees in some developed 
countries suffered from absolute lack of access to medicines, caused 
mainly by rising unemployment and decreasing or no health insurance 
(140). Those without insurance were less likely than indigenous children 
to access health care and medicines (44, 45). Furthermore, those Asylum 
Seekers still awaiting decisions on their application or appeals are 
forbidden to work, and this creates an economic barrier (cannot pay for 
transportation) to their access to health care and medicines (126). 
 
Two Refugee parents in this study felt travel costs to healthcare services 
such as a hospital could be another factor that affected their access to 
obtain health care and medicines. They felt that because of such financial 
problems they may miss appointments at the hospital, or face difficulty in 
obtaining medicines from a chemist.  
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A study conducted in Australia on mental health difficulties among some 
detained families revealed that having a parent in detention caused 
additional barriers in the form of family disruption (167). Consequently 
stress was a major problem in these families. Parents reported a marked 
decrease in their parenting abilities as a result of detention, which caused 
them distress. 
 
Parents from the Asylum seeker and Refugee group in this study felt that 
detention was another barrier to their access to health care and 
medicines.  Only one Asylum Seeker mother reported that the father had 
been detained. As a result, the family was leaderless and suffering 
psychologically and the mother had neither the knowledge nor the ability 
to cope. She stated that, all of these create barriers to their access to 
health care. 
 
OTC medicines 
In recent years a significant culture change has taken place in the way 
health care is accessed in the UK, gradually taking the focus away from 
GPs and giving more responsibility to local community pharmacists.  
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The background to this culture change started when the government, in 
DGULYHWRHIIHFWLPSURYHPHQWVWRWKH1+6SXEOLVKHG³7KH1+63ODQ´LQ
-XO\7KLV3ODQLQSDUWLQWURGXFHGWKHLGHDRIµSDWLHQW-FHQWUHGFDUH¶
It made proposals to integrate the pharmacy more within the NHS, in 
order to improve the patient care. Community pharmacists were afforded 
new roles which took the focus away from their dispensing role. Later on 
in 2005, through a strategic document, the Pharmacy service was 
FODVVLILHGLQWRWKUHHGLVWLQFWSDUWVµHVVHQWLDO¶µDGYDQFHG¶DQGµHQKDQFHG¶
The objective of these new services, in the main, was aimed at making 
patient access to medicines better and also to reduce the burden on GPs 
(325). 
 
,W LV WKH µHQKDQFHG¶ VHUYLFHZKLFK LV RIparticular interest to my study. 
Minor ailment schemes are a primary example of this pharmacy service 
at a local level. In practice what the minor ailment scheme entails is that 
a patient can go to the community pharmacist to seek advice and receive 
treatmHQW VXEMHFW WR WKH SUREOHP EHLQJ D PLQRU DLOPHQW 7KLV µILOWHU¶
which sieves out a significant proportion of ailments that a GP normally 
deals with allows, in theory at least, the GP to focus on providing a 
quality service for the more serious conditions. 
The Pharmacy White Paper in 2008 reinforced this message by giving 
support to minor ailment schemes as the way forward in terms of 
increasing health care capacity without compromising the safe and 
effective delivery of healthcare. Clear definitions have to be given for 
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minor ailments as well as the specific list of medicines and the types of 
patients that are eligible. For example the typical minor ailments include 
conditions such as constipation, hay fever, coughs and colds and patients 
could be elderly patients, children or those on low income. This scheme 
removed the payment barrier where those who are exempt from 
prescription charges can be supplied with limited formulary medications 
free of charge by the community pharmacist for minor ailments (325, 
326).  
 
Patients have been generally supportive of the scheme but had 
reservations about privacy and confidentiality and also the choice 
between the pharmacist and GP (327). Importantly they also highlighted 
that the scheme was lacking for some ailments. 
 
The minor ailment scheme commenced in April 2009 and the objectives 
were consistent with minor ailment schemes in general, i.e. reducing the 
burden on GPs by redirecting certain less serious conditions to 
pharmacists. A study has clearly demonstrated that more than 50% of 
patients who used this scheme would have otherwise accessed other 
branches of the NHS (325). This would have cost an extra £6000 per 
month. This demonstrates significant cost saving as a result of 
introducing the new scheme (325).  
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Recently, efforts were made to explore the impact of the minor ailment 
scheme on deprived ethnic communities. Understandably, delivery of 
healthcare to these minorities presents its own unique challenges 
because they are typically the most disadvantaged groups in the 
community. They tend to have greater health needs than the general 
community. 
 
The difficult issue of healthcare for Asylum Seekers and Refugees is well 
highlighted. A group of over 500 Refugees arrived in a south London 
community in early 2001(328). They were mainly Kosovan/Albanian but 
some were Middle Eastern and some from sub-Saharan Africa. Although 
they only remained in the area for 5-14 days, considerable pressure was 
put on the primary care services. The local practices were already 
strained in terms of capacity before the influx of Refugees and this 
resulted in many of them not being able to register with a local general 
practice. The problem was further accentuated by the fact that most of 
them did not have sufficient money to purchase medicines for minor 
illness. The net effect of this situation resulted in a significant number of 
Refugees attending local hospital A&E departments and many of them 
arriving via emergency ambulance because they did not have access to 
any transport (328).  
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Parmentier et al (328) piloted and evaluated what is essentially a version 
of the minor ailment scheme tailored to effectively deal with the Refugee 
situation. After understanding that they were steered away from 
obtaining OTC medications due to cost i.e. obtaining a prescription from 
the GP is free of charge but OTC medicine has to be bought at market 
prices for minor illnesses, they looked at how they could facilitate 
Refugees to avoid using the GP in the first instance. To reduce the 
burden on the primary local care service from Refugees a voucher 
system was brought in. This voucher could then be presented at the 
specified local pharmacy and exchanged for a medication on the 
predetermined list. 
 
This scheme proved hugely successful in reducing GP consultations for 
minor illnesses. 184 Refugees were issued a total of 200 vouchers over 
five months. Only 1% of those issued a voucher consulted a GP. 
Although a user satisfaction survey could not be carried out, because 
standardised satisfaction ratings are difficult to implement across several 
languages, the success of the scheme is demonstrated by the high 
proportion of vouchers taken to participating pharmacists (328). 
 
My study found that Asylum Seeker and Refugee parents were less likely 
to purchase OTC analgesics than those in the control group. This may be 
for one of two reasons.  Firstly, the financial situation for Refugees and 
Asylum Seekers is extremely difficult. Such families are unlikely to be 
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able to afford OTC analgesics. The other reason is that the majority of 
Refugee parents felt they would prefer to take their children to the doctor 
when they become ill. None of the participating parents mentioned any 
reasons for this, though they could include the fear of any parent of 
giving medicines without medical advice. Taking cultural factors and lack 
of knowledge about use of medicines into account amongst this group 
could be other reasons for not giving OTC analgesics.  
 
This study also did not cover the issue of language being a barrier to 
accessing the minor ailment scheme. It has identified that this issue also 
needs consideration when looking at access. In particular this is 
demonstrated by the general inability of the Refugee parents to 
communicate with pharmacists to explain the condition of their child 
especially those who poorly or did not speak English at all. They feel that 
the GP is able to diagnose the condition even if they do not speak English 
well. Another issue could be the lack of knowledge of the scheme and 
how to access it. When questioned on the options available to them, they 
RQO\ UHIHUUHG WR *3 DQG +RVSLWDO DFFHVV DQG QRW WKH µPLQRU DLOPHQW¶
scheme which is available in Derby. 
 
&KLOGUHQ¶VKHDOWKDQGLPPXQLVDWLRQ 
Children in both Refugee and control groups were well balanced in terms 
of number, health, age and immunisation status.  
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Children of Asylum Seekers and Refugees who come from unsafe 
countries may not have had the opportunity to complete their 
immunisations (120). Primary care in the home country may be poor, 
with low immunisation rates and limited or no records being kept or 
available (119). These children may be less likely than indigenous 
children to receive essential immunisation. Lack of records often lead to 
their missing of  subsequent vaccinations (140).  
 
In contrast, the vast majority of children from the Refugee group 
involved in this study had a high rate of immunisation and good health 
status, reported by the parents. This high rate indicated that parents of 
Refugees were aware of the importance of immunisation and their ability 
to access NHS services freely. I assume a possible explanation for this 
positive result is that all the Refugee participants in this study were 
already in contact with Refugee Action, and they may therefore be 
assumed to be aware of the healthcare system.  
 
Number of illnesses and medicines  
Recent research in North America has revealed that in both the USA and 
Canada, children of different ethnic minority groups and/or those without 
insurance may be less likely than indigenous children to access health 
care (45-47). They found that black American children were less likely 
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than their white counterparts to receive a prescription medicine. 
Similarly, uninsured American children were less likely than those with 
private insurance to receive a prescription medicine (46). A recent 
prospective study in Canada highlighted that premature white Canadian 
neonates were more likely to receive a variety of medicines and 
interventions than aboriginal (Northern First Americans, Inuit and Metis) 
premature neonates (47). Another study, however, found no difference in 
the treatment of children from different ethnic backgrounds presenting 
with long bone fractures in the emergency departments (138). 
 
An American study examining the relationship between immigration 
status and access to health care, found WKDWFLWL]HQV¶FKLOGUHQKDGHasier 
access than non-FLWL]HQV¶ (141). Those children whose parents had lived 
in the US for less than five years were less likely to have health 
insurance than other groups within the population. It also recorded that 
these children received fewer prescriptions, and were at a higher risk of 
not getting specific treatment plans for certain medical conditions, than 
white children or African American children.  
 
In EU countries, the provision of health care for Asylum Seekers varies 
widely in availability and quality. It is worth noticing that in some EU 
countries where asylum applications are refused, their rights to health 
care are restricted to emergency treatment. Problems of access for 
Asylum Seekers are also compounded by the length of time the asylum 
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claims process may take, which can range from a few months to several 
years. In Germany, for example, Asylum Seekers and Refugees are given 
access to the same health care as German nationals only three years 
after arrival. However, in Luxembourg, this is granted after three months 
(43).   
 
In the UK, free access to the NHS was formerly offered to failed asylum 
seekers. They are entitled to all NHS services and though they can be 
registered with a GP, can only be issued with an exemption certificate for 
prescription, dental and optical care charges once accommodation has 
been allocated(126, 147). Since 2004 the government has strict 
regulations for failed Asylum Seekers and they only have access to some 
primary care which could soon be withdrawn (43, 115). The current 
situation is that failed Asylum Seekers are only allowed access to 
emergency treatment or the continuation of treatment that they had 
already been receiving from NHS hospitals. Children, however, would still 
be allowed free health care (132).  
 
The findings of this study revealed that both Refugee and control children 
reported similar number of illnesses in both the past month and the past 
six months; and number of medicines used over both periods. Asylum 
Seekers and Refugees in the UK have free access to NHS services and 
this makes their situation different to those in other countries that have a 
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health insurance system. Moreover, no failed Asylum Seekers were 
included in my group of parents.  
  
Refugee children did not differ from the control children in relation to the 
number of medicines they received. This finding is reassuring in that it 
suggests that Asylum Seekers and Refugees are able to access health 
care and medicines as well as the indigenous population. However, all 
the parents in this study were already in contact with Refugee Action, a 
support group specifically set up to help Refugees and guide them. There 
may well be ± almost certainly are ± others who have not yet 
encountered Refugee Action or similar charities or organisations, who are 
therefore not in the system. Their access to medicines may be very 
different. These refugees are, however, outside the scope of this study. 
There is still much further research to be undertaken in this field. 
 
Attitudes towards health conditions 
Two main findings emerged from this part of the study. Firstly, Refugee 
parents are less likely to, give analgesics for earache. Secondly, they are 
less likely to inform others about their epileptic children. They will be 
discussed further in the next sections.  
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Pain (earache) 
The findings of this study revealed that attitudes to the treatment of 
earache showed some differences but also similarities. Twice as many of 
the control group parents would give an analgesic for earache as those in 
the Refugee group. All those in both groups who said they would do this 
also said they would explore the causes of the pain first. Some would 
also try alternative treatments before using medication. Those who would 
not give analgesics initially would try to obtain a medical opinion; and 
would also apply alternative treatment first. 
 
The cultural background of a family may contribute to variations in 
assessment and management of pain experience in children. Previous 
studies have revealed the influence of cultural differences to the attitude 
towards pain (329-331). Different ethnic groups and cultures have 
different norms for the management of pain.    
 
Failure to understand the nature of experienced pain in children could act 
as an initial barrier to effective or optimal treatment. Denying pain in 
childhood, minimising the significance symptoms, hesitating to give 
effective analgesics, and cultural myth that children do not experience 
pain are the most common barriers to effective management of pain in 
children. 
 
  
223 
Concerns regarding using pain medications because of serious side 
effects or the development of dependency and tolerance sometimes 
inhibit parents from giving such medicines effectively. Fear of tolerance 
and the belief that giving analgesics early in pain will result in analgesics 
not working later, when the pain is greater are barriers to the effective 
management of pain in children (331, 332). However, the results of my 
study did not detect any evidence for the effect of these barriers in the 
SDUHQW¶VDWWLWXGHVWRZDUGVpain treatment.   
 
Epilepsy  
The attitudes to the treatment of epilepsy showed also both differences 
and similarities. Most parents in both groups reported a good knowledge 
of epilepsy and the importance of treatment for it, with only two (both 
Refugee mothers) not having heard of it.  All said they would consult a 
doctor and treat it regularly. Some felt epilepsy in the family would cause 
them concern, but their anxieties would not lead them to avoid or 
prevent treatment.  
 
In keeping with previous literature, the findings of this study are 
supportive in that Refugee parents were less likely to inform relatives 
DQG IULHQGVDERXW WKHLU FKLOG¶VHSLOHSV\SRVVLEO\ IURP IHDURI VWLJPDRU
for cultural reasons. Whereas only two thirds of the Refugee parents 
would tell their families and friends if their children were sufferers, all the 
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control group parents said they would. There was also a trend for 
5HIXJHH SDUHQWV WR EH OHVV OLNHO\ WR LQIRUP WKH VFKRRO RI WKHLU FKLOG¶V
epilepsy. Of those Refugee parents who would do so, some would only 
tell the head teacher or class teacher. 
 
Results of this study also show that the cultural beliefs of Refugees may 
LPSDFW RQ WKHLU FKLOGUHQ¶V DFFHVV WR PHGLFLQHV DQG PDQDJHPHQW 
&RQFHUQVRYHUVWLJPDFRXOGEHDIDFWRUWKDWLQIOXHQFHVSDUHQWV¶DWWLWXGHV
towards its treatment. It is worth noting that Asylum Seeker and Refugee 
parents from Southern Asia (such as Pakistan and Afghanistan) who took 
part in this study, though they were few, appear less inclined to tell 
RWKHUVDERXWWKHLUFKLOG¶VHSLOHSV\Informing those people who are often 
with the child, such as, relatives, neighbours, good friends and teachers, 
ZRXOG LPSDFW RQ FKLOG¶V PDQDJHPHQW RI VHL]XUHV ,W LV HVVHQWLDO WR WHOO
them so that they know how to help if their child has a seizure.   
 
Some ethnic groups seeking asylum in the UK may avoid seeking health 
care due to the stigma associated with their refugee status (126, 213, 
214). The impact of stigma might affect the chance of these groups 
accessing medicines and medical care. The perceived stigma associated 
with medical diagnosis of epilepsy is a potential barrier in accessing 
Western health services by some ethnic groups (215). For example, 
south-east Asian Refugees believe that alternative Asian treatment for 
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psychiatric disorders is better than Western health care. Confidence in 
their indigenous treatment and fear of shame induces a reluctance to 
seek healthcare and treatment (218, 333).  
 
Across the world and throughout history, there have been negative 
attitudes about epilepsy. Epilepsy has been considered as contagious or a 
form of mental illness which cannot be treated (334). Negative attitudes 
towards epilepsy among some communities were associated with various 
factors including lower level of education, older age and not having heard 
of or witnessed anyone having a seizure (335).  
 
The consequences of epilepsy in terms of stigma differ around the world, 
depending on the cultural and community health background. Many 
SDUHQWVLQVRPHFXOWXUHVGRQ¶WZDQWWRUHSRUWFDVHVRIFKLOGUHQ¶VHSLOHSV\ 
(336).  
 
A study was conducted on the issue of epilepsy and identity in a minority 
ethnic group (people of Pakistani origin) living in the UK (334). It 
provides some interesting insights on their experience of stigma and 
discrimination. It was noted that in this community the issue of marriage 
ZDV³FHQWUDOWRWKHH[SHULHQFHRIVWLJPDDQG3UHMXGLFH¶¶(334). Most men 
are unwilling to accept a proposal from a girl who has epilepsy. Epilepsy 
is thought to be a hereditary disorder. Some families also stated that 
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they would restrict a person with epilepsy from marrying someone from 
their household (335). 
 
There is also a misbelief that women with epilepsy cannot bear children. 
Thus, female patients with epilepsy often remain single. Women from 
this community experience many more difficulties in coping with pressure 
from society and family. Therefore, they conceal their epilepsy during 
marriage negotiations (337, 338). Some SHRSOHGRQ¶WDOORZWKHLUFKLOGWR
play with children with epilepsy. They think that epileptics should be 
isolated from the normal population. Fear of encountering negative 
attitudes among their community have led parents with an epileptic child 
to restrict their social activities and so become socially isolated(339).  
 
Limited knowledge and misconception about epilepsy may explain the 
limited access to its treatment in some developing countries (340). The 
low rate of treatment or treatment gap of this condition in such countries 
is often influenced significantly by several barriers. These barriers include 
cultural beliefs, poverty, stigma, limited number of both qualified 
healthcare staff and unavailability of healthcare services and essential 
anti epileptic drugs (AEDs). People in some communities are often 
unaware of effective treatment that is available at specialised health 
centres. Traditional remedies such as massage, prayers and traditional 
healers are commonly used.  
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Unfortunately, a number of health professionals in these devolving 
countries, for example in Lao, shared the population traditional beliefs 
and practices, especially stigma when regarding the matter of marrying 
(340). They may be reluctant to diagnose or prescribe AEDs. They are 
also unaware of long-term treatment. Treatment of epileptic children in 
the psychiatric department instead of on a paediatric ward may increase 
WKHSHRSOH¶VFRQIXVLon of epilepsy as a mental illness (68, 340). A survey 
was undertaken in 2009 to assess attitudes towards epilepsy with doctors 
working with children in Lao (340). It was noted that a number of them 
had never diagnosed epilepsy or prescribed AEDs. Few had received basic 
training in epilepsy and its management. Lack of guidelines concerning 
epilepsy leads doctors to treat it according to their own experiences.  
 
Diagnosis and management of epilepsy in children by reducing or 
stopping the recurrence of VHL]XUHV ZLOO LPSDFW SRVLWLYHO\ RQ IDPLO\¶V
acceptance of the illness and the psychological consequence on the child 
(341). My study findings reveal that there are some similarities to the 
previous finding in literature especially to those related to SDUHQWV¶
cultural beliefs and stigma towards epilepsy treatment.     
 
Asthma 
More control group parents than Refugee parents were aware of asthma 
and its risks. Some already had personal experience of it in their families, 
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and would therefore know what to expect. Attitudes regarding treatment 
were broadly similar between the two groups. Virtually the same number 
RI SDUHQWV LQ HDFK JURXS ZDV ZLOOLQJ WR IROORZ D GRFWRU¶V LQVWUXFWLRQV
regarding inhalers and would use them if they proved effective.   
    
6.5 Summary 
The findings of this study are reassuring in that access to health care and 
medicines for children of Refugees interviewed was good. It is recognised 
that only Asylum Seekers and Refugees who had made contact with 
Refugee Action were included within this study. Asylum Seekers and 
Refugees outside of the system, especially those living illegally within the 
UK, may not have the same access to health care and medicines. Despite 
the positive access to health care and medicines, there were several 
issues identified in a small number of parents which are listed below. 
 
x 18% of Asylum Seekers and Refugees encountered barriers 
such as language skills and lack of financial resources.  
x Financial difficulty in purchasing OTC medicines was 
identified as a significant problem for some Asylum Seeker 
and Refugee families. 
x Asylum Seeker and Refugee parents were less likely to give 
analgesia to children in pain based on the scenarios. This 
  
229 
may be related to the desire to see a doctor before the 
administration of analgesia or due to cost. 
x Stigma associated with the medical diagnosis of epilepsy 
appeared to be a greater problem in Asylum Seeker and 
Refugee families. Refugee parents were more likely to 
FKRRVHQRWWRLQIRUPRWKHUVDERXWWKHLUFKLOG¶VHSLOHSV\ 
 
Access to health care is an essential human right. Children are dependent 
upon both their parents and the health system for ensuring access to 
health care. This study has identified problems both within the system 
and also in relation to parental beliefs that may affect the access to 
health care and treatment for children. It is important that both of these 
potential barriers are addressed in order to improve the health of 
children of Asylum Seekers and Refugees.  
 
In the same way that Chapter 6 gives and discusses the findings for 
Asylum Seekers and Refugees, Chapter 7 gives and discusses the 
findings for Gypsies and Travellers. 
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CHAPTER SEVEN 
RESULTS AND DISCUSSION 
Gypsies and Travellers 
7.1 Introduction 
&KDSWHUVHYHQSUHVHQWVWKHILQGLQJVUHODWLQJWRWKHDFFHVVRIWKH³DWULVN´
group comprising Gypsies and Travellers, to health care and medicines in 
the East Midlands region of the UK. The intention of this chapter is to 
analyse, collate and discuss the responses from the two participant 
groups of parents. 
 
The presentation of WKLVFKDSWHU¶VILQGLQJVLV divided into three sections. 
The first section addresses the sociodemographic characteristics of the 
SDUWLFLSDWLQJ SDUHQWV 7KH VHFRQG VHFWLRQ DGGUHVVHV FKLOGUHQ¶V KHDOWK
VWDWXVDQGXVHRIKHDOWKVHUYLFHV7KHWKLUGVHFWLRQSUHVHQWVWKHSDUHQWV¶
attitudes towards health care access and the treatment of certain medical 
conditions (pain, asthma, and epilepsy). The discussion then considers 
the key findings.   
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7.2 Participants 
7.2.1 Socio demographic characteristics 
The parents of 97 families agreed to participate in this part of the study. 
)RUW\VHYHQIDPLOLHVIRUPHGWKH³DWULVN´JURXSDQGIRUPHGWKHFRQWURO
group. For each family, one parent was interviewed. Most of the 
interviewed parents were females (91) and only six were males. The 
overall median age of the 97 interviewed parents was 33 years (range 
18-51).  
 
Fifty families of Gypsies and Travellers were initially included in this study. 
However, three of these families had children with an age range of 16 - 
18 years, which falls well outside that (0.2 to 15 years) of the remaining 
47 families. These three families were therefore excluded, to avoid any 
effect of these outliers on the overall results.  
 
The 50 families of the control group in this part of the study included 45 
of the 50 families from the control group in the previous part of the study 
(described in chapter 6). In order to ensure a control group of children 
with similar ages to the children of the Travellers, we excluded five 
families who only had young children. Five new families were then 
recruited to replace the excluded ones. 
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The 97 families had a total of 218 children who were also involved in this 
part of the study. One hundred and thirteen of these children were in the 
µµDWULVN¶¶JURXSDQGFKLOGUHQZHUHLQWKHFRQWUROJURXS$JHVRIWKH
children in both groups ranged between 0.2 and 15 years. Most of them 
(209) lived with both parents; as for the remaining nine children, the 
mother or the father was the primary custodian for them. 
 
7.2.2 Gypsies and Travellers 
7KLVVHFRQGµµDWULVN¶¶JURXSFRPSULVHGIDPLOLHVFor each family, one 
parent was interviewed and all these parents were females. Four parents 
declined to participate in the study. All those who participated were 
British citizens. Their ages ranged between 18 and 51 years, with a 
median of 30 years. Sixteen of the parents had chronic illnesses. Six 
reported chronic anaemia, four had hypertension, three had depression 
and three had asthma (table 7.1).    
 
The non-working rate was high with a high number of participating 
housewives (43). The median number of years in the present 
accommodation or site was only six months. The median number of 
years in the current location (the East Midlands area) however was eight 
years. About half of the parents (23) had good links with the local 
community. The remaining 24 parents did not mention the status of their 
relationship with the community (table 7.1).  
  
233 
 
7.2.3 Control Group  
Fifty families agreed to participate in the control group. For each family, 
one parent was interviewed. The majority (44) were females. All the 
parents who participated as controls were British citizens who have at 
OHDVWRQHFKLOGDQG OLYH LQWKH(DVW0LGODQGVDUHD3DUHQWV¶DJHVUDQJHG
between 19 and 46 years with a median of 36.5 years. Most participating 
parents (45) were normally fit and well. However, five of the parents 
reported a chronic illness. Three had asthma, and two reported stress 
and depression.   
 
The employment status report showed that 30 of the participants in the 
control group were employed, and the remaining 20 were housewives. 
 
The median number of years in the present accommodation and current 
location was relatively high (7 and 21.5 years, respectively). This finding 
obviously reflects the high rate of links with the local community (table 
7.1).   
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          Table 7.1: Socio demographics of parents 
 Travellers (T- 
Group) 
N=47 
Control (C-Group) 
N=50 
P-value 
Gender 
Male 
female 
 
  0         
47             
 
               6       (12%) 
44 
 
.015 
Age (Y) 
           Median 
               Range   
 
30 
18-51 
 
36.5 
19-46 
 
.039 
3DUHQWV¶+HDOWK 
(fit and well)/ 
                  Yes 
       No               
 
                31   
               16     (32%) 
 
               45      
                5      (10%) 
 
.004 
Occupation 
          Work 
           None 
 
                4      (8.5%)   
43 
 
 
              30     (60%) 
20 
 
 
.000 
Median No. of 
Years in Present 
Accommodation 
0.5 7 .000 
Median No. of 
Years in Current 
Locality  
8 21.5 .000 
Linkswith Locality  
Yes 
No 
Not stated 
 
               23      (49%) 
0 
24 
 
             48      (94%) 
0 
2 
 
1.000 
 
 
The Travellers and controls showed a significant difference between the 
number of male and female parents in each group. The Traveller groups 
only included female parents, whereas the control group had six male 
parents, Mann-Whitney Test (p=0.01; table 7.1).  
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The parents of traveller children (median age 30 years) were significantly 
younger than the control parents (median age 36.5 years), t-test 
(p=0.03; table 7.1).  
 
The two groups also differed significantly in term of occupation, with the 
traveller group reporting a significantly higher number of non-working 
parents compared to the controls, Mann-Whitney Test (p= WDEOH
7.1).  
 
Traveller parents reported significantly poorer health compared to the 
controls, Mann-Whitney Test (p = 0.004; table 7.1). Sixteen of the 
Traveller parents, and 5 of the control parents reported that they were 
not well. 
 
As anticipated, the Travellers had lived for a significantly shorter time in 
their present accommodation and current locality compared to the 
controls, t-test (p  WDEOH .1). This is mainly related to their 
continuous travelling around the country.  
 
7.3 Access to Health Care and Medicines 
The parents were asked about their experiences with the health care 
system in the UK during the past month as well as during the past six 
months. Two main themes emerged from the data collected, which were 
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VXEMHFWLYHO\RUJDQLVHGLQWRWKHIROORZLQJDUHDVFKLOGUHQ¶VKHDOWKDQGXVH
of health services, attitudes towards treatment and knowledge of some 
medical conditions such as pain, asthma, and epilepsy. 
 
7.3.1 General Access to Health Care and Medicines 
7.3.1.1 Gypsies and Travellers 
None of the Traveller parents claimed to face any difficulty in registering 
with the GPs or in obtaining medicines. The median number of days since 
their last visit to the GP was 12.5 days. Nine families had not visited the 
GP during the past month or the past six months.  
 
Two thirds (32) of them did not pay for medicines for their children, and 
six of them stated that they purchased OTC medicines directly from a 
chemist (table 7.2). Seventeen of the parents reported that they used 
medicines and vitamins, cod liver oil, etc for their ill children. Parents 
indicated that they obtained these medicines either from a chemist or 
from friends or relatives (table 7.2). They often preferred to take their 
children to an emergency department or to walk-in centres when they 
became ill.  
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7.3.1.2 Control group 
The median number of days since their last visit to the GP (either parents 
alone or with children) was 15 days. Six families had not visited the GP 
during the past month or the past six months.  
 
None of the parents said they experienced any difficulty in accessing 
health care and medicines. Half the parents (25) indicated that they 
would prefer to purchase analgesics for their ill children directly from 
chemists rather than go to the GP to get a prescription. Twelve parents 
indicated that they normally give their children some medicines at home, 
such as analgesics and vitamins, which they bought from chemists or 
were given by neighbours. They often preferred to contact their GP or 
use NHS Direct when their children were ill (table 7.2).  
 
 
 
 
 
 
 
 
 
 
 
 
  
238 
      Table 7.2: General access to health care and medicine 
 Travellers (T- 
Group) 
N=47 
Control (C-
Group) 
N=50 
P-value 
Registration with 
 GP 
               Yes 
                No 
 
              47    (100%) 
0 
 
 
             50   (100%) 
0 
 
1.000 
No. of Days Since 
the Last Visit to GP 
Median  
Range 
No. of families visited  
GP  
 
              
12.5 days   
1-730 days 
38 
 
            
15  days   
1-730 days 
44 
 
 
.883 
Difficulties 
Yes 
No  
Not stated 
 
 0 
40 
 7 
 
0 
44 
 6 
 
1.000 
Recently Purchased 
OTCs        
                 Yes 
  No  
Not stated  
 
                  
               6   (12.8%) 
32 
 9 
 
                        
            25   (50%) 
15 
10 
 
 
.000 
Home Remedy 
Yes 
No 
No stated 
 
              17   (36.2%) 
  30 
0 
 
            12    (24%) 
37 
               1 
 
.215 
 
The Traveller and control groups did not differ in terms of having 
registered with a GP or in the use of home remedies or herbal medicines 
at home for their ill children. In addition, there was no significant 
difference between the groups in the number of days since their last visit 
to a GP (either by themselves or with their children).  
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Both the Traveller and control parents also reported that they did not 
often experience any difficulty in obtaining medicines or accessing 
healthcare services.  
 
Traveller parents, however, were significantly less likely to purchase OTC 
medicines such as analgesics for their ill children, in contrast to the 
control group, Mann-Whitney Test (p=WDEOH.2).  
 
7.3.2 &KLOGUHQ¶V+HDOWK 
7.3.2.1 Gypsies and Travellers  
The total number of chiOGUHQ LQ WKH ³DW ULVN´ JURXS ZDV  ZLWK D
PHGLDQ QXPEHU RI WZR FKLOGUHQ SHU IDPLO\ 7KH FKLOGUHQ¶V DJHV UDQJHG
from 0.2 to 15 years (median 6 years). The majority (81) of them were 
normally fit and well. Approximately one third (32) of the Traveller 
children had a chronic illness. The majority (24) of them were asthmatic. 
Four children had a disability, two had diabetes and two had epilepsy. 
 
The results revealed that the majority (101) of the Traveller children 
were up-to-date with their immunisations. However, 12 of them had not 
received their immunisations (table 7.3).  
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7.3.2.2 Control group 
There were 105 children in the control group, with a median of two 
children per family. Their ages ranged from 0.2 to 15 years with a 
median age of 5 years.   
Most of the control children (98) were in good health. Seven children had 
a chronic illness; four had asthma, one had epilepsy, one had ADHD and 
one had arthritis. All the control children were fully immunised (table 7.3). 
  
     Table 7.3: Data for the children 
 Traveller (T-
Group) 
N=113 
Control (C-Group) 
N=105 
P-value 
Median no. of 
Children/Family 
2 2 .143 
 Age (Y) 
Median 
IQR 
Range 
 
6 
2.75-9.5 
0.2-15 
 
5 
2.25-10 
0.2-15 
 
.897 
&KLOGUHQ¶V+HDOWK 
 (fit and well) /Yes 
                        No 
 
81      
              32   (28.3%) 
 
 98           
                    7        (6.7%) 
 
 
.000 
Child 
Immunisation         
                        Yes 
                           No  
 
            101   (89.4%) 
              12    (10.6%) 
 
                    105     (100%) 
  0 
 
.001 
 
The Traveller and control groups did not significantly differ in terms of 
WKHQXPEHURIFKLOGUHQDQGWKHFKLOGUHQ¶VDJHV 
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There was a significant GLIIHUHQFH LQ WKH FKLOGUHQ¶V UHSRUWHG KHDOWK
Traveller children were more likely to have poor health compared to the 
controls, Mann-Whitney Test (p  WDEOH.3). They were also less 
likely to be fully immunised, Mann-Whitney Test (p=.001; table 7.3).  
 
7.3.2.3  Number of illnesses and medicines in the last month 
In the last month, of the 113 children from the Traveller group, 34 (30%) 
had experienced 35 illnesses with a median of one illness per child.  
 
A total of 37 medicines (median 1 medicine/child) were prescribed to 30 
of the 34 children who had experienced illnesses in the last month (table 
7.4). Twenty nine (78%) of the 37 medicines were prescribed by a doctor 
either from GP or A&E department at the hospital and the remainder 
were OTC medicines (table 7.5). 
 
Thirty-three children from the control group (31%) had experienced 
illnesses in the last month.  
 
A total of 49 medicines were taken by 28 of these children (median 2 
medicines / child) (table 7.4). Nineteen (39%) of the 49 medicines were 
prescribed by a doctor either from a GP or A&E department at the 
hospital and the remainder were OTC medicines (table 7.5). 
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      Table 7.4: Number of illnesses and medicines in the last month   
 No. of Children 
with an Illness 
Total No. of 
Illnesses 
Total No. of 
Medicines 
No. of Medicines /Ill Child 
Median IQR Range  
Traveller  
(T-Group) 
34 35 37 1 1-2 1-2 
Control  
(C-Group) 
33 33 49 2 1-2 1-4 
P-value  .507 .004    
 
There was no difference in the number of reported illnesses between 
Traveller and the control children during the last month, Chi-Square Test 
(p =0.50; table 7.4). 
 
Traveller children were likely to receive a significantly lower number of 
medicines than the control children during the past month, Chi-Square 
Test (p =.004; table 7.4). This was due to the lower number of OTC 
medicines these children received. However, they actually received more 
prescribed medicines than the control group of children (p=WDEOH
7.5). 
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 Table 7.5: Medicines in the last month 
                                         Prescribed Medicines                    OTC Medicines 
Traveller Group  29 (78%) 8 (22%) 
Control Group 19 (39%) 30 (61%) 
P-value .000 .000 
 
Analgesics/antipyretics were the most frequent group of medicines used 
by both groups over the last month. Antibiotics and inhalers were the two 
other groups of medicines frequently used, especially in the Travellers 
(figure 7.1). 
 
            Figure 7.1: Medicines in the last month 
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7.3.2.4 Number of illnesses and medicines in the last six 
months 
Twice as many children experienced an illness in the past six months 
(126) than over the past month (67).  
 
Fifty seven (50%) of the 113 children from the Travellers group 
experienced a total of 70 illnesses. Fifty of the 57 children who 
experienced illnesses received a total of 64 medicines with a median of 
one medicine per ill child (table 7.6). Forty five (70%) of the 64 
medicines were prescribed by a doctor either from a GP or A&E 
department at the hospital and the remainder were OTC medicines (table 
7.7). 
 
Sixty nine (66%) of the 105 from the control children experienced a total 
of 78 illnesses in the last six months. Fifty-two of these children received 
a total of the 81 medicines (median 1/ill child) (table 7.6). Twenty nine 
(36%) of 81 medicines were prescribed by a doctor either from a GP or 
A&E department at the hospital and the remainder were OTC medicines 
(table 7.7). 
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        Table 7.6: Number of illnesses and medicines in the last six months   
 No. of Children 
with Illness  
Total No. of 
Illnesses  
Total No. of 
Medicines   
No. of Medicines/Ill Child 
Median IQR Range  
Traveller 
(T-Group) 
57 70 64 1 1-2 1-3 
Control  
(C-Group) 
69 78 81 1 1-2 1-4 
P-value  .165 .034    
 
There was no difference between the number of illnesses reported by the 
Traveller children over the past six months and by the control children, 
Chi-Square Test (p = 0.16; table 7.6).  
 
Traveller children received a significantly lower number of medicines than 
the control children over the past six months, Chi-Square Test (p = .034; 
table 7.6). This was due to the lower number of OTC medicines these 
children received. However, they actually received more prescribed 
medicines than the control group RIFKLOGUHQS WDEOH.7). 
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 Table 7.7: Medicines in the last six months 
                                  Prescribed Medicines                 OTC Medicines 
Traveller Group  45 (70%) 19 (30%) 
Control Group 29 (36%) 52 (64%) 
P-value  .000                    .000 
 
 
Analgesics/antipyretics were the most frequent group of medicines used 
by both groups over the past six months. Antibiotics and inhalers were 
the two other groups of medicines frequently used, especially in the 
Travellers (figure 7.2). 
 
            Figure 7.2: Medicines in the last six months 
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7.3.3 Attitudes 
The third main theme is the attitudes of the participating parents towards 
the treatment of certain medical conditions such as pain, asthma, and 
epilepsy. 
 
7.3.3.1 Attitudes towards pain (earache)   
The majority of parents in both groups said they would give analgesics 
for earache. However, a significantly higher number of parents in the 
Traveller group would not give analgesics for earache without consulting 
a doctor, Mann-Whitney Test (p=.003; table 7.8).  Fifteen Traveller 
parents and four control parents would not give analgesics.   
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  Table 7.8: Attitudes towards medical conditions   
 
 
Parents from both groups who preferred not to start giving medicine for 
earache at home, indicated that they would try to contact their GPs or 
ring the NHS Direct in order to get a medical opinion. They would prefer 
to see the doctor first to diagnose the problem before giving treatment. 
However, a few of the parents would try other options before they 
contacted their GPs or gave any medicine. They would first try to comfort 
 Travellers (T- Group) 
N=47 
Control (C-Group) 
N=50 
P-value 
Give Rx for 
 Earache 
 
                          Yes 
No 
             32   46  .003 
             15        (32%)   4            (8%)  
Know about  
Epilepsy 
 
Yes    47       (100%) 50     (100%) 1.000 
 No                  0   0  
Happy to Treat 
 Epilepsy 
 
Yes 47   (100%) 50     (100%) 1.000 
  No    0   0  
Happy to Tell  
family & friends 
 
Yes  47     (100%) 50      (100%) 1.000 
  No    0   0  
Happy to Tell  
School 
 
Yes  47     (100%) 50     (100%) 1.000 
  No    0   0  
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him/her with a warm bandage to the ear, and then take the child to A&E 
or to see a GP. 
 
Overall, Traveller parents were less likely to give an OTC analgesic for 
treating earache than the control parents. Common responses of Gypsy 
and Traveller parents are summarised in table 7.20, (see Appendix F) 
and those belonging to the control group are summarised in table 6.24, 
(see Appendix D2). 
 
7.3.3.2 Attitudes towards asthma  
The majority of Traveller and control parents did not show a noticeable 
difference in their attitudes towards asthma. Notably, results indicated a 
high incidence of asthma in both groups and a number of parents and 
children were asthmatic.  
 
Twenty of the Traveller parents but only 13 of the control parents 
indicated that they were aware of the risk of asthma and understood the 
importance of medication. Six parents from both groups revealed that 
they already had experience of asthma and they would know what to 
expect. Therefore, they would not panic or feel too worried about it.     
 
The majority of the parents in both groups (24 from the Travellers and 
30 from the controls) expressed their willingness to follow the 
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instructions of doctors by giving inhalers for asthma. These parents 
indicated that they would use inhalers for asthma if the medicines helped 
WKHLUFKLOG¶VFRQGLWLRQ6HYHQFRQWUROSDUHQWVDQGWKUHH7UDYHOOHUSDUHQWV
said that they would be worried and anxious about the health risks of this 
condition, so they would seek advice on how to control it in the case of a 
VHYHUHDWWDFNRULILWDSSHDUVWREHKDUPLQJWKHLUFKLOG¶VKHDOWK 
 
In general, parents from both groups had a high level of awareness 
about asthma and of using inhalers. Common responses of Gypsy and 
Traveller parents are summarised in tables 7.21, (see Appendix F) and 
those belonging to the control group are summarised in table 6.25, (see 
Appendix D2). 
 
 
7.3.3.3 Attitude towards epilepsy  
All parents, irrespective of their group, had similar attitudes towards the 
condition of epilepsy. They expressed good knowledge and understanding 
of its health risks. They did not show any significant difference in their 
attitudes towards the treatment of epilepsy or telling others such as 
friends and schools about thHLUFKLOG¶VHSLOHSV\WDEOH.8).   
 
Parents from both groups showed awareness of the importance of 
treatment. They would not hesitate to give medicines or to consult a 
doctor if their child were to develop epilepsy.  However, a few of them 
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said they would be very concerned about this illness. Their emotions 
would not, however, prevent them from giving the recommended 
treatment. Common responses of Gypsy and Traveller parents are 
summarised in tables 7.22, (see Appendix F) and those belonging to the 
control group are summarised in table 6.26, (see Appendix D2). 
  
Overall, both groups of parents had a high level of knowledge and 
DZDUHQHVVRIHSLOHSV\7KH\FRQVLGHUHGWKDWWKHLUFKLOGUHQ¶VKHDOWKLVRQH
of their responsibilities. Therefore, they would do whatever was best for 
their children. 
 
7.4 Discussion   
This chapter has presented the results of semi-structured interviews of 
parents from Traveller and control groups. The interviews covered a wide 
range of themes, including the sociodemographics of participating 
parents, access to health care and medicines, FKLOGUHQ¶V KHDOWK DQG
parental attitudes towards pain, asthma, and epilepsy. The Traveller 
parents were significantly younger than the control group parents, 
though the children in both groups were similar in number and age. 
 
Occupation   
The male Gypsies and Travellers tend towards self-employment (272), 
preferably in family groups. Employment is usually in fields such as 
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market trading, gardening, building and collecting and dealing in scrap 
metal. Due to literacy problems stemming from their cultural reluctance 
to accessing secondary education, they find it difficult to find other work. 
They often live in poverty with all its attendant and problematic 
implications for health care for both adults and children (261, 262).  
 
The findings of this study found that, significantly more Traveller parents 
were unemployed than those in the control group. This may be 
attributable to high number of housewives in the Traveller group. The 
women are usually responsible for the care of the children.  
 
Accommodation and current locality 
Geographical barriers are considerable for Gypsies and Travellers, 
particularly given their nomadic way of life, since they are constantly 
being moved on from wherever they may be encamped regardless of 
how far this may move them from healthcare facilities (72, 74, 262).  
 
As anticipated, the length of time Gypsies and Travellers had been in 
their present accommodation and current locality was significantly 
shorter than that of the more settled control group. One possible reason 
is their lifestyle, as they tend to be on the move from one area to 
another around the country. Their travelling pattern and chronic 
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accommodation issues might act as barriers on their access to health 
care.  
 
Parental health   
A previous study reported that the health of Gypsies and Travellers is 
demonstrably worse than the rest of the population, even when 
compared with other deprived groups (254). They have a high rate of 
long-term illness and disability. 
 
They are also regularly subjected to a range of stress-inducing factors 
including unemployment, racism, bereavement, chronic accommodation 
issues, and discrimination - by both public services and the public at 
large (284). There are comparatively few legal sites nationally, following 
the removal in 1994 of local authoritieV¶ OHJDO REOLJDWLRQ WR SURYLGH
SHUPDQHQW VLWHV IRU 7UDYHOOHUV¶ WUDLOHUV 7KLV KDV SURGXFHG FRQVWDQW
anxiety over eviction from illegal sites, which affects the health and 
mental health of the whole community (247, 266). 
 
When compared with a control group from a deprived local area, a study 
identified much greater self-reported depression and anxiety rates in the 
Gypsy and Traveller group(255). They also had a greater risk of early 
death from chronic diseases (255). 
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The finding of this study supported the literature that Gypsy and 
Traveller parents were significantly more prone to ill health problems. 
They reported a variety of health conditions such as long-term illnesses 
in addition to a range of disabilities. These all may have a negative 
impact on their quality of life. Their poor health may be directly 
attributed to unsatisfactory and unhealthy locations, lack of hygiene 
facilities, social hardship and a poor environment. Additionally, chronic 
accommodation issues may result in deteriorating health. 
 
Depression was a significant problem for several Traveller parents. Some 
of them reported considerable anxiety and significant levels of stress and 
depression. They felt that there was no escape from a very poor 
campsite. They expressed concern, over eviction from illegal sites, and 
about future life.   
 
Registration with GPs   
Previous studies have highlighted the negative attitude and behaviour of 
some GPs which may create barriers for Travellers (243, 248, 249). The 
most common problem for Travellers is difficulty in accessing primary 
FDUH WKURXJK *3V EHFDXVH RI WKH ODWWHU¶V insistence on their having a 
permanent address. Other GPs will only provide temporary registration, 
thereby excluding them from screening and a range of other services. In 
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extreme cases, registration is allegedly refused altogether (250, 251). 
Those who move most frequently have the greatest problems. As a result 
of being compulsorily moved on, Travellers have to depend increasingly 
on walk-in centres and A&E departments. Follow-up is therefore difficult, 
especially in the absence or difficulty of GP registration. This results in 
interruption, delays and discontinuity in medical treatment (253).  
 
However, neither Traveller nor control groups, who took part in this 
study, had experienced problems in registering with a GP. There was also 
no significant difference between the groups in the number of days since 
the last visit to a GP, with or without a child.  
 
Difficulty was described by only one Traveller parent when visiting a local 
GP. This parent, who had moved to the East Midlands, said that her new 
local GP asked her next time to go back to the GP where she was 
registered.  
 
OTC medicines 
Gypsies and Travellers are constantly being moved on from wherever 
they may be encamped regardless of how far this may move them from 
healthcare facilities. The typical isolation of their accommodation sites 
may make it difficult for them to reach health services and obtain 
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medicines (263). Furthermore, they often live in poverty with all its 
attendant and problematic implications in obtaining health care and 
medicines (261, 262).  
 
7KLV VWXG\ VKRZV WKDW WKH ³DW ULVN´ JURXS were less likely to purchase 
OTC medicines compared to the control group. The lower number of 
purchased medicines could be due to their health beliefs or attitudes 
towards illnesses or due to financial difficulties. Additionally, campsites 
are generally placed far away from services, such as a local pharmacy or 
supermarket. These factors may all contribute to the lower number of 
OTC medicines used by their children.   
  
Another factor could be the variety of illnesses that the ³DWULVN´FKLOGUHQ
groups experienced, such as asthma, chest infection, eczema, pneumonia 
and meningitis. All those presenting with these conditions consulted a 
doctor whether in a GP surgery or in a hospital A&E department. 
Therefore, being issued a free NHS prescription for the above illnesses, is 
a considerable reason for not needing to purchase OTC medicines.  
 
&KLOGUHQ¶VKHDOWK 
A study in the UK reported that *\SV\ DQG 7UDYHOOHU¶V FKLOGUHQ ZHUH
suffering higher rates of illness than their peers (261). The traditional 
nomadic way of life of Gypsies and Travellers creates barriers of its own 
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WKDWKDYHPDMRULPSOLFDWLRQVIRUFKLOGUHQ¶VKHDOWK$ lack of safe, healthy 
sites and the constant fear of eviction from roadside and illegal sites, all 
may have a negative impact on physical and psychological health of 
FKLOGUHQIURPWKLV³DWULVN´JURXS(261, 262). 
 
It has also been found that infant mortality among these communities 
was three times higher than in the population at large (259). Stillbirth 
and miscarriage rates were also found to be high (254). Alcohol abuse 
often causes  premature death among young members of these groups 
(260).  
 
The findings of my study indicate that the Traveller children reported 
significantly poorer health than those in the control group. My results 
show that about 30% of the children from the Traveller group reported a 
variety of health conditions.  The incidence of asthma (21%) was 
relatively high among children in this group. Some Traveller families 
reported that all their children were currently asthmatic or had had 
asthma prior to the study. The chronic, wet and damp conditions of 
inadequate campsites may be a contributory factor to asthma and other 
respiratory problems.  Increased levels of smoking by parents may also 
be a contributory factor but unfortunately we did not obtain information 
from parents regarding smoking habits.  Many of the interviewed parents 
from this group stated that their child was fit and well. However, when 
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we asked them about their attitudes towards asthma, some said that 
their children were currently asthmatic and often suffered from breathing 
difficulties. Many Travellers did not consider asthma an illness. 
 
Immunisation  
It has previously been reported that the immunisation rates were 
significantly lower for Gypsy and Traveller children than for the general 
population (267). Lack of knowledge and illiteracy, resulting in the 
inability to read promotional literature are significant factors in 
compounding the low rates.  Furthermore, district child health record 
systems and parental recall methods are unreliable for this mobile 
population. Evidence suggests that parental choice not to have vaccines, 
perhaps due to pollution taboos or adverse MMR TV campaigns, still plays 
a significant role in the low figures (266). Other parents have been 
VKRZQ WR EHOLHYH WKDW SHUWXVVLV DQG PHDVOHV ZHUH µnormaO¶ RU HYHQ
µstrengthening¶LOOQHVVHV0DQ\XQYDFFLQDWHG*\SV\DQG7UDYHOOHUchildren 
caught measles in the 2006-7 epidemic, leading to numerous health 
problems and, in one instance, death (267, 268, 342). 
 
Another study compared a group of Gypsy and Traveller children to a 
control group (266). This study revealed that Traveller and Gypsy 
children had significantly lower rates for the completion of immunisation 
programmes for pertussis, measles, diphtheria/tetanus and poliomyelitis 
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than the control group. It also indicated that the low immunisation rates 
were attributable to both poor access to health services and the rejection 
of certain vaccines by the Traveller and Gypsy parents. 
 
The findings of this study indicate that the completion rate for the 
primary course of all types of immunisations was significantly lower 
among Traveller children than those in the control group. This may be 
due to their parents choosing not to have their children immunised. 
 
Those parents from the Traveller group who did not give their children 
the essential vaccines indicated that they do not like MMR. This is due 
partly to their cultural beliefs and traditions and partly to their fear of 
side effects such as fever after immunisation. Increasing parental 
awareness of the importance of immunisation in relation to child health is 
required to improve immunisation rates in children of Travellers.  
 
Number of experienced illnesses 
*\SVLHV DQG 7UDYHOOHUV¶ DFFHVV WR KHDOWK FDUH VHUYLces has been 
investigated in previous studies (248, 249). These studies indicate that, 
for a wide variety of reasons, Gypsies and Travellers tend to make less 
use of health services than other members of the population, despite 
having a greater need of them. 
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States of health are described in terms of restrictions on ability to 
perform daily tasks. A survey by Van Cleemput et al (74) indicated that 
some Gypsies and Travellers described an inability to obtain relief for 
unmanageable symptoms, and were resigned to a low expectation of 
improvement (74). Acceptance and expectation of ill-health is also 
pervasive. This acceptance is consistent with an inverse relationship of 
access to health care in relation to need, though the relevance of some 
symptoms is not always understood (72, 74). 
 
The findings of this study were not consistent with what has previously 
been found in the literature. Although, the children of Travellers were 
more likely to have health problems, they did not differ in the number of 
reported illnesses experienced over the previous month and six months 
in comparison with the control children.  
 
Number of medicines  
Traveller children were found to have received a lower number of 
medicines during the previous month and six months. The parents were 
less likely to purchase OTC medicines and OTC analgesics/antipyretics in 
particular. There are two possible explanations for the lower number of 
OTC medicines. One is the preference of parents for not giving any 
medicine without consulting a doctor. The other is that the parents could 
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not afford to purchase medicines for their children. Other contributory 
factors are the practical problems associated with purchasing OTC 
medicines if the family lives some distance from a pharmacy.  This 
distance may be of major importance, especially if it is the mother who is 
expected to purchase the OTC medicines and the father who has the 
transport (243, 261, 262). Unfortunately we did not ask specific 
questions regarding the individual role of parents but this is an area for 
future research   
 
Attitudes towards health conditions  
Attitudes to the treatment of earache pain, asthma and epilepsy showed 
both differences and similarities. 
Pain (earache) 
Whereas parents in both groups would give an analgesic for earache, 
more Travellers would not give an analgesic without consulting a doctor 
than those in the control group. Travellers were also less likely to give an 
OTC medicine. Those in both groups who preferred not to give analgesics 
at home would try to obtain a medical diagnosis by approaching a GP or 
going to a hospital A&E department. 
 
Historically, many children with pain did not receive analgesia. This 
included children undergoing major cardiac surgery in hospital. This was 
because of the misconception that children did not feel pain. It is 
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increasingly being recognised that children do experience pain and it is 
important that they receive adequate analgesia. Previous studies have 
KLJKOLJKWHG DWWLWXGHV ZLWKLQ WKH *\SVLHV DQG 7UDYHOOHUV¶ FRPPXQLW\
regarding treatment with medicines (343). These have included a lack of 
belief in prescribed treatment, concern about side effects or wanting 
nothing to do with mainstream medicine (252, 343). It is not clear from 
my studies whether parents of Traveller children were reluctant to give 
analgesia because they did not feel the treatment of pain was important 
or whether they had concerns regarding the need for a medical review of 
their child before giving analgesia or cost.  
Asthma  
There was a high level of awareness of asthma, and use of inhalers to 
control it, in both groups. The incidence of asthma among the parents 
and children in both groups was high and they therefore knew what to 
expect. Because of this familiarity, neither group would panic in the 
event of a severe attack. Attitudes regarding treatment were broadly 
similar between the two groups, with parents in both being willing to 
IROORZDGRFWRU¶V LQVWUXFWLRQVUHJDUGLQJ LQKDOHUVDQGWRXVHWKHPLIWKH\
proved effective for their children.  
Epilepsy  
Parents in both groups also had a good knowledge of epilepsy and the 
importance of treatment for it, and understood the risks. They had 
similar attitudes towards it and said they would consult a doctor and use 
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medication to treat it. Both groups also had similar attitudes towards 
telling their families, friends and school if their children were sufferers.  
 
2YHUDOO ERWK JURXSV WRRN UHVSRQVLELOLW\ IRU WKHLU FKLOGUHQ¶V KHDOWK DQG
would do whatever was best for them.  
 
7.5 Summary  
7KLVVWXG\KDVLGHQWLILHGVHYHUDOLVVXHVWKDWPD\DIIHFWDFFHVVRI*\SV\¶V
DQG7UDYHOOHU¶VFKLOGUHQWRKHDOWKFDUHDQGPHGLFLQHV 
 
x Poor health among Gypsies and Traveller communities (both 
in adults and children) has been identified as one of the 
major problems associated with their traditional nomadic 
way of life and chronic accommodation issues. This study 
UHYHDOHG WKDW ERWKSDUHQWV DQG FKLOGUHQ IURP WKLV ³DW ULVN´
group have poorer health than the control group. 
x The attitude of some Gypsy and Traveller parents not to 
immunise their children is a significant barrier to good 
health for the children from this community.  Research 
needs to be performed as to what the barriers to 
immunisation are within the Traveller community. 
  
264 
x Purchasing OTC medicines identified as a significant problem 
for some Gypsy and Traveller families. This could be due to 
the desire to consult a doctor before treatment or financial 
difficulties.  
x Gypsy and Traveller parents were less likely to give 
analgesics to children in pain based on the scenarios. This 
may be related to the desire to see a doctor before the 
administration of analgesia or inability to pay for OTC 
medicines.  
 
Access to health care is an essential human right. Children are 
dependent upon both their parents and the health system for 
ensuring access to health care. This study has identified problems 
both within the system and also in relation to parental beliefs that 
may affect the access to health care and treatment for children. It 
is important that both of these potential barriers are addressed in 
order to improve the health of children of Gypsies and Travellers.  
 
With all the descriptions, discussions and evaluations in place in 
Chapters 1-7, Chapter 8 summarises the research undertaken for 
this thesis, draws conclusions from it and suggests paths for 
further research in this area. 
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CHAPTER EIGHT 
GENERAL DISCUSSION AND CONCLUSION 
 
8.1 Aim  
The purpose of my thesis was to investigate the access to health care 
and safe and appropriate medicines for children. It looked at the quality 
of the medicines children receive and also access to medicines from 
GHILQHG³DWULVN´JURXSV 
 
8.2 Substandard and counterfeit medicines 
It is essential that medicines used for children are of a high quality and 
safe. The use of substandard and counterfeit drugs may result in 
inadequate treatment or toxicity. Unfortunately poor quality products still 
exist in both low-income and high-income countries (66, 67).  
 
There are international efforts from organisations such as the WHO to 
reduce the risk of counterfeit medicines especially in children, by 
LQFUHDVLQJ KHDOWK SURIHVVLRQDOV¶ DZDUHQHVV RI WKH LVVXH , VWDUWHG P\
research by highlighting the impact of diethylene glycol (DEG) in 
FRXQWHUIHLWDQGVXEVWDQGDUGPHGLFLQHVRQFKLOGUHQ¶VKHDOWK 
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Incidents of mass poisoning with DEG have occurred in a variety of 
countries over the last two decades. More than 300 children died as a 
consequence in Nigeria, Bangladesh, India, Argentina and Haiti. DEG may 
be present in medicines because the medicines are counterfeit and it has 
been used as an illegal solvent. It may also be present in substandard 
medicines due to contamination. The key issue for health professionals is 
that they do not often recognise the clinical presentation of DEG 
poisoning. My review of DEG toxicity highlighted the most common signs 
and symptoms following ingestion of DEG, to support early recognition 
and prevent further deaths. Health professionals need to be aware that 
counterfeit or substandard medicines may result in acute illnesses. 
 
8.3 Access  
My study of the access to medicines in children of Asylum 
Seekers/Refugees and Travellers involved the collection of both 
quantitative and qualitative data. Both sets of data highlighted issues 
regarding access in relation to health care and medicines.   
 
All participating parents in my study had a good basic understanding of 
the English health system. None of them experienced any difficulty in 
registration with GPs. They reported that the NHS met their needs, 
especially in registering with GPs. There was an awareness among all the 
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participating parents of how to use health care services. They knew 
where to go when their children became ill, saying they would take them 
to a GP, walk-in centre, or hospital emergency department. This may be 
related to their links with support groups such as Refugee Action and 
Derbyshire Gypsy Liaison group who often provide them with advice. 
 
0\VWXG\UHYHDOHGWKDWSDUHQWVIURP³DWULVN´JURXSVDUHPRUH OLNHO\WR
have health problems than those in the control group. One third of both 
Refugee parents and Traveller parents reported a variety of chronic 
health conditions. These health problems may have a negative impact on 
their quality of life and that of their children.  
 
It is worth noting that the Refugee parents were the group most likely to 
report difficulties in accessing health care. 18% indicated that they 
experienced some difficulties while obtaining medicines. The two main 
barriers identified were language and financial difficulties. Problems in 
relation to understanding or speaking English resulted in difficulties in 
communication with health workers. Financial difficulties were such that 
affording the bus fare to visit a health centre/hospital was a major issue.    
   
&KLOGUHQIURPWKH7UDYHOOHUV¶JURXSZHUHmore likely to have significantly 
poorer health than those in the control group. The incidence of asthma 
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was relatively high (22%) among children in this group. Inadequate 
accommodation is likely to have been a contributory factor (344, 345). 
 
The completion rate for the primary course of all types of immunisations 
was significantly lower among Traveller children than other groups. The 
reluctance of some parents in this group to immunise their children may 
have DVXEVWDQWLDOQHJDWLYHLPSDFWRQWKHLUFKLOGUHQ¶VIXWXUHKHDOWK 
 
8.3.1 Access to medicines  
Traveller children received a lower number of medicines during the 
previous month and six months. This was related to the lower number of 
OTC medicines used in this group. There are several possible 
explanations for the lower use of OTC medicines. Firstly, Travellers often 
live in poverty and may have major financial problems which make the 
purchase of OTC medicines difficult. Distance may also be of importance, 
especially when campsites are generally placed far away from services, 
such as a local pharmacy or supermarket. Another possible explanation is 
the preference of these parents for not giving any medicine without 
consulting a doctor.  
 
3HUKDSV PRVW LQWHUHVWLQJ LV WKH WHQGHQF\ RI SDUHQWV LQ ERWK ³DW ULVN´
groups not to purchase OTC analgesics. This may be for any of the 
following reasons. Firstly, the financial situation for these families can be 
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extremely difficult. Such families are unlikely to be able to afford OTC 
analgesics. Cultural factors and lack of knowledge about the use of 
medicines amongst these groups could also be reasons for the preference 
of some parents to take their children to the doctor when they become ill.  
 
8.3.2 Attitudes  
My study revealed that attitudes to the treatment of certain medical 
conditions such as pain, asthma and epilepsy, showed some differences 
but also similarities. 
 
Participating parents expressed different attitudes towards the treatment 
of pain. 3DUHQWVIURP³DWULVN´JURXSVwere less likely to give analgesics 
for treating earache than those in the control group who expressed their 
knowledge of the condition and its treatment by giving OTC analgesics. 
Parents IURPµµDWULVN¶¶JURXSV said that they initially would try to obtain a 
medical opinion by consulting a doctor. It is possible that the reluctance 
to initially treat pain with OTC analgesics relates to different cultural 
attitudes towards pain in children. It is also possible that the financial 
GLIILFXOWLHVH[SHULHQFHGE\SDUHQWVIURPERWKRIWKH³DWULVN´JURXSVDUH
such that they rarely consider purchasing OTC analgesics.   
 
With regard to informing others about epilepsy once one of their children 
was diagnosed as epileptic, parents showed different attitudes. More than 
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one third of parents from the Refugee group were reluctant to tell others 
about their chilG¶V HSLOHSV\. They said they would prefer not to inform 
friends and/or other relatives about it. There was also a trend for 
5HIXJHH SDUHQWV WR EH OHVV OLNHO\ WR LQIRUP WKH VFKRRO RI WKHLU FKLOG¶V
epilepsy. Of those parents who would do so, some would only tell the 
head teacher or class teacher. Cultural beliefs and concerns over stigma 
FRXOG EH VLJQLILFDQW IDFWRUV WKDW LQIOXHQFH SDUHQWV¶ DWWLWXGHV WRZDUGV
PDQDJHPHQW RI WKHLU FKLOGUHQ¶V HSLOHSV\ (340). Limited knowledge and 
misconceptions about epilepsy and its managements may explain these 
findings.  
 
The findings of this study support the literature regarding the existence 
RIEDUULHUV DQGDWWLWXGHV WKDWPD\DIIHFW DFFHVV RI ³DW ULVN´ FKLOGUHQ WR
health care and medicines. Although this study suggests that at risk 
groups have good access to healthcare and medicines, it is clear that 
they need more support to enable them to have better access and 
overcome any barrier they may encounter.  
  
8.4 Limitations  
While many interesting findings materialised from this pilot study, there 
are some obvious limitations that must be considered:  
x Those in the sample may not be representative of the whole 
SRSXODWLRQRI³DWULVN´JURXSVLQWKH8.%\LQFUHDVLQJWKHQXPEHU
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of samples, and extending the study to include more areas in the 
8. DFFHVV WR KHDOWK FDUH DQG PHGLFLQHV LQ WKH ³DW ULVN´ JURXSV
could be more comprehensively observed.  
x There were difficulties in accessing these groups directly, since 
they have fairly enclosed communities. Their reluctance to go into 
detail might relate to their fear of such information being used 
against them. It is thus possible that a number of parents chose 
not to participate in this study. The recent reduction of funding by 
the new government to charities supporting these minorities has 
also made the situation significantly worse. Refugee Action in 
Nottingham was closed last year due to funding cuts. It is possible 
that without support from charities such as Refugee Action, access 
to healthcare and medicines for the children of these groups will 
deteriorate.  
x  Interviews were conducted only with Asylum Seekers and 
Refugees who had made contact with Refugee Action in 
Nottingham and thus were in the system. However, there may be 
Asylum seekers or Refugees who have not made contact with a 
charity who are having difficulties accessing health care. 
 
8.5 Future studies  
The following are suggestions for future studies:   
x Studies in other geographical parts of the UK. 
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x 6WXGLHVLQYROYLQJRWKHU³DW ULVN´FKLOGUHQ¶VJURXSVVXFKDVFKLOGUHQ
in care. 
x ,QWHUYLHZV ZLWK SDUHQWV IURP ³DW ULVN´ JURXSV LQ UHODWLRQ WR
attitudes towards immunisations and OTC medicines. 
x Studies of Refugees and Asylum Seekers who have not made 
contact with charities such as Refugee Action. 
x $Q HYDOXDWLRQ RI WKH LPSDFW RI WKH SDUHQWV¶ HGXFDWLRQ RQ WKHLU
FKLOGUHQ¶VKHDOWKDQGWKHLUDFFHVVWRKHDOWKFDUHDQGPHGLFLQHV 
 
8.6 Recommendations 
7KHUHDUHVRPHUHFRPPHQGDWLRQVIRUEHWWHUDFFHVVIRU³DWULVN´JURXSV 
x Increasing the awareness of such groups of schemes such as the 
community pharmacy minor ailment scheme where available. 
x ,QFUHDVLQJ WKH DZDUHQHVV RI FKLOGUHQ¶V LPPXQLVDWLRQ LQ VSHFLILF
groups as a parental responsibility serving the child's best 
interests.  
x Availability of support groups and interpreters will contribute to 
EHWWHUDFFHVVIRU³DWULVN´JURXSV 
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8.7 Conclusion 
&KLOGUHQ¶V DFFHVV WR DSSURSULDWH DQG VDIH PHGLFLQHV LV HVVHQWLDO IRU
achieving good child health. The use of counterfeit and substandard 
medicines often results in treatment failure or significant toxicity. The 
cases of DEG toxicity highlighted in this thesis illustrate the tragic 
consequences of the impact of substandard and counterfeit medicines on 
FKLOGUHQ¶VKHDOWK+HDOWKSURIHVVLRQDOVQHHGWREHDZDUH of the existence 
of counterfeit and substandard medicines and their presentation.  
 
The findings of this pilot study indicate that in our area, the East 
0LGODQGVKHDOWKFDUHVHUYLFHVDUHDYDLODEOHWRERWKWKH³DWULVN´JURXSV-
Asylum Seekers/Refugees and Travellers. Asylum Seekers and Refugees, 
however, may encounter some barriers in their access to health care and 
medicines. Differences in cultural beliefs, language and financial 
problems, are all considered as potential barriers to access for this group. 
To benefit fully from the UK healthcare system they need access to 
language classes as well as interpreters. Without such services they 
cannot communicate properly with health and social workers and receive 
appropriate care. 
 
The main barriers identified in the Travellers group were in relation to 
attitudes towards immunisation and OTC medicines. It is likely that 
cultural differences and financial difficulties were the main contributory 
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factors to the lower immunisation rates and the use of OTC medicines 
respectively.  
 
Parental attitude towards management and treatment of health 
FRQGLWLRQVDUHDVLJQLILFDQWIDFWRULQWKHLUFKLOG¶VKHDOWK,WLVKRSHGWKDW
the implications of these findings will be recognised within the NHS and 
lessons learned for improving access to health services for these groups.  
 
 
 
 
 
 
 
 
 
 
 
 
  
275 
REFERENCES  
1. Zucker H, Rägo L. Access to essential medicines for children: the World Health 
Organization's global response. Clinical Pharmacology & Therapeutics. 
2007;82(5):503-505. 
2. Summersett GM, Richards GE, Melzer SM, Sugarman JR, Kletter GB. Effectiveness 
of a rural pediatric diabetes management program. Pediatric Diabetes. 
2003;4(3):137-142. 
3. Choonara I. Children's medicines-a global problem. Archives of Disease in 
Childhood. 2009;94(6):467. 
4. Liebman MN. Personalized medicine: a perspective on the patient, disease and 
causal diagnostics. Personalized Medicine. 2007;4(2):171-174. 
5. Charen T. The etymology of medicine. Bulletin of the Medical Library Association. 
1951;39(3):216. 
6. MacLeod S, Peterson R, Wang Y, Li Z, Gui Y, Schaller J. Challenges in international 
pediatric pharmacology. Pediatric Drugs. 2007;9(4):215-218. 
7. Cantani A. Bronchiolitis in infants. European Review for Medical and 
Pharmacological Sciences. 1999;3:195-196. 
8. Eber E, Zach M. Long term sequelae of bronchopulmonary dysplasia (chronic lung 
disease of infancy). Thorax. 2001;56(4):317-323. 
9. Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications 
for safety. Drug Safety. 2002;25(1):1-5. 
10. Turner S LA, Nunn AJ, Choonara I. Unlicensed drug use on paediatric wards.  BMJ. 
1998; 316: 343-345. 
11. Berkovitch M CI, Jacqz-ŝŐƌĂŝŶĞƚĂů ?/ŵƉƌŽǀŝŶŐƌĞƐĞĂƌĐŚĂŶĚĂĐĐĞƐƐƚŽĐŚŝůĚƌĞŶ ?Ɛ
medicines worldwide.  Paed Perinat Drug Therapy 2008; 8: 138-139. 
12. McIntyre J, Conroy S, Avery A, Corns H, Choonara I. Unlicensed and off label 
prescribing of drugs in general practice. Archives of Disease in Childhood. 
2000;83(6):498-501. 
13. ŚŽŽŶĂƌĂ / ? /ŵƉƌŽǀŝŶŐ ĐŚŝůĚƌĞŶ ?Ɛ ŵĞĚŝĐŝŶĞƐ ?Archives of Disease in Childhood. 
2006;91(7):550-551. 
14. Conroy S CI, Impicciatore P et al.  Survey of unlicensed and off- label drug use in 
paediatric wards in European countries.  BMJ. 2000; 320: 79-82. 
15. Choonara I. Regulation of drugs for children in Europe.  BMJ. 2007; 335: 1221-
1222.  
  
276 
 
16. ZĂŐƵƉĂƚŚǇ Z ? dŽƌĚŽĨĨ : ? EŽƌƌŝƐ W ? ZĞŝƚŚ  ? ĐĐĞƐƐ ƚŽ ĐŚŝůĚƌĞŶ ?Ɛ ŵĞĚŝĐŝŶĞƐ ŝŶ ƚŚĞ
United Kingdom, Australia and New Zealand in 1998, 2002 and 2007. Pharmacy 
World & Science. 2010;32(3):386-393. 
17. Nunn T, Williams J. Formulation of medicines for children. British Journal of 
Clinical Pharmacology. 2005;59(6):674-676. 
18. WHO. Report of the Partners Meeting on Better Medicines for Children, WHO 
Headquarters, Geneva, Switzerland 13-14 May 2009. Available from: 
www.who.int/childmedicines/progress/Partners_Meeting_June2009.pdf. 
Accessed October 2009. 
19. Schirm E, Tobi H, De Vries T, Choonara I, Berg L. Lack of appropriate formulations 
of medicines for children in the community. Acta Paediatrica. 2003;92(12):1486-
1489. 
20. Standing J, Tuleu C. Paediatric formulations--getting to the heart of the problem. 
International Journal of Pharmaceutics. 2005;300(1-2):56-66. 
21. ŚŽŽŶĂƌĂ / ? ĂƵĐŚŶĞƌ , ? WƵďůŝƐŚŝŶŐ ƚŚĞ ĞǀŝĚĞŶĐĞ ĨŽƌ ĐŚŝůĚƌĞŶ ?Ɛ ŵĞĚŝĐŝŶĞƐ ?
Archives of Disease in Childhood. 2008;93(10):815-815. 
22. McCarthy C, Hewitt S, Choonara I. Pain in young children attending an accident 
and emergency department. Journal of Accident & Emergency Medicine. 
2000;17(4):265-267. 
23. Wardlaw T, Salama P, Johansson EW, Mason E. Pneumonia: the leading killer of 
children. Lancet. 2006;368(9541):1048-1049. 
24. Gans-Brangs KR, Plourde PV. The evolution of legislation to regulate pediatric 
clinical trials: Present and continuing challenges. Advanced Drug Delivery Reviews. 
2006;58(1):106-115. 
25. Bonetta L. Pediatric study of medicines becomes mandatory. Nature Medicine. 
2000;6(10):1069-1069. 
26. Wendler D, Varma S. Minimal risk in pediatric research. Ophthalmology. 
2006;149(6):855-861. 
27. Tauer CA. Testing drugs in pediatric populations: the FDA mandate. 
Accountability in Research. 1999;7(1):37. 
28. Grieve J, Tordoff J, Reith D, Norris P. Effect of the pediatric exclusivity provision 
on children's access to medicines. British Journal of Clinical Pharmacology. 
2005;59(6):730-735. 
29. Attaran A. How do patents and economic policies affect access to essential 
medicines in developing countries?. Health Affairs. 2004;23(3):155. 
  
277 
30. Dunne J. The European Regulation on medicines for paediatric use. Paediatric 
Respiratory Reviews. 2007;8(2):177-183. 
31. Pecoul B, Chirac P, Trouiller P, Pinel J. Access to essential drugs in poor countries: 
a lost battle? . JAMA. 1999;281(4):361. 
32. Yamin A. Not just a tragedy: Access to medications as a right under International 
Law. Boston University.  International Law Journal. 2003;21:325. 
33. Pemberton S, Gordon D, Nandy S, Pantazis C, Townsend P. Child rights and child 
poverty: can the international framework of children's rights be used to improve 
child survival rates?. PLoS Medicine. 2007;4(10): 1567-1570. 
34. Griffith R, Tengnah C. Equality and anti-discrimination legislation in health care. 
British Journal of Community Nursing. 2010;15(3):130. 
35. Kar SS PH, Mohanta GP. Concept of essential medicines and rational use in public 
health. Indian Journal of Community Medicine. 2010;35:10-13. 
36. Hogerzeil HV. Essential medicines and human rights: what can they learn from 
each other? Bulletin of the World Health Organization. 2006;84(5):371-375. 
37. Quick J. Essential medicines twenty-five years on: closing the access gap. Health 
Policy and Planning. 2003;18(1):1-3. 
38. Hogerzeil H. The concept of essential medicines: lessons for rich countries. BMJ. 
2004;329(7475):1169. 
39. Schuklenk U, Ashcroft R. Affordable access to essential medication in developing 
countries: conflicts between ethical and economic imperatives. Journal of 
Medicine and Philosophy. 2002;27(2):179. 
40. Banerjee A, Hollis A, Pogge T. The Health Impact Fund: incentives for improving 
access to medicines. Lancet. 2010;12(9709):166. 
41. Ashcroft R. Access to essential medicines: A Hobbesian social contract approach. 
Developing World Bioethics. 2005;5(2):121-141. 
42. Watal J. Access to essential medicines in developing countries: does the WTO 
TRIPS agreement hinder it?. Science, Technology and Innovation Discussion Paper. 
2000;8. 
43. Norredam M, Mygind A, Krasnik A. Access to health care for asylum seekers in the 
European Union ? a comparative study of country policies. The European Journal 
of Public Health. 2006;16(3):285. 
44. Redlener I. Overcoming barriers to health care access for medically underserved 
children. The Journal of Ambulatory Care Management. 1993;16(1):21. 
  
278 
45. Pletcher M J KSG, Kohn M A, Gonzales R. Trends in opioids prescribing by 
race/ethnicity for patients seeking care in US emergency departments.  
JAMA .2008; 299: 70-78. 
46. Chen A Y CRKR. Factors associated with prescription drug expenditures among 
children: an analysis of the medical expenditure panel survey.  Pediatrics. 2002; 
109: 728-732. 
47. Reime B TAW, Lee S K, Canadian Neonatal Network. Treatment differences 
between Aboriginal and white infants admitted to Canadian neonatal intensive 
care units.  Paed Perinat Epidemiol. 2007; 21: 532-540. 
48. Videau J, Fundafunda B. Generic drugs: the hidden issues of quality and cost. 
WHO Drug Information. 2000;14(2):77-81. 
49. Obaid A. Quality of ceftriaxone in Pakistan: reality and resonance. Pakistan 
Journal of Pharmaceutical Sciences. 2009;22(2):220. 
50. Taylor RB, Shakoor O, Behrens RH, Everard M, Low AS, Wangboonskul J, et al. 
Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. The Lancet. 
2001;357(9272):1933-1936. 
51. Wondemagegnehu E. Counterfeit and substandard drugs in Myanmar and Viet 
Nam. Geneva: World Health Organization. 1999. WHO/EDM/QSM/99.3. Available 
at:  www.WHO.Int/medicines/pdf/S2276e/S2276e.pdf. 
52. Shakoor O, Taylor R, Behrens R. Assessment of the incidence of substandard 
drugs in developing countries. Tropical Medicine & International Health. 
1997;2(9):839-845. 
53. Angaran D. Quality assurance to quality improvement: measuring and monitoring 
pharmaceutical care. American Journal of Hospital Pharmacy. 1991;48(9):1901. 
54. Cockburn R, Newton P, Agyarko E, Akunyili D, White N. The global threat of 
counterfeit drugs: why industry and governments must communicate the dangers. 
PLoS Medicine. 2005;2(4):302. 
55. Newton PN, Fernandez FM, Green MD, Primo-Carpenter J, White NJ. Counterfeit 
and substandard anti-infectives in developing countries. Antimicrobial Resistance 
in Developing Countries. 2010:413-443. 
56. Caudron JM, Ford N, Henkens M, Mace C, KiddleϋMonroe R, Pinel J. Substandard 
medicines in resourceϋpoor settings: a problem that can no longer be ignored. 
Tropical Medicine & International Health. 2008;13(8):1062-1072. 
57. Burns W. WHO launches taskforce to fight counterfeit drugs. Bulletin of the World 
Health Organization. 2006;84:689-690. 
58. Outterson K, Smith R. Counterfeit drugs: the good, the bad and the ugly. Albany 
Law Journal of Science and Technology. 2006;15:525-543. 
  
279 
59. Nayyar GML, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial 
drugs in southeast Asia and sub-Saharan Africa. The Lancet Infectious Diseases. 
2012;12(6):488-496. 
60. Chaplin S. Counterfeit medicines: a cause for concern in the UK?. Prescriber. 
2007;18(14):16-21. 
61. Reidenberg M, Conner B. Counterfeit and substandard drugs. Clinical 
Pharmacology & Therapeutics. 2001;69(4):189-193. 
 
62.
 http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvic
e/Adviceandinformationforconsumers/counterfeitmedicinesanddevices/Falsified
MedicineRecallsandpreviouslyseencounterfeits/index.htm. Accessed 5 
September  2011. 
63. Wertheimer A, Santella T. Counterfeit drugs: defining the problem and finding 
solutions. Expert Opin. Drug Safety. 2005;4(4):619-622. 
64. K ?ƌŝĞŶ<>^: ?,ĞĐĚŝǀĞƌƚĞƚĂů ? ĨŽƌ ƚŚĞĐƵƚĞZĞŶĂů& ŝůƵƌĞ /ŶǀĞƐƚŝŐĂƚŝŽŶdĞĂŵ ?
Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol 
poisoning.  JAMA. 1998; 279: 1175-1180. 
65. Milne CP. Racing the Globalization of Infectious Diseases: Lessons from the 
Tortoise and the Hare. New England Journal of International and Comparative 
Law. 2004;11:1-89. 
66. Bonati M. Once again, children are the main victims of fake drugs. Archives of 
Disease in Childhood. 2009;94(6):468. 
67. Newacheck PW, Hughes DC, Stoddard JJ. Children's access to primary care: 
differences by race, income, and insurance status. Pediatrics. 1996;97(1):26. 
68. Barennes H, Tran D, Latthaphasavang V, Preux P, Odermatt P. Epilepsy in Lao PDR: 
From research to treatment intervention. Neurology Asia. 2008;13:27-31. 
69. de Boer H M MM, Sander J W. The global burden and stigma of epilepsy. Epilepsy 
Behav .2008; 12: 540-546. 
70. Amoroso C ZA, Somerville E, Grove N. Epilepsy and stigma.  Lancet. 2006; 367: 
1143-1144. 
71. Wadsworth M. Inequalities in child health. Archives of Disease in Childhood. 
1988;63(4):353. 
72. Van Cleemput P. Health care needs of travellers.  Archives of Disease in  
Childhood. 2000; 82: 32-37. 
  
280 
73. Reeves M dWG, Murshali H et al. Access to health care for people seeking asylum 
in the UK.  British Journal of General Practice. 2006; 56: 306-308. 
74. Van Cleemput P, Parry G, Thomas K, Peters J, Cooper C. Health-related beliefs and 
experiences of Gypsies and Travellers: a qualitative study. BMJ. 2007;61(3):205-
210. 
75. Marraffa J, Holland MG, Stork CM et al. Diethylene glycol: widely used solvent 
presents serious poisoning potential.  Journal Emergency Medicine. 2008; 35: 401-
406. 
76. Hanif M MM, Ronan A, Rahman D, Donovan JJ, Bennish ML. Fatal renal failure 
caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. 
BMJ.1995; 311: 8-91.  
77. Okuonghae HO II, Lawson JO, Nwana EJC. Diethylene glycol poisoning in Nigerian 
children.  Ann Trop Pediatr. 1992; 12: 235-238. 
78. Singh J DA, Khare S et al. Diethylene glycol poisoning in Gurgaon, India, 1998.  Bull 
World Health Organ. 2001; 79: 88-95. 
79. Ferrari LA GL. Clinical parameters, post-mortem analysis and estimation of lethal 
dose in victims of a massive intoxication with diethylene glycol.  Forensic Science 
International. 2005; 153: 45-51. 
80. Geiling EMK CP. Pathologic effects of elixir of sulfanilamide (diethylene glycol) 
poisoning.  JAMA. 1938; 111: 919-926. 
81. Bowie MD MD. Diethylene glycol poisoning in children.  South Africa Medical 
Journal. 1972; 46: 931-934. 
82. Cantarall MC FJ, Camps J, Sans M, Piera L. Acute intoxication due to topical 
application of diethylene glycol.  Annals of Internal Medicine Journal. 1987; 106: 
478-479. 
83. Lin B-L ZZ-X, Chong U-T et al. Venous diethylene glycol poisoning in patients with 
preexisting severe liver disease in China.  World Journal of Gastroenterology. 
2008; 14: 3236-3241. 
84. Pandya S. An unmitigated tragedy.  BMJ. 1988; 297: 117-119. 
85. Hari P JY, Kabra SK. Fatal encephalopathy and renal failure caused by diethylene 
glycol poisoning.  Journal of Tropical Paediatrics. 2006; 52: 442-444. 
86. Alfred S CP, Wigmore T, Stachowski E, Graudins A. Delayed neurologic sequelae 
resulting from epidemic diethylene glycol poisoning.  Clinical Toxicology. 2005; 43: 
155-159. 
87. Rentz ED LL, Mujica OJ et al. Outbreak of acute renal failure in Panama in 2006: a 
case-control study.  Bull World Health Organ.2008; 86: 749-756. 
  
281 
88. www.nytimes.com/2009/02/07/world/africa/07nigeria.html.  Accessed 16 Nov 
2009. 
89. The US Food and Drug Administration.  FDA advises consumers to avoid 
toothpaste from China containing harmful chemical.  FDA News. 2007; 7-97. 
90. Pérez E LJ, Tomás I, Diz P. Letter to the editor: toothpastes with diethylene glycol.  
Med Oral Patol Oral Cir Bucal. 2008; 13: E222-E223. 
91. Gautam CS UA, Singal GL. Spurious and counterfeit drugs: a growing industry in 
the developing world.  Postgraduate Medical Journal. 2009; 85: 251-256. 
92. Newton PN MR, Fernandez F et al.  Manslaughter by fake artesunate in Asia  W will 
Africa be next?.  PLoS Med. 2006; 3: e197. 
93. www.eaasm.eu/Media_centre/News/April_2008.  Accessed 16 Nov 2009. 
94. Couper M. Strategies for the rational use of antimicrobials. Clinical Infectious 
Diseases. 1997;24(Supplement 1):S154-S156. 
95. Clarkson A CS, Burroughs K, Choonara I. Surveillance for adverse drug reactions in 
children: a paediatric regional monitoring centre.  Paediatric and Perinatal Drug 
Therapy. 2004; 6: 20-23. 
96. EĂŚĂƚĂD ?^ĂĨĞƚǇŽĨ “ŝŶĞƌƚ ?ĂĚditives or excipients in paediatric medicines.  Arch 
Dis Child Fetal Neonatal Ed. 2009; 94: F392-F393. 
97. Brophy PD TM, Gardner J, Bunchman TE, Smoyer WE. Childhood diethylene glycol 
poisoning treated with alcohol dehydrogenase inhibitor fomepizole and 
hemodialysis.  American Journal of Kidney Diseases. 2000; 35: 958-962. 
98. Borron SW BF, Garnier R. Intravenous 4-methylpyrazole as an antidote for 
diethylene glycol and triethylene glycol poisoning.  A case report.  Veterinary and 
Human Toxicolology. 1997; 39: 26-28. 
99. Brabander N WM, de Decker K, de Weerdt A, Jorens PG. Fomepizole as a 
therapeutic strategy in paediatric methanol poisoning.  A case report and review 
of the literature. European Journal of Pediatrics. 2005; 164: 158-161. 
100. Bestic M BM, Reed M. Fomepizole: a critical assessment of current dosing 
recommendations.  Journal of Clinical Pharmacolology. 2009; 49: 130-137. 
101. Saladino R SM. Accidental and intentional poisonings with ethylene glycol in 
infancy: Diagnostic clues and management. Pediatric emergency care. 1991; 7: 93. 
102. Lepik KJ, Levy AR, Sobolev BG, et al.  Adverse drug events associated with the 
antidotes for methanol and ethylene glycol poisoning: a comparison of ethanol 
and fomepizole. Annals of Emergency Medicine. 2009; 53: 439-450. 
103. Sivilotti MA. Ethanol: Tastes Great! Fomepizole: Less Filling!. Annals of Emergency 
Medicine. 2009; 53: 451-453. 
  
282 
104. Aday LA, Andersen RM. Equity of access to medical care: a conceptual and 
empirical overview. Medical Care. 1981;19(12):4-27. 
105. Millman ML. Access to health care in America: Nationall Academy Press. 
Washington DC; 1993. Available at: http://www.nap.edu/catalog/2009.html. 
106. Rogers A, Flowers J, Pencheon D. Improving access needs a whole systems 
approach. BMJ. 1999;319(7214):866. 
107. Penchansky R, Thomas JW. The concept of access: definition and relationship to 
consumer satisfaction. Medical Care. 1981:127-140. 
108. Maxwell RJ. Quality assessment in health. BMJ. 1984;288(6428):1470-1471. 
109. Cunningham WE, Hays RD, Ettl MK, Dixon WJ, Liu RCC, Beck CK, et al. The 
prospective effect of access to medical care on health-related quality-of-life 
outcomes in patients with symptomatic HIV disease. Medical care. 1998:295-306. 
110. Hull SA, Boomla K. Primary care for refugees and asylum seekers: If the NHS stops 
free care for all groups, charities may offer the only safety net. BMJ. 
2006;332(7533):62. 
111. Office of the High Commissioner for Human Rights. International covenant on 
economic, social and cultural rights. Article 12. 1976. Available at: 
www.unhchr.ch/html/menu3/b/a_cescr.htm. 
112. Gulliford M, Morgan M, Hughes D, Beech R, Figeroa-Munoz J, Gibson B, et al. 
Access to Health Care: Report of a scoping exercise for the National Co-ordinating 
Centre for NHS Service Delivery and Organisation R & D (NCCSDO). London: 
NCCSDO. 2001. 
113. Gulliford M, Figueroa-Munoz J, Morgan M, Hughes D, Gibson B, Beech R, et al. 
What does' access to health care'mean?. Journal of Health Services Research & 
policy. 2002;7(3):186. 
114. St Clair PA, Smeriglio VL, Alexander CS, Connell FA, Niebyl JR. Situational and 
financial barriers to prenatal care in a sample of low-income, inner-city women. 
Public Health Reports. 1990;105(3):264. 
115. Hargreaves S, Holmes A, Friedland JS. Charging failed asylum seekers for health 
care in the UK. Lancet. 2005;365(9461):732-733. 
116. Phillips J. Asylum seekers and refugees: what are the facts? Department of 
Parliamentary Services, Canberra. 2010. 
117. United Nations High Commission for Refugees (UNHCR), 2011 Global trends, 
Geneva, 20 June 2011,  [viewed 19 november 2011]. Available from: 
http://www.unhcr.org/statistics. 
  
283 
118. United Nations High Commission for Refugees (UNHCR), 2008 Global trends, 
Geneva, June 2009, p. 3, [viewed 13 April 2011]. Available from: 
http://www.unhcr.org/4a375c426.html.   
119. Jones D, Gill PS. Refugees and primary care: tackling the inequalities. BMJ. 
1998;317(7170):1444. 
120. Burnett A, Peel M. Asylum seekers and refugees in Britain: Health needs of 
asylum seekers and refugees. BMJ. 2001;322(7285):544. 
121. Cherrill J HH, Cocking C et al. Clinical trials: the viewpoint of children with a 
chronic illness compared to healthy children.  Archives of Disease Childhood. (In 
press). 
122. Hall P. Failed asylum seekers and health care. BMJ. 2006;333(7559):109. 
123.  UNHCR, Convention relating to the status of refugees, UNHCR, Geneva, 2007, p. 
16, [viewed 9 March2011]. Available from: 
http://www.unhcr.org/3b66c2aa10.pdf  . 
124. Britons confused over refugees: The Guardian, April 2011, p.8, [viewed 18 April 
2011]. Available from: http://www.guardian.co.uk/. 
125. Dussán KB, Galbraith EM, Grzybowski M, Vautaw BM, Murray L, Eagle KA. Effects 
of a refugee elective on medical student perceptions. BMC Medical Education. 
2009;9(1):15. 
126. Burnett A, Peel M. What brings asylum seekers to the United Kingdom?. BMJ. 
2001;322(7284):485. 
127. Chris H, Jonathan C, Nicholas S. Fit for purpose yet. The Independent Asylum 
ŽŵŵŝƐƐŝŽŶ ?Ɛ /ŶƚĞƌŝŵ &ŝŶĚŝŶŐƐ. London; 2008. Available at: www.independent 
asylum commission.org.UK.  
128. www.fph.org.uk/uploads/bs_aslym_seeker_health.pdf .  Accessed October 2010  
129. hE,Z ? ‘tŚŽĂƌĞƌĞĨƵŐĞĞƐ ? ? ?hE,ZǁĞďƉĂŐĞ, [viewed 19 April 2011]. Available 
from: http://unhcr.org.ua/main.php?article_id=5&view=full . 
130. International Organization for Migration (IOM). World migration 2003: managing 
migration  W challenges and responses for people on the move, Chapter 5. Health  W 
an Essential Aspect of Migration Management. IOM Publications, 2003, [viewed 8 
June 2010]. Available at: www.iom.int/jahia/webdav/site/myjahiasite/ 
shared/shared/mainsite/published_docs/books/wmr2003/chap05p85_96.pdf. 
131. François G, Hambach R, Van Sprundel M, Devillé W, Van Hal G. Inspecting asylum 
seekers upon entry ? a medico Wethical complex. The European Journal of Public 
Health. 2008;18(6):552. 
132. Newdick C. Treating failed asylum seekers in the NHS. BMJ. 2009;338:b1614. 
  
284 
133. Sundquist J, Johansson SE. The influence of exile and repatriation on mental and 
physical health. Social Psychiatry and Psychiatric Epidemiology. 1996;31(1):21-28. 
134. Goldfeld AE, Mollica RF, Pesavento BH, Faraone SV. The physical and 
psychological sequelae of torture.  JAMA. 1988;259(18):2725. 
135. Laban CJ, Gernaat HBPE, Komproe IH, Schreuders BA, De Jong JTVM. Impact of a 
long asylum procedure on the prevalence of psychiatric disorders in Iraqi asylum 
seekers in The Netherlands. The Journal of Nervous and Mental Disease. 
2004;192(12):843. 
136. Bischoff A, Bovier PA, Isah R, Franoise G, Ariel E, Louis L. Language barriers 
between nurses and asylum seekers: their impact on symptom reporting and 
referral. Social Science & Medicine. 2003;57(3):503-512. 
137. Keller AS, Rosenfeld B, Trinh-Shevrin C, Meserve C, Sachs E, Leviss JA, et al. 
Mental health of detained asylum seekers. The Lancet. 2003;362(9397):1721-1723. 
138. Yen K KM, Stremski E S, Gorelick M H. Effect of ethnicity and race on the use of 
pain medications in children with long bone fractures in the emergency 
department. Annals of Emergency  Medicine. 2003; 42: 41-47. 
139. Wasserman RC, Croft CA, Brotherton SE. Preschool vision screening in pediatric 
practice: a study from the Pediatric Research in Office Settings (PROS) Network. 
Pediatrics. 1992;89(5):834. 
140. Wood PR, Hidalgo HA, Prihoda TJ, Kromer ME. Hispanic children with asthma: 
morbidity. Pediatrics. 1993;91(1):62. 
141. Halfon N, Wood DL, Valdez RB, Pereyra M, Duan N. Medicaid enrollment and 
health services access by Latino children in inner-city Los Angeles. JAMA. 
1997;277(8):636. 
142. Newacheck PW, Hughes DC, Cisternas M. Children and health insurance: an 
overview of recent trends. Health Affairs. 1995;14(1):244. 
143. Hahn BA. Children's health: racial and ethnic differences in the use of prescription 
medications. Pediatrics. 1995;95(5):727. 
144. Finkelstein JA, Brown RW, Schneider LC, Weiss ST, Quintana JM, Goldmann DA, et 
al. Quality of care for preschool children with asthma: the role of social factors 
and practice setting. Pediatrics. 1995;95(3):389. 
145. Gilthorpe MS, Lay-Yee R, Wilson RC, Walters S, Griffiths RK, Bedi R. Variations in 
hospitalization rates for asthma among black and minority ethnic communities. 
Respiratory Medicine. 1998;92(4):642-648. 
146. Melzak S, Kasabova S. Working with children and adolescents from Kosovo. 
London: Medical Foundation for the Care of Victims of Torture. (Medical 
Foundation Series) 1999. Available at: www.torture care.org.UK. 
  
285 
147. Booth ML, Bernard D, Quine S, Kang MS, Usherwood T, Alperstein G, et al. Access 
to health care among Australian adolescents young people's perspectives and 
their sociodemographic distribution. Journal of Adolescent Health. 2004;34(1):97-
103. 
148. Connelly J, Schweiger M. The health risks of the UK's new asylum act. BMJ. 
2000;321(7252):5. 
149. Adams KM, Gardiner LD, Assefi N. Healthcare challenges from the developing 
world: post-immigration refugee medicine. BMJ. 2004;328(7455):1548. 
150. Feldman R. Primary health care for refugees and asylum seekers: a review of the 
literature and a framework for services. Public Health. 2006;120(9):809-816. 
151. Aldous J, Bardsley M, Daniell R, Gair R, Jacobson B, Lowdell C, et al. Refugee 
health in London ? >ŽŶĚŽŶ P ,ĞĂůƚŚ ŽĨ >ŽŶĚŽŶĞƌƐ ? ƉƌŽũĞĐƚ ? ĂƐƚ >ŽŶĚŽŶ ĂŶĚ ŝƚǇ
Health Authority. 1999. 
152. Wilson R. Improving the health of asylum seekers in Northern and Yorkshire: a 
report on service provision and needs. Northern & Yorkshire Public Health 
Observatory, Tandem Communications and Research. 2002. 
153. Healy J, McKee M. Asylum Seekers and Refugees in the United Kingdom. 
Accessing Healthcare. 2004;1(9):183-207. 
154. Trafford P, Winkler F. Refugees and primary care Participative development in 
general practice.  London, the Royal College of General Practitioners; 2000. 
155. Three Boroughs Primary Health Care Team, Refugee Health Team LSL. December 
2005. Available from: 
http://www.threeboroughs.nhs.uk/index.php?PID=0000000223. 
156. Hargreaves S. New report highlights negative health effects of UK asylum system. 
Lancet. 2000;356(9248):2168. 
157. Andersen R, Lewis SZ, Giachello AL, Aday LA, Chiu G. Access to medical care 
among the Hispanic population of the southwestern United States. Journal of 
Health and Social Behavior. 1981;22(1):78-89. 
158. Ramsay R, Turner S. Refugees' health needs. The British Journal of General 
Practice. 1993;43(376):480. 
159. Romero-Ortuno R. Eligibility of non-residents for NHS treatment: failed asylum 
seekers should not be denied access to free NHS care. BMJ. 2004;329(7467):683. 
160. World Health Organization. Revision of the International Health Regulations 2005. 
WHA58.3. Available at: www.who.int/csr/ihr/WHA58_3-en.pdf. [veiwed 6 March 
2010]. 
161. Directive C. 9/EC of 27 January 2003 laying down minimum standards for the 
reception of asylum seekers. Official Journal of the European Union. 2003;6:2003. 
  
286 
162. Weekers J, Siem H. Is compulsory overseas medical screening of migrants 
justifiable?. Public Health Reports. 1997;112(5):396. 
163. Burnett A, Peel M. Asylum seekers and refugees in Britain: The health of survivors 
of torture and organised violence. BMJ. 2001;322(7286):606. 
164. World Health Organization. The right to know  W new approaches to HIV testing 
and counselling. 2003. WHO/HIV2003.08. Available at: 
www.who.int/hiv/pub/vct/pub34/en/index.html [viewed 12 March 2010]. 
165. UNAIDS/IOM. UNAIDS/IOM statement on HIV/AIDS-related travel restrictions. 
June 2004, [veiwed 12 March 2010]. Available at: 
www.iom.int/jahia/webdav/site/myjahiasite/shared/shared/mainsite/activities/
health/UNAIDS_IOM_statement_travel_restrictions.pdf . 
166. Silove D, Steel Z, Mollica R. Detention of asylum seekers: assault on health, 
human rights, and social development. Lancet. 2001;357(9266):1436-1437. 
167. Mares S, Jureidini J. Psychiatric assessment of children and families in 
immigration detention Wclinical, administrative and ethical issues. Australian and 
New Zealand Journal of Public Health. 2004;28(6):520-526. 
168. Malloch MS, Stanley E. The detention of asylum seekers in the UK. Punishment & 
Society. 2005;7(1):53. 
169. Steel Z, Momartin S, Bateman C, Hafshejani A, Silove DM, Everson N, et al. 
Psychiatric status of asylum seeker families held for a protracted period in a 
remote detention centre in Australia. Australian and New Zealand journal of 
public health. 2004;28(6):527-536. 
170. Fazel M, Silove D. Detention of refugees. BMJ. 2006;332(7536):251. 
171. Robjant K, Hassan R, Katona C. Mental health implications of detaining asylum 
seekers: systematic review. The British Journal of Psychiatry. 2009;194(4):306. 
172. Lewis MA, Rachelefsky G, Lewis CE, Leake B, Richards W. The termination of a 
randomized clinical trial for poor Hispanic children. Archives of Pediatrics and 
Adolescent Medicine. 1994;148(4):364. 
173. Flores G, Farrell E, Cook K, Rock S, Morton J, Teele J. Preventable pediatric 
hospitalizations and suboptimal use of services despite universal coverage. 
Ambulatory Child Health. 1996;1:223-234. 
174. Gergen PJ, Ezzati T, Russell H. DTP immunization status and tetanus antitoxin 
titers of Mexican American children ages six months through eleven years. 
American Journal of Public Health. 1988;78(11):1446. 
175. Hogan H. Meeting health needs of asylum seekers: white paper will make access 
to health care more difficult. BMJ. 1999;318(7184):671. 
  
287 
176. Singer R. Asylum seekers: an ethical response to their plight. Lancet. 
2004;363(9424):1904. 
177. Williams PD. Why failed asylum seekers must not be denied access to the NHS. 
BMJ. 2004;329(7460):298. 
178. Montgomery S, Le Feuvre P, Dar S, von Kaehne P. Health care for asylum seekers. 
BMJ. 2000;321(7265):893-893. 
179. Murphy A, Lynch M, Bury G. " Céad Míle Fáilte"--an assessment of the screening 
of 178 Bosnian refugees to Ireland. Irish medical journal. 1994;87(6):174. 
180. Wilson R. Improving the health of asylum seekers: An overview. Occasional Paper 
No 5, Northern and Yorkshire Public Health Observation Wolfson Research 
Institute, University of Durham; 2002. website: www.NYPHO.org.uk. 
181. Johnson M. Asylum Seekers in dispersal Whealthcare issues. Home Office Online 
report, 2003; 13(03).  Available from:[http:/ / 
www.nrac.scot.nhs.uk/docs/NHS_Boards/Glasgow/Asylum%20seekers%20in%20
dispersal%20-%20healthcare%20issues.pdf]. Accessed in April 2010. 
182. Hakesley-Brown R. Refugee Nurses Task Force: An Update. Asylum Seeker 
Newsletter. 2004;13:8. 
183. Gosling R, Lambeth S. The Needs of Young Refugees in Lambeth, Southwark and 
Lewisham: A Report: Community Health South London NHS Trust; 2000. 
184. Burnett A, Fassil Y. Meeting the Health Needs of Refugee and Asylum Seekers in 
the UK: An Information and Resource Pack for Health Workers (London: 
Directorate of Health and Social Care, Department of Health). 2002. 
185. Kansu F. Assessing the health needs of Turkish and Kurdish speaking women in 
Hackney. London: Open Doors Sexual Health Project, St Leonard's Primary Care. 
1997. 
186. Department of Health, East of England Regional Assembly, Medical Foundation 
for Victims of Torture, Refugee Council, University of East London, West Norfolk 
Primary Care NHS Trust. HARPWEB ? Health for asylum seekers and refugees 
portal. Available from: http://www.harpweb.org.uk/index.php. 
187. Cornelius LJ. Barriers to medical care for white, black, and Hispanic American 
children. Journal of the National Medical Association. 1993;85(4):281. 
188. Mendoza FS, Ventura SJ, Valdez RB, Castillo RO, Saldivar LE, Baisden K, et al. 
Selected measures of health status for Mexican-American, mainland Puerto Rican, 
and Cuban-American children. JAMA. 1991;265(2):227. 
189. Bhui K, Audini B, Singh S, Duffett R, Bhugra D. Representation of asylum seekers 
and refugees among psychiatric inpatients in London. Psychiatric Services. 
2006;57(2):270. 
  
288 
190. Carey-Wood J, Duke K, Karn V. The settlement of refugees in Britain.  London: 
HMSO; 1995. (Home Office Research Study 141.) 
191. Patel N, Fatimilehin I. Racism and mental health. C. Newnes, G. Holmes, & D. C 
(Eds.), Thinking About Psychiatry and The Future of the Mental Health System. 
Ross-on-Wye: PCCS Books. 1999. 
192. Bhui K, Abdi A, Abdi M, Pereira S, Dualeh M, Robertson D, et al. Traumatic events, 
migration characteristics and psychiatric symptoms among Somali refugees. 
Social Psychiatry and Psychiatric Epidemiology. 2003;38(1):35-43. 
193. Cowen T, Project RHA. Unequal treatment: findings from a refugee health survey 
in Barnet: Barnet Voluntary Service Council; 2001. 
194. Fassil Y. Looking after the health of refugees. BMJ. 2000;321(7252):59. 
195. Shrestha NM, Sharma B, Van Ommeren M, Regmi S, Makaju R, Komproe I, et al. 
Impact of torture on refugees displaced within the developing world.  JAMA. 
1998;280(5):443-448. 
196. London Assembly, Mayor of London. Access to primary care: a joint London 
Assembly and Mayor of London scrutiny report. London: Greater London 
Authority; 2003. 
197. Harris K, Maxwell C. A needs assessment in a refugee mental health project in 
north-east London: extending the counselling model to community support. 
Medicine, Conflict and Survival. 2000;16(2):201-215. 
198. Thompson K. Experiences of a refugee support psychology service. London: 
Waltham Forest. 2002. 
199. Webster A, Jaimes CR. The mental health needs of refugees in Lambeth: results of 
a consultation exercise with refugee community organisations. Refugee Outreach 
Team Community Health South London NHS Trust, South London and the 
Maudsley NHS Trust, London. 2000. 
 
200. Wilson R. Yorkshire and Humberside Refugee Support Centre. Findings of 
research into mental health services for refugees and asylum seekers, and 
perceptions of need among service providers, Yorkshire and Humberside Region. 
Yorkshire and Humberside Refugee Support Centre. 2003. 
201. Uba L. Cultural barriers to health care for southeast Asian refugees. Public Health 
Reports. 1992;107(5):544. 
202. Carlin J, Sokoloff B. Mental health treatment issues for Southeast Asian refugee 
children. Southeast Asian mental health: treatment, prevention, services, training, 
and research, edited by T. Owan. US Department of Health and Human Services, 
DHHS Publication No.(ADM). 1985;85:1399. 
  
289 
203. Brainard J, Zaharlick A. Changing health beliefs and behaviors of resettled Laotian 
refugees: Ethnic variation in adaptation. Social Science & Medicine. 
1989;29(7):845-852. 
204. Tung TM. The Indochinese Refugees as Patients. Journal of Refugee Resettlement. 
1980;1(1):53-60. 
205. Thao X. Southeast Asian refugees of Rhode Island: the Hmong perception of 
illness. Rhode Island Medical Journal. 1984;67(7):323. 
206. Egawa J, Tashima N, Murase K, Project PAMHR. Indigenous healers in Southeast 
Asian refugee communities: Pacific Asian Mental Health Research Project; 1982. 
207. Aronson L. Traditional Cambodian health beliefs and practices. Understanding 
Cambodian traditions will facilitate their care in a Western setting. Rhode Island 
Medical Journal. 1987;70(2):73. 
208. Faller HS. Perinatal needs of immigrant Hmong women: surveys of women and 
health care providers. Public Health Reports. 1985;100(3):340. 
209. Deinard AS, Dunnigan T. Hmong Health Care--Reflections on a Six-Year Experience. 
International Migration Review. 1987;21(3):857-865. 
210. U.S. General Accounting Office: Asian Americans: a status report. U.S. 
Government Printing Office, Washington, DC, March 1990. 
211. Muecke MA. In search of healers ? Southeast Asian refugees in the American 
health care system. Western Journal of Medicine. 1983;139(6):835. 
212. Mikhail BI. Hispanic mothers' beliefs and practices regarding selected children's 
health problems. Western Journal of Nursing Research. 1994;16(6):623. 
213. Mental health care system works to meet needs of Southeast Asian refugees. 
Refugee Rep 6: 1-5 (1985). 
214. Lin-Fu JS. Population characteristics and health care needs of Asian Pacific 
Americans. Public Health Reports. 1988;103(1):18. 
215. Link BG, Phelan JC. Stigma and its public health implications. Lancet. 
2006;367(9509):528-528. 
216. Farina A, Allen JG, Saul BBB. The role of the stigmatized person in affecting social 
relationships. Journal of Personality. 1968;36(2):169-182. 
217. Bhatia R, Wallace P. Experiences of refugees and asylum seekers in general 
practice: a qualitative study. BMC Family Practice. 2007;8(1):48. 
218. Kmietowicz  Z. Doctors turn away refugees, conference told. BMJ. 
2001;323(7314):653. 
  
290 
219. Corrigan P. How stigma interferes with mental health care. American Psychologist. 
2004;59(7):614. 
220. Wong EC, Marshall GN, Schell TL, Elliott MN, Hambarsoomians K, Chun CA, et al. 
Barriers to mental health care utilization for US Cambodian refugees. Journal of 
Consulting and Clinical Psychology. 2006;74(6):1116. 
221. Leong FTL, Lau ASL. Barriers to providing effective mental health services to Asian 
Americans. Mental Health Services Research. 2001;3(4):201-214. 
222. Sue DW, Sue D. Counseling the culturally different: Theory and practice: John 
Wiley & Sons; 1990. 
223. O'Mahony JM, Donnelly TT. The influence of culture on immigrant women's 
mental health care experiences from the perspectives of health care providers. 
Issues in Mental Health Nursing. 2007;28(5):453-471. 
224. Bhui K, Stansfeld S, Hull S, Priebe S, Mole F, Feder G. Ethnic variations in 
pathways to and use of specialist mental health services in the UK Systematic 
review. The British Journal of Psychiatry. 2003;182(2):105-116. 
225. Commander M, Cochrane R, Sashidharan S, Akilu F, Wildsmith E. Mental health 
care for Asian, black and white patients with non-affective psychoses: pathways 
to the psychiatric hospital, in-patient and after-care. Social Psychiatry and 
Psychiatric Epidemiology. 1999;34(9):484-491. 
226. ZĞŝĚƉĂƚŚ  ?ŚĂŶ <z ?'ŝĨĨŽƌĚ ^D ?ůůŽƚĞǇ W ?  ‘,Ğ ŚĂƚŚ ƚ Ğ &ƌĞŶĐŚ ƉŽǆ ? P ƐƚŝŐŵĂ ?
social value and social exclusion. Sociology of Health & Illness. 2005;27(4):468-
489. 
227. Lipsedge M. Mental health: access to care for black and ethnic minority people'. 
Access to Health Care for People from Black and Ethnic Minorities. London: Royal 
College of Physicians. 1993. 
228. Hoang GN, Erickson RV. Cultural barriers to effective medical care among 
Indochinese patients.  Annual Review of Medicine. 1985;36(1):229-239. 
229. Ishisaka H, Nguyen Q, Okimoto J. The role of culture in the mental health 
treatment of Indochinese refugees. Southeast Asian Mental Health: Treatment, 
Prevention, Services, Training and Research. Washington, DC, US DHHS. 1985:41-
63. 
230. Gong-Guy E, Cravens RB, Patterson TE. Clinical issues in mental health service 
delivery to refugees. American Psychologist. 1991;46(6):642. 
231. Lum R. A community-based mental health service to Southeast Asian refugees. 
Southeast Asian Mental Health: Treatment, Prevention, Services, Training, and 
Research. Washington, DC: US Department of Health and Human Services. 1985. 
  
291 
232. Gibbs JT, Fuery D. Mental health and well-being of black women: Toward 
strategies of empowerment. American Journal of Community Psychology. 
1994;22(4):559-582. 
233. James SA, LaCroix AZ, Kleinbaum DG, Strogatz DS. John Henryism and blood 
pressure differences among black men. II. The role of occupational stressors. 
Journal of Behavioral Medicine. 1984;7(3):259-275. 
234. Gorst-Unsworth C, Goldenberg E. Psychological sequelae of torture and organised 
violence suffered by refugees from Iraq. Trauma-related factors compared with 
social factors in exile. The British Journal of Psychiatry. 1998;172(1):90. 
235. McAfee B. Instead of medicine. Report of the Bosnian mental health pilot project. 
Refugee Action: London; 1998. 
236. Epstein H. A life in the day of Perico Rodriguez. Sunday Times. 1996 Feb 18. 
237. Watters C. The mental health needs of refugees and asylum seekers: key issues in 
research and service development. Current issues of asylum law and policy. 
Aldershot: Ashgate. 1998:282 W297. 
238. Noël MP, Robert A, Brysbaert M. Does language really matter when doing 
arithmetic? Reply to Campbell. Cognition. 1998;67(3):365-373. 
239. Hall AG. Medicaid's impact on access to and utilization of health care services 
among racial and ethnic minority children. Journal of Urban Health. 
1998;75(4):677-692. 
240. Riportella-Muller R, Selby-Harrington ML, Richardson LA, Donat PL, Luchok KJ, 
Quade D. Barriers to the use of preventive health care services for children. Public 
Health Reports. 1996;111(1):71. 
241. Peters J, Parry GD, Van Cleemput P, Moore J, Cooper CL, Walters SJ. Health and 
use of health services: a comparison between Gypsies and Travellers and other 
ethnic groups. Ethnicity & Health. 2009;14(4):359-377. 
242. www.kent.gov.uk/.../gypsies_and_travellers/definition.aspx. Accessed Jan 2010. 
243. Cemlyn S, Greenfields M, Burnett S, Matthews Z, Whitwell C. Inequalities 
experienced by Gypsy and Traveller communities: A review: Equality and Human 
Rights Commission; 2009. 
244. Home R. Negotiating security of tenure for peri-urban settlement: traveller-
gypsies and the planning system in the United Kingdom. Habitat International. 
2002;26(3):335-346. 
245.  Traveller Health: A National Strategy 2002-2005,Irish Medical Journal,  
http://www.imj.ie. 
246. Okely J. The traveller-gypsies. The Journal of Intercultural Studies. 1984; 5(4): 61-
64. 
  
292 
247. Parry G, Van Cleemput P, Peters J, Walters S, Thomas K, Cooper C. Health status 
of Gypsies and Travellers in England. BMJ. 2007;61(3):198-204. 
248. Hawes D. Gypsies, Travellers and the Health Service a study in inequality. Bristol 
the Policy Press; 1997. 
249. Jenkins M. EŽdƌĂǀĞůůĞƌƐ ?ƌĞƉŽƌƚŽĨ'ǇƉƐǇĂŶĚdƌĂǀĞůůĞƌtŽŵĞŶ ?ƐĞǆƉĞƌŝĞŶĐĞƐŽĨ
Maternity Care. London: Maternity Alliance. 2004. 
250. Scottish Executive. Response to the Equal Opportunities Committee Report 2001: 
Inquiry Into Gypsy Travellers And Public Sector Policies. Edinburgh: Scottish 
Executive. Available at: http://cci.scot.nhs.uk/library3/government/gtoctober-
00.asp. [Accessed 1 September 2008]. 
251. Scottish Executive. Fair for All: Improving the Health of Ethnic Minority Groups 
and the Wider Community in Scotland. Edinburgh, The Stationery Office. 2001. 
252. Beach H. Comparing the use of an Accident and Emergency Department by 
children from two Local Authority Gypsy sites with that of their neighbours. 
Public Health. 2006;120(9):882-884. 
253. Richardson J, Bloxsom J, Greenfields M. East Kent Gypsy and Traveller 
Accommodation Assessment Report (2007-2012). 2007. 
254. Parry G, Van Cleemput P, Peters J, Moore J, Walters S, Thomas K, et al. The health 
status of gypsies and travellers in England. Report of Department of Health 
Inequalities in Health Research Initiative Project. 2004;121:7500. 
255. Roberts AA, J. Lewis, H. & Wilkinson, C. ŽŵŵƵŶŝƚǇ WƌĂĐƚŝƚŝŽŶĞƌƐ ? ĂŶĚ ,ĞĂůƚŚ
sŝƐŝƚŽƌƐ ? ƐƐŽĐĂƚŝŽŶ  ?W,s ? ŶŶƵĂů ŽŶĨĞƌĞŶĐĞ ? ŽƌŽŶĂƌǇ,ĞĂƌƚ ŝƐĞĂƐĞ ĂŶĚ
Mental Health in Gypsies and Travellers in Wrexham: Redressing the balance. 
Torquay, 31 Ocotober  W 2 November 2007. Available at: 
http://www.amicus-cphva.org/pdf/B2.2%20Helen%20Lewis.pdf  
256. Dorset Health Authority / Friends Families and Travellers (FFT). Report of the Pilot 
Health Promotion Project with Travellers in Dorset 1997-98. Brighton: Friends, 
Families and Travellers Support Group. 1999 
257. Saunders R. The Forgotten Minority. Diabetes Update.  2007:26-29. 
258. Pahl JM, Vaile MSB. Health and health care among travellers. University of Kent 
Health Services Research Unit, Canterbury: Cambridge Univ Press; 1986. 
259. Baker M. Gypsies and Travellers: The Leeds Baseline Census 2004-2005. Leeds 
Racial Equality Council, Leeds. 2005. 
260. Brack JM, S. dƌĂǀĞůůĞƌƐ ? >ĂƐƚ ZŝŐŚƚƐ P ƌĞƐƉŽŶĚŝŶŐ ƚŽ ĚĞĂƚŚ ŝŶ ĂĐƵůƚƵƌĂů ĐŽŶƚĞǆƚ ? 
Dublin: Parish of the Travelling People. 2007. 
  
293 
261. Pahl J, Vaile M. Health and health care among travellers. Journal of Social Policy. 
1988;17(02):195-213. 
262. Feder G. Traveller gypsies and primary care. The Journal of the Royal College of 
General Practitioners. 1989;39(327):425. 
263. Lawrence H. On the road to better health. Emergency nurse: the journal of the 
RCN Accident and Emergency Nursing Association. 2007;15(5):12. 
264. Lynch E. Travellers' tales. Nursing standard (Royal College of Nursing (Great 
Britain): 1987). 2006;20(41):20. 
265. Jeffrey J, Davis J, Hoult H. Afro-ĂƌŝďďĞĂŶ ĂŶĚ ƚƌĂǀĞůůŝŶŐ ĨĂŵŝůŝĞƐ ? ŚĞĂůƚŚŶĞĞĚƐ. 
Health visiting specialist and higher level practice. 2000:373-397. 
266. Feder GS, Vaclavik T, Streetly A. Traveller Gypsies and childhood immunization: a 
study in east London. The British Journal of General Practice. 1993;43(372):281. 
267. Hollinger M, Farrell B. Traveller Gypsies and childhood immunization. The British 
Journal of General Practice. 1993;43(376):482. 
268. Cohuet S, Morgan O, Bukasa A, Heathcock R, White J, Brown K, et al. Outbreak of 
measles among Irish travellers in England, March to May 2007. Euro Surveill. 
2007;12(6):E070614. 
269. Carr-Hill S. Health care for travellers. BMJ (Clinical research ed.). 
1987;294(6579):1098. 
270. Mayall D. Gypsy-travellers in nineteenth-century society: Cambridge Univ Pr; 1988. 
271. Clark C, Greenfields M. Here to Stay: The Gypsies and Travellers of Britain: 
University of Hertfordshire Press; 2006. 
272. Greenfields M. Gypsies, Travellers and legal matters. Here to stay: The Gypsies 
and Travellers of Britain. 2006:133 W81. 
273. Dion X. Gypsies and Travellers: cultural influences on health. Community 
Practitioner. 2008;81(6):31-34. 
274. Van Cleemput P. Social exclusion of Gypsies and Travellers: health impact. Journal 
of Research in Nursing. 2010;15(4):315. 
275. Greenfields M, Home R. Assessing Gypsies and Travellers needs: Partnership 
working and'The Cambridge Project'. Romani Studies. 2006;16(2):105-131. 
276. Heron S, Barry J, Fitzgerald M, Mac Lachlan M. The psychosocial health of Irish 
Traveller mothers. Cultivating pluralism: Psychological, social and cultural 
perspectives on a changing Ireland. 2000:93-116. 
277. Lehti A, Mattson B. Health, attitude to care and pattern of attendance among 
gypsy women ? a general practice perspective. Family Practice. 2001;18(4):445. 
  
294 
278. Pill R, Stott NCH. Concepts of illness causation and responsibility: some 
preliminary data from a sample of working class mothers. Social Science & 
Medicine. 1982;16(1):43-52. 
279. Smart H, Titterton M, Clark C. A literature review of the health of Gypsy/Traveller 
families in Scotland: the challenges for health promotion. Health Education. 
2003;103(3):156-165. 
280. Linthwaite P, Sampson K, Fund StC. The health of Traveller mothers and children 
in East Anglia: Save the Children; 1983. 
281. Crawley H. Moving forward: the provision of accommodation for Travellers and 
Gypsies: Institute for Public Policy Research; 2004. 
282. Spencer L, Ritchie J, Lewis J, Dillon L. Quality in Qualitative Evaluation: A 
framework for assessing research evidence. Social Research. 2003(21/08/05). 
283. Niner P. Accommodating nomadism? An examination of accommodation options 
for Gypsies and Travellers in England. Housing Studies. 2004;19(2):141-159. 
284. Appleton L, Hagan T, Goward P, Repper J, Wilson R. Smail's contribution to 
understanding the needs of the socially excluded: the case of gypsy and traveller 
women. Clinical Psychology. 2003;24:40-46. 
285. Greenfields M. Gypsies, Travellers and accommodation. 2009. 
286. Goward P, Repper J, Appleton L, Hagan T. Crossing boundaries. Identifying and 
meeting the mental health needs of Gypsies and Travellers. Journal of Mental 
Health. 2006;15(3):315-327. 
287. Johnson B, Christensen LB. Educational research: Quantitative, qualitative, and 
mixed approaches: Sage Publications, Inc; 2007. 
288. Roundtree K, Laing T. Writing by degree: a practical guide to writing theses and 
research papers. Longman, Auckland. 1996. 
289. Miles MB, Huberman AM. Qualitative data analysis: An expanded sourcebook. 
1994. Beverly Hills: Sage Publications. 1994. 
290. Miles MB, Huberman AM. Qualitative data analysis: Sage Publ.; 1999. 
291. Denscombe M, Corporation E. The good research guide: Open Univ. Press; 1998. 
292. Creswell JW. Qualitative Inquiry and Research Design: Choosing among Five 
Approaches [with CD-ROM]. SAGE Publications (CA). 2006:416. 
293. Bouma GD, Ling R, Wilkinson L. The research process: Oxford University Press, 
Oxford; 1993. 
294. Denzin NK, Lincoln YS. The discipline and practice of qualitative research. 
Handbook of Qualitative Research. 2000;2:1-28. 
  
295 
295. Banister P, Burman E, Parker I, Taylor M, Tindall C. Qualitative methods in 
psychology: Open University Press; 1995. 
296. Maykut PS, Morehouse R, Morehouse RE. Beginning qualitative research: A 
philosophic and practical guide: Routledge; 1994. 
297. Johnson RB, Onwuegbuzie AJ. Mixed methods research: A research paradigm 
whose time has come. Educational Researcher. 2004;33(7):14-26. 
298. Kvale S. Interviews: An introduction to qualitative research interviewing: Sage 
Publications, Inc; 1996. 
299. Bell J. Doing your research project: a guide for first-time researchers in education, 
health and social science: Open Univ Pr; 2005. 
300. Cohen L, Manion L, Morrison K, Morrison KRB. Research methods in education: 
Psychology Press; 2007. 
301. Bums R. Introduction to research methods. New South Wales: Longrnan. 2000. 
302. Patton MJ. Qualitative research on college students: Philosophical and 
methodological comparisons with the quantitative approach. Journal of College 
Student Development. 1991. 
303. Robson C. Real world research: A resource for social scientists and practitioner-
researchers: Wiley-Blackwell; 2002. 
304. Fontana A, Frey JH. The interview: From structured questions to negotiated text. 
Handbook of Qualitative Research. 2000;2:645-672. 
305. Bryman A. Social research methods . Oxford University Press, Oxford: CSIRO; 2001. 
306. Briggs CL. Learning how to ask: A sociolinguistic appraisal of the role of the 
interview in social science research: Cambridge Univ Pr; 1986. 
307. Wilson GL, & Goodall, H. L. The Craft of Interviewing. New York: McGraw 
Publishing. 1991. 
308. Anderson GJ. Fundamentals of educational research: Routledge; 1998. 
309. Bogdan RC, Biklen SK. Qualitative research in education. An introduction to theory 
and methods: Allyn & Bacon, A Viacom Company, 160 Gould St., Needham 
Heights, MA 02194; Internet: www. abacon. com.; 1998. 
310. Keats DM. Interviewing: A practical guide for students and professionals: Univ of 
New South Wales; 1999. 
311. Hutchinson SA, Campus JS. Education and Grounded Theory1. Qualitative 
Research in Education: Focus and Methods. 1988:122. 
312. Flick U. An introduction to qualitative research: Sage Publications Ltd; 2009. 
  
296 
313. Patton MQ. How to use qualitative methods in evaluation: Sage; 1994. 
314. Merriam SB. Qualitative Research and Case Study Applications in Education. 
Revised and Expanded from" Case Study Research in Education.": Jossey-Bass 
Publishers. Avalable at: www.josseybass. com.  1998. 
315. Liedtka JM. Exploring ethical issues using personal interviews. Business Ethics 
Quarterly. 1992;2(2):161-181. 
316. Stringer ET. Action research in education: Prentice Hall; 2003. 
317. Robson K, Robson M. «Your place or mine? Ethics, the researcher and Internet» In 
Ethical Dilemmas in qualitative research, sous la direction de T. Welland et L. 
Pugsley. Burlington: Ashgate; 2002. 
318. Anderson GL. Toward authentic participation: Deconstructing the discourses of 
participatory reforms in education. American Educational Research Journal. 
1998;35(4):571. 
319. Goodwin WL, Goodwin LD. Understanding quantitative and qualitative research 
in early childhood education: Teachers College Pr; 1996. 
320. Tolich M, Davidson C. Starting fieldwork: An introduction to qualitative research 
in New Zealand: Oxford Univ Pr; 1999. 
321. Bishop R, Glynn T. Culture counts: changing power relations in education. 
(Palmerston North, Dunmore Press). 1999. 
322. Oppenheim AN. Questionnaire design, interviewing and attitude measurement: 
Pinter Pub Ltd; 1998. 
323. Djuric G, Daye S. A rapid health care needs assessment report on the health needs 
of asylum seekers and refugees living in the London borough of Hounslow. 
Hounslow Primary Care Trust, London. 2003. 
324. Holl JL, Szilagyi PG, Rodewald LE, Byrd RS, Weitzman ML. Profile of uninsured 
children in the United States. Archives of Pediatrics and Adolescent Medicine. 
1995;149(4):398. 
325. Baqir W, Todda A, Learoyda T, Sima Y, Mortona L. Cost effectiveness of 
community pharmacy minor ailment schemes. International Journal of Pharmacy 
Practice. 2010;18(Supplement 2):3. 
326. Pumtong S, Boardman HF, Anderson CW. Pharmacists' perspectives on the 
Pharmacy First Minor Ailments Scheme. International Journal of Pharmacy 
Practice. 2008;16(2):73-80. 
327. Vohra S. A community pharmacy minor ailment scheme-: effective, rapid and 
convenient. Pharmaceutical journal. 2006;276(7406):754-756. 
  
297 
328. Parmentier H, Golding S, Ashworth M, Rowlands G. Community pharmacy 
treatment of minor ailments in refugees. Journal of Clinical Pharmacy and 
Therapeutics. 2004;29(5):465-469. 
329. Banoub-Baddour S, Laryea M. Children in pain: A culturally sensitive perspective 
for child care professionals. Journal of Child & Youth Care. 1991. 
330. Pfefferbaum B, Adams J, Aceves J. The influence of culture on pain in Anglo and 
Hispanic children with cancer. Journal of the American Academy of Child & 
Adolescent Psychiatry. 1990;29(4):642-647. 
331. Craig KD, Lilley CM, Gilbert CA. Barriers to optimal pain management in infants, 
children, and adolescents social barriers to optimal pain management in infants 
and children. The Clinical Journal of Pain. 1996;12(3):232. 
332. Schechter NL. The undertreatment of pain in children: an overview. Pediatric 
Clinics of North America. 1989;36(4):781. 
333. Link BG, Cullen FT, Struening E, Shrout PE, Dohrenwend BP. A modified labeling 
theory approach to mental disorders: An empirical assessment. American 
Sociological Review. 1989;54(3):400-423. 
334. ZŚŽĚĞƐW: ?^ŵĂůůE ?/ƐŵĂŝů, ?tƌŝŐŚƚ:W ? ‘tŚĂƚƌĞĂůůǇ ĂŶŶŽǇƐŵĞŝƐƉĞŽƉůĞƚĂŬĞŝƚ
ůŝŬĞ ŝƚ ?Ɛ Ă ĚŝƐĂďŝůŝƚǇ ? ? ĞƉŝůĞƉƐǇ ? ĚŝƐĂďŝůŝƚǇ ĂŶĚ ŝĚĞŶƚŝƚǇ ĂŵŽŶŐ ƉĞŽƉůĞ ŽĨ WĂŬŝƐƚĂŶŝ
origin living in the UK. Ethnicity and Health. 2008;13(1):1-21. 
335. Jacoby A. Epilepsy and stigma: An update and critical review. Current Neurology 
and Neuroscience Reports. 2008;8(4):339-344. 
336. Lim YJ, Chan SY, Ko Y. Stigma and health-related quality of life in Asian adults 
with epilepsy. Epilepsy Research. 2009;87(2-3):107-119. 
337. Santosh D, Kumar TS, Sarma PS, Radhakrishnan K. Women with onset of epilepsy 
prior to marriage: Disclose or conceal?. Epilepsia. 2007;48(5):1007-1010. 
338. Radhakrishnan K, Pandian J, Santhoshkumar T, Thomas S, Deetha T, Sarma P, et al. 
Prevalence, knowledge, attitude, and practice of epilepsy in Kerala, South India. 
Epilepsia. 2000;41(8):1027-1035. 
339. Shafiq M, Tanwir M, Tariq A, Kasi P, Zafar M, Saleem A, et al. Epilepsy: Public 
knowledge and attitude in a slum area of Karachi, Pakistan. Seizure. 
2007;16(4):330-337. 
340. Barennes H, Sengkhamyong K, Sambany EM, Koffi PN, Chivorakul P, Empis G, et al. 
Children's access to treatment for epilepsy: experience from the Lao People's 
Democratic Republic. Archives of Disease in Childhood. 2011;96(3):309-313. 
341. Datta SS, Premkumar TS, Fielding S, Chandy S, Kumar S, Eagles J, et al. Impact of 
pediatric epilepsy on Indian families: influence of psychopathology and seizure 
related variables. Epilepsy & Behavior. 2006;9(1):145-151. 
  
298 
342. Nursing Times. Measles Hits Travellers. News report 31/5/2007. London: The 
Nursing Times. 2007 
343. Hall V, Sadouni M, Fuller A. 'ǇƉƐǇĂŶĚdƌĂǀĞůůĞƌƐ ?ĞǆƉĞƌŝĞŶĐĞŽĨƵƐŝŶŐƵƌŐĞŶƚĐĂƌĞ
services within NHS Brighton and Hove boundaries. 2009. 
344. Eggleston PA. Environmental causes of asthma in inner city children. Clinical 
Reviews in Allergy and Immunology. 2000;18(3):311-324. 
345. Platts Mills T, Erwin E, Heymann P, Woodfolk J. Is the hygiene hypothesis still a 
viable explanation for the increased prevalence of asthma?. Allergy. 2005;60:25-
31. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
299 
 
APPENDICES 
APPENDIX A 
A1: Interview questions 
 
&KLOGUHQ¶V$FFHVVWR0HGLFLQHVLQWKH(DVW0LGODQGV 
 Parental interview 
 
 
A. BACKGROUND 
 
Age (years): ««««««««««« Male / Female 
 
No. of adults living in the home: ««««««««««««««««««««  
 
No. of children: ««««««««««««««««««««««««««« 
 
Age of children: «««««««««««««««««««««««««««« 
 
Occupation: ««««««««««««««««««««««««««««« 
 
Country of birth: ««««««««««««««««««««««««««« 
 
If applicable 
 
Country left: «««««««««««««««««««««««««« 
 
Reasons for leaving: «««««««««««««««««««««« 
 
Date of entry to the UK: ««««««««««««««««««««« 
 
Have you had a decision on your asylum claim: «««««««««« 
 
Duration of time in present accommodation: «««««««««««««« 
 
Duration of time in current locality: ««««««««««««««««««« 
 
Contacts in current locality: «««««««««««««««««««««« 
 
Links with community: «««««««««««««««««««««««« 
 
  
300 
B. HEALTH 
 
Are you registered with a GP? 
 
Yes                           No   
 
If no, why is that? 
««««««««««««««««««««««««««« 
 
Date of last visit to GP: 
«««««««««««««««««««««««« 
 
Are you well? 
 
Yes                           No   
 
 
Are you on any medicines? 
 
     Yes                          No 
 
If so, which medicine and from whom do you obtain the medicine? 
««««««««««««««««««««««««««««««««««
«««««««««««««««««««««««««««««««««« 
 
Are your children normally fit and well? 
 
     Yes                            No  
 
 
If not, please give details.  
««««««««««««««««««««««««««««««««««
««««««««««««««««««««««««««««««««« 
 
What do you normally do when your child is unwell? 
.......................................................................................................................... 
««««««««««««««««««««««««««««««««««
««««««««««««««««««««««««««««««««« 
 
Have your children received their immunisations? 
 
       Yes                            No    
 
If so, which?  
««««««««««««««««««««««««««««««««««
««««««««««««««««««««««««««««««««« 
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C. LAST MONTH 
 
Have any of the children been ill in the last month? 
 
       Yes                            No    
 
If so, have they seen a health professional?  If so, state which type? 
««««««««««««««««««««««««««««««««««
«««««««««««««««««««««««««««««««««« 
 
Have any of your children received any medicines in the last month? 
 
       Yes                              No 
 
If so, which medicines? 
««««««««««««««««««««««««««««««««««
«««««««««««««««««««««««««««««««««« 
Were the medicines prescribed and, if so, by whom? 
««««««««««««««««««««««««««««««««« 
Where did you get the medicines from? 
««««««««««««««««««««««««««««««««« 
Did you have to pay for the medicines? 
 
       Yes                              No 
 
«««««««««««««««««««««««««««««««««« 
Were there any difficulties in obtaining the medicines? (Include travel 
costs) 
 
       Yes                              No 
 
«««««««««««««««««««««««««««««««««« 
««««««««««««««««««««««««««««««««« 
Have any of your children received any medicines (including herbal or 
homeopathic remedies) in the last month that you have bought from a 
chemist or obtained from any other individual? 
 
       Yes                              No 
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If so, which medicines and from whom? 
««««««««««««««««««««««««««««««««««
««««««««««««««««««««««««««««««««« 
 
D. LAST SIX MONTHS 
 
Have any of the children been ill in the last six months? 
 
       Yes                            No    
 
If so, have they seen a health professional?  If so, state which type? 
««««««««««««««««««««««««««««««««««
«««««««««««««««««««««««««««««««««« 
 
Have any of your children received any medicines in the last six 
months? 
 
       Yes                              No 
 
If so, which medicines? 
««««««««««««««««««««««««««««««««««
«««««««««««««««««««««««««««««««««« 
Were the medicines prescribed and, if so, by whom? 
««««««««««««««««««««««««««««««««« 
Where did you get the medicines from? 
«««««««««««««««««««««««««««««««««« 
Did you have to pay for the medicines? 
 
       Yes                              No 
 
«««««««««««««««««««««««««««««««««« 
Were there any difficulties in obtaining the medicines? (Include travel 
costs) 
 
       Yes                              No 
 
«««««««««««««««««««««««««««««««««« 
«««««««««««««««««««««««««««««««««« 
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Have any of your children received any medicines (including herbal or 
homeopathic remedies) in the last six months that you have bought 
from a chemist or obtained from any other individual? 
 
       Yes                              No 
 
 
If so, which medicines and from whom? 
««««««««««««««««««««««««««««««««««
«««««««««««««««««««««««««««««««««« 
 
E. GENERAL 
If your child was crying with earache, what would you do? 
««««««««««««««««««««««««««««««««««
«««««««««««««««««««««««««««««««««« 
Would you give your child any medicine for the earache? 
       Yes                              No 
 
If so, which medicines? 
««««««««««««««««««««««««««««««««««
«««««««««««««««««««««««««««««««««« 
If your child developed asthma (difficulty breathing, wheezy) and 
required an inhaler, how would you feel about that? 
«««««««««««««««««««««««««««««««««« 
«««««««««««««««««««««««««««««««««« 
Have you heard of the condition epilepsy (seizures, fits)? 
 
Yes                               No 
 
If your child developed epilepsy and required regular treatment, would 
you want your child to see a doctor regularly? 
 
    Yes                                No 
 
If yes, which doctor would you take them to? 
  
  
  
  
  
304 
««««««««««««««««««««««««««««««««««
«««««««««««««««««««««««««««««««««« 
If the doctor recommended your child received medicine for epilepsy 
on a daily basis for the next two years, how would you feel about that? 
«««««««««««««««««««««««««««««««««« 
«««««««««««««««««««««««««««««««««« 
 
Would you be happy to inform your friends/relatives that your child has 
epilepsy? 
 
 
    Yes                                   No 
 
 
Would you be happy to inform the school that your child has epilepsy? 
 
 
    Yes                                 No 
 
 
We would value your comments on the way you were approached to 
participate in this research. 
«««««««««««««««««««««««««««««««««« 
««««««««««««««««««««««««««««««««««
«««««««««««««««««««««««««««««««««« 
 
Do you think we could have approached you in a more appropriate 
manner? 
««««««««««««««««««««««««««««««««««
« 
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A2: Westfield Poster   
 
 
 
 
ARE YOU A 
PARENT? 
 
 
WOULD YOU LIKE TO 
HELP OUR RESEARCH 
BY ANSWERING A 
FEW QUESTIONS 
ABOUT MEDICINES 
FOR CHILDREN? 
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A3: (WKLF¶V&RPPLWWHHDSSURYDO 
 
  
307 
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A4: Information Sheet  
 
INFORMATION DOCUMENT 
 
 
Children's access to medicines in the East Midlands - a pilot study  
 
Investigators: Prof Imti Choonara, Dr Helen Sammons, Dr Parag Tambe    
                         Postgraduate student Saad Alkahtani, Research Nurse Janine Cherrill 
We are inviting you to take part in a research study.  Research is a way we try to find 
out the answers to questions. This is part of a research study to find out what you 
think about healthcare in the UK. Before you decide whether to take part, it is 
important that you understand what the project is about and what you will have to do. 
Please take time to read this and ask if there is anything that is not clear. 
 
Why are we doing this research study? 
We would like to find out what you think about of healthcare in the UK.  We wish to 
determine whether all children receive medicines. We also wish to explore attitudes 
towards the treatment of medical conditions such as asthma, epilepsy and pain. 
 
Why have I been chosen? 
Because you are a parent and we want to know what you think.  
 
Do I have to take part?  
It is up to you to decide. You do not have to take part.  If you say no, this will not 
affect you or your children. We will describe the study and go through this 
information, which we will then give to you. We will then ask you to sign a consent 
form to show that you have agreed to take part and you will be able to keep a copy of 
this. You are free to withdraw at any time, without giving a reason. This will not 
affect the standard of care you receive. 
 
What will you ask me to do? 
We will ask you a few questions. 
 
What will I get out of taking part in this project? 
7KHUHVHDUFKZLOOKHOSWRLGHQWLI\LIWKHUHDUHDQ\SUREOHPVLQUHODWLRQWRFKLOGUHQ¶V
access to medicines in several different groups and will hopefully identify ways of 
LPSURYLQJFKLOGUHQ¶VDFFHVVWRPHGLFLQHV7KLVSLORWVWXG\ZLOOJLYHLQGLYLGXDOVZKR 
have difficulty accessing health care the opportunity to state their opinions about any 
barriers to their children receiving medicines that they require.   
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Will my taking part in this study be private (confidential)? 
All information which is collected during the course of the research will be kept 
strictly confidential, and any information will have the name removed so that you 
cannot be recognised.  
 
:KDWZLOOKDSSHQLIZHGRQ¶WZDQWWRFDUU\RQZLWKWKHVWXG\" 
If you withdraw from the study, we will stop collecting data about your opinions on 
access to healthcare for your children. 
 
What if there is a problem? 
In case you have a complaint on your treatment by a member of staff or anything to 
do with the study, you can initially approach the lead investigator.  If this achieves 
no satisfactory outcome, you should then contact the Ethics Committee Secretary, 
Mrs Louise Sabir, Division of Therapeutics and Molecular Medicine, D Floor, South 
%ORFN4XHHQ¶V0HGLFDO&HQWUH1RWWLQJKDP1*8+7HOHSKRQH
E-mail louise.sabir@nottingham.ac.uk  
In the event that something does go wrong and you are harmed during the research 
DQG WKLV LV GXH WR VRPHRQH¶V QHJOLJHQFH WKHQ \RX PD\ KDYH JURXQGV IRU D OHJDO
action for compensation against the University of Nottingham but you may have to 
pay your legal costs.  
 
Who is organising this study? 
This study is being sponsored by the Academic Division of Child Health, University 
RI 1RWWLQJKDP 'HUE\VKLUH &KLOGUHQ¶V +RVSLWDO The principal investigator is 
Professor Imti Choonara. 
 
 Who has reviewed the study? 
All research is looked at by an independent group of people, called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity. This study has been 
reviewed and approved by the University of Nottingham Medical School Ethics 
Committee.  
Thank you for reading this ± please ask any questions if you need to 
Further Information and contact details 
 
Investigators:   Professor Imti Choonara 
    Professor in Child Health, University of Nottingham 
                                                Academic Division of Child Health 
    Clinical Sciences Building 
    Medical School 
    'HUE\VKLUH&KLOGUHQ¶V+RVSLWDO 
    Derby DE22 3DT 
    01332 724693 
Dr Parag Tambe, Research Nurse Janine Cherrill or 
Postgraduate Student Saad Alkahtani                                   
                                                01332 724696 
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A5: Consent Form 
 
7LWOHRI3URMHFW&KLOGUHQ¶V$FFHVVWR0HGLFLQHLQWKH(DVW0LGODQGV- a pilot study 
 
Name of Investigators: Professor Imti Choonara, Dr Helen Sammons, Janine Cherrill, Saad Alkhatani, 
Claire Millward and Dr Parag Tambe 
 
+HDOWK\9ROXQWHHU¶V&RQVHQW)RUP 
Please read this form and sign it once the above named or their designated 
representative, has explained fully the aims and procedures of the study to you 
 
x I voluntarily agree to take part in this study. 
 
x I confirm that I have been given a full explanation by the above named and 
that I have read and understand the information sheet given to me which is 
attached. 
 
x I have been given the opportunity to ask questions and discuss the study 
with one of the above investigators or their deputies on all aspects of the 
study and have understood the advice and information given as a result. 
 
x I agree to the above investigators contacting my general practitioner [and 
teaching or university authority if appropriate] to make known my 
participation in the study where relevant. 
 
x I authorise the investigators to disclose the results of my participation in the 
study but not my name. 
 
x I understand that information about me recorded during the study will be 
kept in a secure database.  If data is transferred to others it will be made 
anonymous.  Data will be kept for 7 years after the results of this study have 
been published. 
 
x I understand that I can ask for further instructions or explanations at any 
time. 
 
x I understand that I am free to withdraw from the study at any time, without 
having to give a reason for withdrawing. 
 
x I confirm that I have disclosed relevant medical information before the 
study. 
Name: «««««««««««««««««««««««««««««««««« 
 
Address:   «««««««««««««««««««««««««««««««« 
 
Telephone number«««««««««««««««««««««««««««« 
 
Signature:  ««««««««««««««««Date:  «««««««««««« 
 
I confirm that I have fully explained the purpose of the study and what is involved to: 
 
I have given the above named a copy of this form together with the information sheet. 
 
,QYHVWLJDWRU¶V6LJQDWXUH  «««««««««Name«««««««««««« 
 
Study Volunteer Number««««««««««««««««««««««««« 
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APPENDIX B 
  Qualitative research review guidelines ± RATS 
  ASK THIS OF THE MANUSCRIPT THIS SHOULD BE INCLUDED IN THE MANUSCRIPT 
R Relevance of study question   
  Is the research question interesting? Research question explicitly stated 
  Is the research question relevant to clinical 
practice, public health, or policy? 
 
Research question justified and linked to the existing knowledge base 
(empirical research, theory, policy) 
A Appropriateness of qualitative method   
  Is qualitative methodology the best approach 
for the study aims? 
Interviews: experience, perceptions, 
behaviour, practice, process 
Focus groups: group dynamics, convenience, 
non-sensitive topics 
Ethnography: culture, organizational 
behaviour, interaction 
Textual analysis: documents, art, 
representations, conversations 
 
Study design described and justified e.g., why was a particular method 
(i.e., interviews) chosen? 
T Transparency of procedures   
  Sampling   
  Are the participants selected the most 
appropriate to provide access to type of 
knowledge sought by the study? 
Is the sampling strategy appropriate? 
Criteria for selecting the study sample justified and explained 
theoretical: based on pre conceived or emergent theory 
purposive: diversity of opinion 
volunteer: feasibility, hard-to-reach groups 
  Recruitment   
  Was recruitment conducted using appropriate 
methods? 
Is the sampling strategy appropriate? 
Details of how recruitment was conducted and by whom 
  Could there be selection bias? Details of who chose not to participate and why 
  Data collection   
  Was collection of data systematic and 
comprehensive? 
Method (s) outlined and examples given (e.g., interview questions) 
  Are characteristics of the study group and 
setting clear? 
Study group and setting clearly described 
  Why and when was data collection stopped, 
and is this reasonable? 
End of data collection justified and described 
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  Role of researchers   
  Is the researcher (s) appropriate? How might 
they bias (good and bad) the conduct of the 
study and results?  
Do the researchers occupy dual roles (clinician and researcher)? 
Are the ethics of this discussed?Do the researcher(s) critically examine 
their own influence on the formulation of the research question, data 
collection, and interpretation? 
  Ethics   
  Was informed consent sought and granted? Informed consent process explicitly and clearly detailed 
  :HUH SDUWLFLSDQWV¶ DQRQ\PLW\ DQG
confidentiality ensured? 
Anonymity and confidentiality discussed 
  Was approval from an appropriate ethics 
committee received? 
Ethics approval cited 
S Soundness of interpretive approach   
  Analysis   
  Is the type of analysis appropriate for the 
type of study? 
thematic: exploratory, descriptive, hypothesis 
generating 
framework: e.g., policy 
constant comparison/grounded theory: 
theory generating, analytical 
Analytic approach described in depth and justified 
  Are the interpretations clearly presented and 
adequately supported by the evidence? 
Are quotes used and are these appropriate 
and effective? 
Indicators of quality: Description of how themes were derived from the 
data (inductive or deductive) 
Evidence of alternative explanations being sought 
Analysis and presentation of negative or deviant cases 
Description of the basis on which quotes were chosen 
Semi-quantification when appropriate 
Illumination of context and/or meaning, richly detailed 
  Was trustworthiness/reliability of the data 
and interpretations checked? 
Method of reliability check described and justified 
e.g., was an audit trail, triangulation, or member checking employed? 
Did an independent analyst review data and contest themes? How were 
disagreements resolved?  
  Discussion and presentation   
  Are findings sufficiently grounded in a 
theoretical or conceptual framework? 
Is adequate account taken of previous 
knowledge and how the findings add?  
Findings presented with reference to existing theoretical and empirical 
literature, and how they contribute 
  Are the limitations thoughtfully considered?  Strengths and limitations explicitly described and discussed 
  Is the manuscript well written and accessible? Evidence of following guidelines (format, word count) 
Detail of methods or additional quotes contained in appendix 
Written for a health sciences audience 
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APPENDIX C 
Statistical analysis:   
Asylum Seekers and Refugees 
  
Table 6.10: Comparison across Refugee and Control group (Independent sample 
t-test) 
 
 
  
Group N Mean SD T df Sig. (2-    
tailed) 
Parent age (Y) Refugee 50 36.24 7.358 1.565 98 .121 
Control 50 34.10 6.274 
Duration  in accommodation 
(Y) 
Refugee 50 2.85 2.111 -5.685 51 .000 
Control 50 12.89 12.307 
Duration in locality (Y) Refugee 50 5.43 3.440 -7.272 55 .000 
Control 50 19.82 13.556 
Last visit (D) Refugee 
Control  
49 
45 
27.65 
60.82 
36.112 
119.135 
-1.794 92 .079 
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Table 6.11: Sociodemographics (Mann-Whitney Test)  
Ranks 
 Group N Mean Rank Sum of Ranks 
Gender Refugee 50 34.50 1725.00 
Control 50 66.50 3325.00 
Total 100 
  
Occupation  Refugee 45 45.00 2025.00 
Control 50 50.70 2535.00 
Total 95 
  
Links with locality Refugee 50 48.08 2404.00 
Control 
Total 
48 
98 
50.98 2447.00 
Parents health                    
 
Refugee 
Control 
Total 
50 
50 
100 
44.00 
57.00 
2200.00 
2850.00 
 
 Mann-Whitney Test Two-Sample Kolmogorov-Smirnov Test 
                                                                        Test Statistics
a
 
Mann-
Whitney 
U 
Wilcoxon W Z Sig. (2-
tailed) 
Most Extreme Differences 
absolute positive negative 
 
Kolmogoro
v-Smirnov Z 
 Sig. (2-
tailed) 
Gender 450.000 1725.00 -6.414 .000 .640 .640 .000 
 
3.200 .000 
Occupation  990.000 2025.00 -1.165 .244 .120 .000 -.120 
 
.584 .885 
Links with 
locality 
1129.000 2404.000 -1.324 .186 .059 .059 .000 
 
.293 1.000 
 
Parents 
health 
925.000 2200.000 -3.074 .002        .260               .260             .000          1.300 .068 
a. Grouping Variable: Group 
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Table 6.12: General access to healthcare and medicines (Mann-Whitney Test) 
Ranks 
 Group N Mean Rank Sum of Ranks 
Reg with GP    Refugee 50 50.50 2525.00 
Control 50 50.50 2525.00 
Total 100 
  
Pay for RX  Refugee 49 34.49 1690.00 
Control 39 57.08 2226.00 
Total 88 
  
Difficulties Refugee 50 49.28 2464.00 
Control 41 42.00 1722.00 
Total 91 
  
Home RX Refugee 50 52.34 2617.00 
Control 49 47.61 2333.00 
Total 99 
  
  
  
 
 Mann-Whitney Test Two-Sample Kolmogorov-Smirnov Test 
                                                                           Test Statistics
a 
 
Mann-
Whitney U 
Wilcoxon W Z  Sig. (2-
tailed) 
Most Extreme Differences 
absolute positive negative 
 
Kolmogoro
v-Smirnov Z 
 Sig. (2-
tailed) 
Reg with 
GP    
1250.00 2525.00 .000 1.000 .000 .000 .000 
 
.000 1.000 
Pay for 
OTC  
465.00 1690.00 -5.060 .000 .513 .513 .000 
 
2.392 .000 
Difficulties 861.000 1722.000 -2.667 .008 .160 .000 -.160 
 
.759 .611 
Home RX 1108.00 2333.00 -1.061 .288 .096 .000 -.096 
 
.475 .978 
        
a. Grouping Variable: Group 
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Table 6.13: Data for the children (Mann-Whitney Test) 
Ranks 
 Group N Mean Rank Sum of Ranks 
No. of 
children/family 
Refugee 50 53.88 2694.00 
Control 50 47.12 2356.00 
Total 100 
  
Child health  Refugee 117 110.31 12906.00 
Control 99 106.36 10530.00 
Total 216 
  
Children Ages(Y) Refugee 117 114.41 13386.50 
Control 99 101.51 10049.50 
Total 216 
  
Immunisation Refugee 117 108.08 12645.00 
Control 99 109.00 10791.00 
Total 216 
  
 
 Mann-Whitney Test Two-Sample Kolmogorov-Smirnov Test 
                                                                       Test Statistics
a
 
Mann-
Whitney 
U 
Wilcoxon 
W 
Z  Sig. (2-
tailed) 
Most Extreme Differences 
absolute positive negative 
 
Kolmogoro
v-Smirnov Z 
 Sig. (2-
tailed) 
No. of 
children/family 
1081.000 2356.000 -1.217 .224 .160 .000 -.160 
 
.800 .544 
Child health 5580.000 10530.000 -1.214 .225 .037 .000 -.037 
 
.267 1.000 
Children 
Ages(Y) 
5099.500 10049.500 -1.515 .130 .159 .011 -.159 
 
1.161 .135 
Immunisation 5742.000 12645.000 -.920 .358 .009 .009 .000 
 
.063 1.000 
a. Grouping Variable: Group 
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    Table 6.14: Frequency of illnesses experienced during the last month  
 
No of illnesses Last  
Month 
Group   
Refugee Control Total 
Count % Count % Count % 
1 32 97 35 100 67 98.5 
2 1 3 0 .0 1 1.5 
Total 33 100.0 35 100.0 68 100.0 
 
 Value df Exact. Sig. (2-sided) 
Pearson Chi-Square 1.076a 1 .458 
Likelihood Ratio 1.462 1 .458 
Linear-by-Linear 
Association 
1.061 1 .458 
N of Valid Cases 68   
a. 2 cells (50%) have expected count less than 5. The minimum expected count is .49. 
 
 
 
     Table 6.15: Frequency of medicine used during the last month 
No of medicines 
Last Month 
Group   
Refugee Control Total 
Count % Count % Count % 
1 15 50 10 33.4 25 41.7 
2 14 46.7 18 60 32 53.3 
3 1 3.3 1 3.3 2 3.3 
4 0 .0 1 3.3 1 1.7 
Total 30 100.0 30 100.0 60 100.0 
 
 
 Value df Exact. Sig. (2-sided) 
Pearson Chi-Square 2.500a 4 .638 
Likelihood Ratio 2.894 4 .638 
Linear-by-Linear 
Association 
2.037 1 .223 
N of Valid Cases 60   
a. 4 cells (50.0%) have expected count less than 5. The minimum expected count is .50. 
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     Table 6.16: Medicines in the last month 
Medicines in the Last  
Month 
Group   
Refugee Control Total 
Count % Count % Count % 
OTC Medicines 
Prescribed medicines 
9 20 32         60  41 41.4 
37 80 21 40 58 58.6 
Total 46 100.0 53 100.0 99 100.0 
 
 
 Value df Exact. Sig. (2-sided) 
Pearson Chi-Square 16.906a 1 .000 
Likelihood Ratio 17.658 1 .000 
Linear-by-Linear 
Association 
16.735 1 .000 
N of Valid Cases 99   
a. 0 cells (0%) have expected count less than 5. The minimum expected count is .19.05. 
 
 
      Table 6.17: Frequency of illnesses experienced during the last six months 
No of illnesses Last  
6- Months 
Group   
Refugee Control Total 
Count % Count % Count % 
1 
2 
70 82.4 53 76.8 123 80 
15 17.6 16 23.2 31 20 
Total 85 100.0 69 100.0 154 100.0 
 
 
 Value df Exact. Sig. (2-sided) 
Pearson Chi-Square .727a 1 .424 
Likelihood Ratio .724 1 .424 
Linear-by-Linear 
Association 
.723 1 .424 
N of Valid Cases 154   
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 13.89. 
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      Table 6.18: Frequency of medicine used during the last six months 
No of medicines 
Last six Months 
Group   
Refugee Control Total 
Count % Count % Count % 
 1 
2 
3 
44 66.7 39 63.9 83 65.4 
19 28.8 19 31.2 38 29.9 
3 4.5 3 4.9 6 4.7 
Total 66 100.0 61 100.0 127 100.0 
 
 
 Value df Exact. Sig. (2-sided) 
Pearson Chi-Square .105a 2 .951 
Likelihood Ratio .104 2 .951 
Linear-by-Linear 
Association 
.091 1 .879 
N of Valid Cases 127   
a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 3.02. 
 
 
 
   Table 6.19: Medicines in the last six month 
Medicines in the Last 
Six  Month 
Group   
Refugee Control Total 
Count % Count % Count % 
OTC Medicines 
Prescribed medicines 
17 19 53 62     70 39.5 
74 81 33 38 107 60.5 
Total 91 100.0 86 100.0 177 100.0 
 
 Value df Exact. Sig. (2-sided) 
Pearson Chi-Square 34.111a 1 .000 
Likelihood Ratio 35.409 1 .000 
Linear-by-Linear 
Association 
33.918 1 .000 
N of Valid Cases 177   
a. 0 cells (0%) have expected count less than 5. The minimum expected count is .34.01. 
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Table 6.20: Attitudes (Mann-Whitney Test) 
Ranks 
 Group N Mean Rank Sum of Ranks 
Giving RX for 
earache 
Refugee 50 39.50 1975.00 
Control 50 61.50 3075.00 
Total 100 
  
Know epilepsy  Refugee 50 49.50 2475.00 
Control 50 51.50 2575.00 
Total 100 
  
Treat epilepsy  Refugee 50 50.50 2525.00 
Control 50 50.50 2525.00 
Total 100 
  
Inform friends  Refugee 50 43.50 2175.00 
Control 50 57.50 2875.00 
Total 100 
  
Inform school Refugee 50 49.00 2450.00 
Control 50 52.00 2600.00 
Total 100 
  
 
 Mann-Whitney Test Two-Sample Kolmogorov-Smirnov Test 
                                                                        Test Statistics
a
 
Mann-
Whitney 
U 
Wilcoxon W Z  Sig. (2-
tailed) 
Most Extreme 
Differences.640 
absolute positive negative 
 
Kolmogoro
v-Smirnov 
Z 
 Sig. (2-
tailed) 
Giving RX 
for earache 
700.00 1975.00 -4.621 .000 .440 .440 .000 
 
2.200 .000 
Know 
epilepsy  
1200.000 2475.000 -1.421 .155 .040 .040 .000 
 
.200 1.000 
Treat 
epilepsy  
1250.00 2525.000 .000 1.000 .000 .000 .000 
 
.000 1.000 
Inform 
friends  
900.000 2175.00 -4.015 .000 .280 .280 .000 
 
1.400 .040 
Inform 
school 
1175.000 2450.000 -1.750 .080 .060 .060 .000 
 
.300 1.000 
a. Grouping Variable: Group
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APPENDIX D 
D1: Attitudes tables 
Asylum Seekers and Refugees  
Table 6.21: Categorisation of responses (pain) 
Inductive Categories 3DUWLFLSDQWV¶5HVSRQVHV 
Giving analgesics x Few drops of olive oil, then give paracetamol. If 
still in pain, then take to GP. 
x Check closely to determine whether to give 
paracetamol or to contact GP. 
x If night time, then give analgesics; if day time, 
then contact GP. 
x Administer Calpol; if pain persists, then contact 
GP. 
x Give pain killers and call GP if symptoms get 
worse. 
x Child had ear infection in past, so would give 
pain relief then monitor; if necessary, see GP. 
Seeking advice or health 
care 
x Ring NHS direct first, then administer Calpol. 
x Take to GP or hospital. 
x Would not give anything until doctor prescribes. 
x Visit doctor, because do not know what to do. 
x Nothing to give, because it is difficult to 
diagnose. 
x *R WR *3 EHFDXVH FDQ¶W VHH LQVLGH Har and 
would want a medical opinion.  
Other options x Monitor sleep, eating habits, and temperature 
over a period of 5-7 days. If persists, then take 
to the GP. 
x Check inside the ear for any fluid discharge. 
x Start with breast feeding; if pain persists, then 
go to GP or a walk-in centre.  
x First try a warm bandage, then take to A&E. 
x Comfort him, then seek another option.    
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Table 6.22: Categorisation of responses (asthma) 
Inductive Categories 3DUWLFLSDQWV¶5HVSRQVHV 
Have experience and 
knowledge   
x My youngest has had ongoing chest problems 
and has been prescribed Ventolin, so it is ok to 
give. 
x Brother has asthma, so understand treatment is 
necessary. 
x Eldest has asthma, treat when unwell, so not 
concerned about it. 
x Mum has seasonal asthma and does not 
consider it a real illness. 
x I have asthma, so I know what to expect. 
x Will not panic, it is just a part of the 
medication. 
x ,WGRHVKHOSWRUHGXFHFKLOG¶VGLVWUHVVDQGPDNH
him/her comfortable.   
Happy to follow the 
instructions (administer 
the inhalers) 
x Happy to treat child if one of those things helps. 
x :RXOGEHKDSS\WRWUHDWZRXOGQ¶WEHIXVVHG 
x Nothing, because it could be for any one. Happy 
to give. 
x Cannot see child suffering, so will give inhaler 
as recommended. 
x ,I LW KHOSHG FKLOG¶V FRQGLWLRQ WKHQ ZRXOG IHHO
fine about it. 
Concerned x Concerned; seek advice for how to control 
asthma. 
x Anxious, upset, worried about whether it is a 
severe attack/hurting, because child is in 
trouble, and using an inhaler itself would not 
bother me. 
x Anxious; seek advice on risk. 
x Upset and concerned for child. 
x Not easy; do not know what to do.   
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Table 6.23: Categorisation of responses (epilepsy) 
Inductive categories Participants responses 
Feel happy to give child 
medication and follow 
advice 
x Know the condition, would not hesitate to give 
medicine regularly. 
x It is a health risk; would have to treat, so 
ZRXOGQ¶WKDYHDSUREOHP 
x Eldest child epileptic, so understand importance 
of treatment to control epilepsy.  
x If medication is what is necessary to keep child 
well, then would administer it. 
x When doctor says to give the medicine, would 
give it. 
x Understand the risk, so have to give the 
medicine. 
x Definitely would give the medicine. 
x Ok if it helps to control epilepsy and if it stops 
seizures. 
Concerned, but would 
give medication 
x Worried, but if it was required and necessary 
and we had the full information regarding the 
drugs and side effects, we would proceed. 
x Issue with having a diagnosis, but would not 
panic about daily medicine if it was required. 
x Very anxious and would discuss risks with 
relevant people. 
x If this happened, would be scarred and
distressed. 
x Be worried, but give medication to protect my
child. 
x Very concerned about condition, risks, and drug 
side effects. 
x  Depressed, but if medicine would help, then 
would give 
x :RXOGQ¶WEHKDSS\EXWLIGRFWRUUHFRPPHQGHG
this as best course of action, then would be 
inclined to take his/her advice as the 
professional. 
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D2: Attitudes tables 
Control group 
Table 6.24: Categorisation of responses (pain) 
Inductive categories Participants responses 
Give analgesics x pain killer, then check 
x administer Calpol if persists contact GP 
x give pain killers and call GP if symptoms got 
worse 
x give paracetamol and/or Ibuprofen, monitor the 
situation if no improvement I would see GP 
x Child had ear infection in past, so I would give 
pain relief then monitor and see GP if necessary 
Seeking for advice or 
healthcare 
x Ring NHS direct first, then calpol 
x Take to walk in centre 
x JRWR*3FDQ¶WVHHLQVLGHHDUDQGZRXOGZDQWD
medical opinion  
x Take to the Doctor, keep ear warm when 
outside 
Other options x Would monitor sleep, eating habits, and 
temperature over a period of 5-7 days. If 
persists would take to the GP 
x Check inside the ear for any fluid discharge 
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Table 6.25: Categorisation of responses (asthma) 
Inductive categories Participants responses 
Have experience and 
knowledge   
x My youngest has had ongoing chest problems 
and has been prescribed Ventolin, so ok to give 
x Brother has asthma, so understand treatment is 
necessary 
x Eldest has asthma, treat when un well, so not 
concerned about it 
x Mum has seasonal asthma, does not consider it 
an illness really 
x I have asthma, so would know what to expect 
x I know it is not easy, so I have to treat him 
x A little bit concerned but providing they were 
confident in using the inhaler, it would be ok    
Happy follow the 
instructions (give the 
inhalers) 
x Happy to treat if it one of those things help 
x :RXOGEHKDSS\WRWUHDWZRXOGQ¶WEHIXVVHG 
x Would give inhalers and hope he got better 
x If it helped their condition, I would feel fine 
about it 
x Would look at possible external elements 
causing it, but appreciate inhalers would help 
Concerned x Concerned, Seek advice in how to control 
asthma 
x Anxious, upset, worried about, what if it was a 
sever attack/hurting because my child in 
trouble, and using an inhaler itself would not 
bother me 
x Anxious, seek advice on risk 
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Table 6.26: Categorisation of responses (epilepsy) 
Inductive categories Participants responses 
Feel happy to give child 
medication and follow 
advice 
x I know the condition. Not hesitate to give 
medicine regularly 
x It is health risk, would have to treat, so 
ZRXOGQ¶WKDYHDSUREOHP 
x Eldest child epileptic, so understand importance 
of treatment to control epilepsy  
x If that what is needed to keep my child well, I 
would administer it 
x Happy to do what doctor recommended 
x Ok if it helps control epilepsy and stopped 
seizures 
 
x Whatever would help to make them better 
Concerned, but would 
give medication 
x Worried ,but if it was required and necessary 
and we had had the full information regarding 
the drugs and side effects, we would proceed 
x Issue with having a diagnosis but not panic by 
daily medicine if it was required 
x Very anxious and would discuss risks with 
relevant people 
x Would be worried and concerned, but happy to 
treat it 
x Very concerned about condition and risks and 
drug side effects 
x  Depressed, but if that would help I would give 
x :RXOGQ¶WEHKDSS\EXWLIGRFWRUUHFRPPHQGHG
this as best course of action, I would be inclined 
to take his/her advice as the professional 
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APPENDIX E 
Statistical analysis:  
Gypsies and Travellers   
 
 
 
Table 7.9: Comparison across Traveller and Control group (Independent sample 
t-test) 
 Group N Mean SD t df Sig. (2-
tailed) 
parent age (Y) Traveller 47 32.15 8.827 
-2.116 87.015 .039 
Control 50 35.54 6.893    
duration  in 
accommodation (Y) 
Traveller 33 3.56 6.244 
-3.959 77.572 .000 
Control 50 12.53 11.960    
duration in locality(Y) Traveller 41 10.54 8.031 
-4.642 80.255 .000 
Control 50 22.01 14.040    
Last visit (D) Traveller 
Control  
38 
44 
64.87 
69.32 
143.853 
129.081 
      -.148 75.101 .883 
 
 
 
 
 
 
 
  
328 
 
 
 
Table 7.10: Sociodemographics (Mann-Whitney Test) 
Ranks 
 Group N Mean Rank Sum of Ranks 
Gender Traveller 47 52.00 2444.00 
Control 50 46.18 2309.00 
Total 97 
  
Occupation  Traveller 47 36.13 1698.00 
Control 50 61.10 3055.00 
Total 97 
  
links with locality Traveller 23 36.00 828.00 
Control 48 36.00 1728.00 
Total 71 
  
Parents health Traveller 
Control 
Total 
47 
50 
97 
42.99 
54.65 
 
2020.50 
2732.50 
 
 Mann-Whitney Test 
Two-Sample Kolmogorov-Smirnov Test 
                                                                        Test Statistics
a
 
Mann-
Whitney U 
Wilcoxon W Z  Sig. (2-
tailed) 
Most Extreme Differences 
absolute positive negativ
e 
 
Kolmogorov-
Smirnov Z 
 Sig. (2-
tailed) 
Gender 1034.000 2309.000 -2.439 .015 .120 .120 .000 
 
.591 .876 
Occupation  570.000 1698.000 -5.284 .000 .515 .000    -.515 
 
2.534 .000 
links with 
locality 
552.000 1728.000 .000 1.000 .000 
 
.000  .000 
 
.000 1.000 
Parents health 892.500 2020.500 -2.858 .004   .240               .000             -.240    1.183 .121 
a. Grouping Variable: Group 
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Table 7.11: General access to health care and medicines (Mann-Whitney Test) 
Ranks 
 Group N Mean Rank Sum of Ranks 
Reg with GP    Traveller 47 49.00 2303.00 
Control 50 49.00 2450.00 
Total 97 
  
Pay for RX  Traveller 38 30.16 1146.00 
Control 40 48.38 1935.00 
Total 78 
  
Difficulties Traveller 40 42.50 1700.00 
Control 44 42.50 1870.00 
Total 84 
  
Home RX Traveller 47 51.36 2414.00 
Control 49 45.76 2242.00 
Total 96 
  
  
  
 
 Mann-Whitney Test Two-Sample Kolmogorov-Smirnov Test 
                                                                           Test Statistics
a 
 
Mann-
Whitney 
U 
Wilcoxon 
W 
Z  Sig. 
(2-
tailed) 
Most Extreme 
Differences. 
absolute positive negativ
e 
 
Kolmogoro
v-Smirnov 
Z 
 Sig. (2-
tailed) 
Reg with 
GP    
1175.000 2450.000 .000 1.000 .000 .000 .000 
 
.000 1.000 
Pay for 
OTC  
405.000 1146.000 -4.187 .000 .467 .000    -.467 
 
2.062 .000 
Difficulties 880.000 1870.000 .000 1.000 .000 .000 .000 
 
.000 1.000 
Home RX 1017.00 2242.000 -1.239 .215 .117 .117 .000 
 
.572 .899 
        
a. Grouping Variable: Group 
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Table 7.12: Data for the children (Mann-Whitney Test) 
Ranks 
 Group N Mean Rank Sum of Ranks 
No. of 
children/family 
Traveller 47 53.09 2495.00 
Control 50 45.16 2258.00 
Total 97 
  
Child health  Traveller 113 98.13 11089.00 
Control 105 121.73 12782.00 
Total 218 
  
Children Ages(Y) Traveller 113 110.03 12433.50 
Control 105 108.93 11437.50 
Total 218 
  
Immunisation Traveller 113 103.92 11743.50 
Control 105 115.50 12127.50 
Total 218 
  
 
 Mann-Whitney Test Two-Sample Kolmogorov-Smirnov Test 
                                                                       Test Statistics
a
 
Mann-
Whitney 
U 
Wilcoxo
n W 
Z  Sig. 
(2-
tailed) 
Most Extreme Differences 
absolute positive negativ
e 
 
Kolmogoro
v-Smirnov 
Z 
 Sig. (2-
tailed) 
No. of 
children/famil
y 
983.000 2258.000 -1.466 .143 .154 .154 .000 
 
.758 .613 
Child health 4648.000 11089.000 -4.158 .000 .217 .217 .000 
 
1.597 .012 
Children 
Ages(Y) 
5872.500 11437.500 -.129 .897 .096 .043 -.096 
 
.706 .702 
Immunisation 5302.500 11743.500 -3.427 .001 .106 .106 .000 
 
.783 .571 
a. Grouping Variable: Group 
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      Table 7.13: Frequency of illnesses experienced during the last month 
No of illnesses Last  
Month 
Group   
Traveller Control Total 
Count % Count % Count % 
1 
2 
33 97 33 100 66 98.5 
1 3 0 .0 1 1.5 
Total 34 100.0 33 100.0 67 100.0 
  
 
 Value df Exact. Sig. (2-sided) 
Pearson Chi-Square .985a 1 .507 
Likelihood Ratio 1.371 1 .507 
Linear-by-Linear 
Association 
.971 1 .507 
N of Valid Cases 67   
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 49. 
 
  
 
      Table 7.14: Frequency of medicine used during the last month 
No of medicines 
Last Month 
Group   
Traveller Control Total 
Count % Count % Count % 
 1 
2 
3 
4 
23 76.7 10 35.7 33 56.9 
7 23.3 16 57.1 23 39.7 
0 .0 1 3.6 1 1.7 
0 .0 1 3.6 1 1.7 
Total 30 100.0 28 100.0 58 100.0 
 
 
 Value df Exact. Sig. (2-sided) 
Pearson Chi-Square 10.587a 3 .004 
Likelihood Ratio 11.584 3 .004 
Linear-by-Linear 
Association 
9.802 1 .002 
N of Valid Cases 58   
a. 4 cells (50.0%) have expected count less than 5. The minimum expected count is .48. 
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      Table 7.15: Medicines in the last month 
Medicines in the Last  
Month 
Group   
Traveller Control Total 
Count % Count % Count % 
OTC Medicines 
Prescribed medicines 
8 22 30 61 38 44 
29 78 19 39 48 56 
Total 37 100.0 49 100.0 86 100.0 
 
 Value df Exact. Sig. (2-sided) 
Pearson Chi-Square 13.407a 1 .000 
Likelihood Ratio 13.984 1 .000 
Linear-by-Linear 
Association 
13.251 1 .000 
N of Valid Cases 86   
a. 0 cells (0%) have expected count less than 5. The minimum expected count is .16.35. 
 
 
 
     Table 7.16: Frequency of illnesses experienced during the last six months 
No of illnesses Last  
6- Months 
Group   
Traveller Control Total 
Count % Count % Count % 
 1 
2 
44 77.2 60 87 104 82.5 
13 22.8 9 13 22 17.5 
Total 57 100.0 69 100.0 126 100.0 
 
 
 
 Value df Exact. Sig. (2-sided) 
Pearson Chi-Square 2.065a 1 .165 
Likelihood Ratio 2.058 1 .165 
Linear-by-Linear 
Association 
2.048 1 .165 
N of Valid Cases 126   
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 9.95. 
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      Table 7.17: Frequency of medicine used during the last six months 
No of medicines 
Last six Months 
Group   
Traveller Control Total 
Count % Count % Count % 
 1 
2 
3 
4 
38 76 27 52 65 63.7 
10 20 22 42.3 32 31.4 
2 4 2 3.8 4 3.9 
0 .0 1 1.9 1 1 
Total 50 100.0 52 100.0 102 100.0 
  
 
 Value df Exact. Sig. (2-sided) 
Pearson Chi-Square 7.325a 3 .034 
Likelihood Ratio 7.829 3 .061 
Linear-by-Linear 
Association 
5.107 1 .025 
N of Valid Cases 102   
a. 4 cells (50.0%) have expected count less than 5. The minimum expected count is .49. 
 
 
      Table 7.18: Medicines in the last six months 
Medicines in the Last  
Six Months 
Group   
Traveller Control Total 
Count % Count % Count % 
OTC Medicines 
Prescribed medicines 
19 30 52 64 71 49 
45 70 29 36 74 51 
Total 64 100.0 81 100.0 145 100.0 
 
 Value df Exact. Sig. (2-sided) 
Pearson Chi-Square 17.039a 1 .000 
Likelihood Ratio 17.434 1 .000 
Linear-by-Linear 
Association 
16.921 1 .000 
N of Valid Cases 145   
a. 0 cells (0%) have expected count less than 5. The minimum expected count is .31.34. 
 
  
334 
Table 7.19: Attitudes (Mann-Whitney Test) 
Ranks 
 Group N Mean Rank Sum of Ranks 
Giving RX for 
earache 
Traveller 47 43.02 2022.00 
Control 50 54.62 2731.00 
Total 97 
  
Know epilepsy  Traveller 47 49.00 2303.00 
Control 50 49.00 2450.00 
Total 97 
  
Treat epilepsy  Traveller 47 49.00 2303.00 
Control 50 49.00 2450.00 
Total 97 
  
Inform friends Traveller 47 49.00 2303.00 
Control 50 49.00 2450.00 
Total 97 
  
Inform school  Traveller 47 49.00 2303.00 
Control 50 49.00 2450.00 
Total 97 
  
 
 Mann-Whitney Test Two-Sample Kolmogorov-Smirnov Test 
                                                                        Test Statistics
a
 
Mann-
Whitney 
U 
Wilcoxon 
W 
Z  Sig. 
(2-
tailed) 
Most Extreme 
Differences 
absolute positive negativ
e 
 
Kolmogoro
v-Smirnov 
Z 
 Sig. (2-
tailed) 
Giving RX 
for earache 
894.000 2022.000 -2.951 .003 .239 .000 -.239 
 
1.177 .125 
Know 
epilepsy  
1175.000 2450.000 .000 1.000 .000 .000 .000 
 
.000 1.000 
Treat 
epilepsy  
1175.000 2450.000 .000 1.000 .000 .000 .000 
 
.000 1.000 
Inform 
friends 
1175.000 2450.000 .000 1.000 .000 .000 .000 
 
.000 1.000 
Inform 
school  
1175.000 2450.000 .000 1.000 .000 .000 .000 
 
.000 1.000 
 
a. Grouping Variable: Grou
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APPENDIX F 
Attitudes tables 
Gypsies and Travellers  
 
Table 7.20: Categorisation of responses (pain) 
Inductive Categories 3DUWLFLSDQWV¶5HVSRQVHV 
Give analgesics x Give calpol and ear drops. 
x Give calpol, but still like it checked out. 
x Give pain killer, and then check if no improvement takes 
to GP. 
x Give pain killer only if Dr prescribed. 
x Give paracetamol and/or Ibuprofen, monitor the 
situation if no improvement I would see the GP.  
Seeking advice or health 
care 
x Straight to the GP. 
x Take to walk in centre or A&E. 
x Contact my GP. 
x Ring the NHS direct first. 
x Take to the doctor, keep ear warm when outside. 
Other options x Treat with warm bandage to ear, then if no better see 
the doctor. 
x Phone the family first, then GP for advice. 
x Comfort him and put ear drops. 
x Comfort him, then see another option. 
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Table 7.21: Categorisation of responses (asthma) 
Inductive categories Participants responses 
Have experience and 
knowledge   
 
 
x Both boys have asthma treated with inhalers on 
repeated prescription from GP. 
x $OULJKW \RX ZRXOG KDYH WR EH ZRXOGQ¶W \RX LI
your child?. 
x Mum has asthma, so would be happy to treat. 
x She already has it. 
x All three children had asthma in the past 
treated with inhalers, now use it when needed. 
x Youngest has asthma as baby. 
x Has experience with asthma, so happy to do.  
Happy to follow the 
instructions (give the 
inhalers) 
x Would look at possible external elements 
causing it, but appreciate inhalers would help. 
x Just give it. 
x Happy to treat if it made them better. 
x Would treat as long as child kept healthy. 
Concerned x Worried but would go to the doctor. 
x Slightly concern, but ok. 
x Would be worried but would rather have the 
inhaler than not. 
x Shocked, devastated, frustrated, will give 
medicine if necessary for health.  
x Would try home cure first, an inhaler would be 
a last resort. 
x Would make sure it was careful diagnosed, then 
I will go for doctor opinion to make sure they 
really needed. 
x Not happy but would not ignore it and not 
worried about inhalers.      
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Table 7.22: Categorisation of responses (epilepsy) 
Inductive categories Participants responses 
Feel happy to give child 
medication and follow 
advice 
x Happy to treat, knows what to do in event of a 
seizures.  
x Would expect it to be treated, would want medicine to 
stop it. 
x Understand need to treat, so happy to do. 
x Would just get on with it, do as doctor said. 
x Brother had epilepsy, was treated with medicines, know 
what to do. 
x Would treat with regular medication as eldest child had 
surgery and regular medication as a child. 
x Eldest had epilepsy, treated with anticonvulsant, 
regular medication and visits to specialist, but has now 
been fits free for 2 years. 
Concerned, but would give 
medication  
x Feel anxious, but happy to treat it. 
x Would be upset, but happy to treat if looked after by 
healthcare. 
x Distressed, devastated, but happy to give if it helped 
my child.  
x  Depressed, but if that would help I would give it. 
x Will feel sad about they been ill, but do whatever would 
help to make them better. 
 
 
